IPASE A 3-IN-1 MEDICAL REFERENCE Medical Dictionary Bibliography & Annotated Research Guide TO I NTERNET
R EFERENCES
IPASE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Lipase: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-497-00665-0 1. Lipase-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on lipase. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON LIPASE ....................................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Lipase ............................................................................................ 4 E-Journals: PubMed Central ....................................................................................................... 60 The National Library of Medicine: PubMed ................................................................................ 77 CHAPTER 2. NUTRITION AND LIPASE ........................................................................................... 125 Overview.................................................................................................................................... 125 Finding Nutrition Studies on Lipase ......................................................................................... 125 Federal Resources on Nutrition ................................................................................................. 130 Additional Web Resources ......................................................................................................... 130 CHAPTER 3. ALTERNATIVE MEDICINE AND LIPASE ..................................................................... 133 Overview.................................................................................................................................... 133 National Center for Complementary and Alternative Medicine................................................ 133 Additional Web Resources ......................................................................................................... 158 General References ..................................................................................................................... 161 CHAPTER 4. DISSERTATIONS ON LIPASE ....................................................................................... 163 Overview.................................................................................................................................... 163 Dissertations on Lipase .............................................................................................................. 163 Keeping Current ........................................................................................................................ 165 CHAPTER 5. PATENTS ON LIPASE .................................................................................................. 167 Overview.................................................................................................................................... 167 Patents on Lipase ....................................................................................................................... 167 Patent Applications on Lipase.................................................................................................... 189 Keeping Current ........................................................................................................................ 215 CHAPTER 6. BOOKS ON LIPASE ..................................................................................................... 217 Overview.................................................................................................................................... 217 Chapters on Lipase ..................................................................................................................... 217 CHAPTER 7. MULTIMEDIA ON LIPASE........................................................................................... 221 Overview.................................................................................................................................... 221 Video Recordings ....................................................................................................................... 221 CHAPTER 8. PERIODICALS AND NEWS ON LIPASE........................................................................ 223 Overview.................................................................................................................................... 223 News Services and Press Releases.............................................................................................. 223 Academic Periodicals covering Lipase........................................................................................ 225 CHAPTER 9. RESEARCHING MEDICATIONS .................................................................................. 227 Overview.................................................................................................................................... 227 U.S. Pharmacopeia..................................................................................................................... 227 Commercial Databases ............................................................................................................... 228 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 231 Overview.................................................................................................................................... 231 NIH Guidelines.......................................................................................................................... 231 NIH Databases........................................................................................................................... 233 Other Commercial Databases..................................................................................................... 235 APPENDIX B. PATIENT RESOURCES ............................................................................................... 237 Overview.................................................................................................................................... 237 Patient Guideline Sources.......................................................................................................... 237 Finding Associations.................................................................................................................. 239 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 241 Overview.................................................................................................................................... 241
viii Contents
Preparation................................................................................................................................. 241 Finding a Local Medical Library................................................................................................ 241 Medical Libraries in the U.S. and Canada ................................................................................. 241 ONLINE GLOSSARIES................................................................................................................ 247 Online Dictionary Directories ................................................................................................... 248 LIPASE DICTIONARY ................................................................................................................. 249 INDEX .............................................................................................................................................. 329
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with lipase is indexed in search engines, such as www.google.com or others, a nonsystematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about lipase, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to lipase, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on lipase. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to lipase, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on lipase. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON LIPASE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on lipase.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and lipase, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “lipase” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Exercise Training, Without Weight Loss, Increases Insulin Sensitivity and Postheparin Plasma Lipase Activity in Previously Sedentary Adults Source: Diabetes Care. 26(3): 557-562. March 2003. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article reports on a study undertaken to determine the effects of exercise, without weight loss, on insulin sensitivity (S1) postheparin plasma lipase activity (PHPL), intravenous fat clearance rate (K2), and fasting lipids in sedentary adults. Exercise increased S1 and both lipoprotein lipase and hepatic (liver) lipase activities without altering BMI (body mass index), waist circumference, K2, or fasting lipids. Correlations between changes in LPL and the total-to- HDL cholesterol ratio and
4
Lipase
changes in the LPL-to-HL ratio and waist circumference were significant. The authors conclude that exercise, without weight loss, increases S1 and PHPL activity in previously sedentary adults, without changing K2 or fasting lipid levels. Therefore, even modest amounts of exercise in the absence of weight loss positively affect markers of glucose and fat metabolism in previously sedentary, middle-aged adults. 1 figure. 1 table. 26 references.
Federally Funded Research on Lipase The U.S. Government supports a variety of research studies relating to lipase. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to lipase. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore lipase. The following is typical of the type of information found when searching the CRISP database for lipase: •
Project Title: ALCOHOL AND CHRONIC DISEASE AMONG VULNERABLE POPULATIONS Principal Investigator & Institution: Rimm, Eric B.; Associate Professor; Nutrition; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02115 Timing: Fiscal Year 2004; Project Start 01-SEP-1997; Project End 31-MAR-2009 Summary: (provided by applicant): Among healthy populations, the benefits of moderate alcohol consumption are well documented. However, more than 7.5 million Americans are survivors of myocardial infarction (MI) and the epidemic of obesity has given rise to an even larger unhealthy population with dyslipidemia,hypertension, low HDL-C, and hyperglycemia (i.e. metabolic syndrome). The influence that alcohol has on prognosis among these "at risk" groups is crucial for informed decision-making by patients, physicians, and policy-makers. We propose to examine alcohol and chronic disease in vulnerable populations among 121,700 women (32,826 with stored blood samples) in the Nurses' Health Study (1976-2006) and 51,529 men (18,100 with stored blood samples) in the Health Professionals Follow-up Study (1986-2006). First, we will study alcohol intake and risk of mortality among an estimated 3,345 women and 2,835 men with confirmed incident non-fatal MI. Secondly, using blood markers of dyslipidemia and abnormal glucose homeostasis, we will examine alcohol and coronary heart disease (CHD) among participants with metabolic syndrome in a nested case control (1:2) study among the projected 680 women and 534 men who provided blood samples and subsequently developed CHD. Finally, because the purported benefit of
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
5
alcohol consumption is attributed principally to increased HDL-C, we will examine CHD risk associated with gene-alcohol interactions in genes that modulate HDL-C levels. Specifically, alcohol dehydrogenase-3, hepatic lipase, lipoprotein lipase, cholesteryl ester transport protein, and endothelial lipase. The well characterized large cohorts of women and men with stored blood samples provide an unparalleled opportunity to elucidate the health effects of alcohol among high risk patients. Furthermore, knowledge of populations that may benefit from alcohol (or be at greatest risk) will help in the understanding of the pathophysiology of CHD and aid in the development of more complete clinical guidelines for the growing population of individuals at risk for coronary disease and mortality. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANIMAL ATHEROSCLEROSIS
MODELS
FOR
LIPID
METABOLISM
AND
Principal Investigator & Institution: Chan, Lawrence; Professor of Medicine; Molecular and Cellular Biology; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 15-DEC-1993; Project End 30-NOV-2005 Summary: (provided by applicant): The primary objective is to advance our knowledge of lipid metabolism and atherosclerosis using animal models. A major area is the role of 12/15-lipoxygenase (LO) in atherosclerosis. 12/l5LOs are lipid-peroxidizing enzymes that oxygenate polyenoic fatty acids to their corresponding hydroperoxy derivatives. 12/15LOs have proatherogenic properties via their capacity to oxidize LDL, as well as antiatherogenic activities via their predominantly anti-inflammatory action. We previously showed that macrophage-specific 15LO overexpression in rabbits protects against atherosclerosis. In pilot experiments we found that, compared to 12/15LO+/+ apoE-/- mice, 12/15LO-/- apoE-/- mice are protected against atherosclerosis, a finding that is at variance with that of. A major goal of this application is to examine the biochemical milieu associated with 12/15LO expression that may underlie the divergent effects of the enzyme on atherosclerosis. Another major area is the role of intracellular lipolysis in lipid homeostasis. We produced perilipin (plin) knockout mice that displayed constitutional activated lipolysis. Perilipin is a major adipose lipid droplet protein that regulates the activity of hormone-sensitive lipase. Plin-/- mice were lean and resistant to diet-induced obesity. Breeding the plin-/- alleles into ob/ob and db/db mice reversed their obesity phenotype. Interestingly, ruptured atherosclerotic plaques in humans and advanced plaques of apoE-/- mice expressed perilipin. We will investigate the role of 12/15LO and perilipin with 5 specific aims. In the first 2 aims, we will study atherosclerosis development in 12/15LO-/- apoE-/- and 12/15LO+/+ apoE-/- mice, and, identify and quantify the eicosanoids and other metabolites in the atherosclerotic aortas from the 2 genotypes. In aims 3 and 4, to obtain mechanistic insight into the obesity-resistant phenotype of plin-/- mice, we will perform biochemical and molecular characterization as well as in vivo stable isotope and energy expenditure experiments on plin+/+ and plin-/- mice with and without ob/ob or db/db background. The creation of non-obese ob/ob and db/db mice (i.e., those that also inherited the plin-/- alleles) provides a unique opportunity to study the role of leptin in lipid and carbohydrate homeostasis in the presence and absence of obesity. Since perilipin, a lipid dropletassociated protein, is expressed in atherosclerotic lesions, in the last aim and in collaboration with we will compare the atherosclerosis susceptibility and plaque morphology of plin-/- and plin+/+ mice bred into apoE-/- and LDLR-/- background. We believe that the mechanistic experiments proposed will advance our understanding of lipid and carbohydrate metabolism, energy homeostasis, and atherosclerosis.
6
Lipase
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTHRACYCLINE CARDIOTOXICITY--OXIDATIVE STRESS Principal Investigator & Institution: Sarvazyan, Narine; Associate Professor; Physiology; Texas Tech University Health Scis Center Health Sciences Center Lubbock, Tx 79430 Timing: Fiscal Year 2002; Project Start 01-APR-1999; Project End 31-MAR-2004 Summary: Doxorubicin and its derivatives are among the most potent anticancer drugs known. Unfortunately their therapeutic efficacy is severely restricted by a doseaccumulated cardiotoxicity. Our preliminary results using adult rat cardiomyocytes as a working model, have shown evidence for the mechanism which could explain how reactive oxygen species generated by doxorubicin provoke myofibrillar degeneration while not causing severe oxidative damage. Specifically, 1) we visualized directly doxorubicin accumulation in cardiac mitochondria and subsequent increase in intracellular oxidation in living cardiomyocytes, 2) observed that doxorubicin administration is associated with redistribution of the protein kinase C epsilon isoform from cytosol to myofibrils, and 3) detected disruption of the periodicity of actin staining after repetitive exposure of myocytes to clinically relevant drug concentrations. Based on these data we propose the following sequence of events: doxorubicin rapidly accumulates in cardiac mitochondria; it then initiates lipid peroxidation via formation of superoxide and drug complexes with transition metals; and although the degree of lipid peroxidation is small and no significant membrane damage occurs, it leads to the activation of phospholipases; lipase thereupon release several second messengers, including arachidonic acid, activating a specific protein kinase C isoform; the kinase then initiates myofibrillar degeneration. To support the above hypothesis we aim to 1) establish a causal relationship between observed doxorubicin-induced kinase translocation and increased free radical formation; 2) to determine whether doxorubicininduced free radicals and/or protein kinase C translocation are prerequisites for changes in myocyte myofibrillar organization and cell contractility; 3) to uncover role of phospholipase A2 in doxorubicin-induced activation of kinase and ensuing changes in myofibrillar organization and contractility. The proposed experiments aim to reveal explicit pathways through which reactive oxygen species are involved in anthracyclineinduced cardiomyopathy. The studies will also provide new information about kinases involvement in myofilament degeneration and interaction between reactive oxygen species and signal transduction pathways. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANTIBODIES TO LIPOPROTEIN LIPASE AND ATHEROSCLEROSIS Principal Investigator & Institution: Reichlin, Morris; Vice President of Research; Oklahoma Medical Research Foundation Oklahoma City, Ok 731045005 Timing: Fiscal Year 2002; Project Start 05-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Premature atherosclerosis in patients with Systemic Lupus Erythematosus (SLE) has been recognized for the past 25 years. As much as a 50fold increase in risk for coronary artery disease has been found in SLE patients compared to controls and an increased risk for thrombotic cerebrovascular disease has also been recognized. In the past decade lipid abnormalities have been recognized in SLE patients that are "proatherogenic". These include elevated LDL cholesterol, low HDL cholesterol and elevated triglyceride levels that are not due to nephrotic syndrome. Careful clinical studies suggest that conventional risk factors such as age, sex, smoking, hypertension, etc., do not completely account for the prevalence of premature
Studies
7
atherosclerosis. Indeed, there appears to be an element of risk conferred by the lupus process itself We postulate that this mechanism of the SLE associated risk lies in autoimmune events that perturb lipid homeostasis in the direction of elevated triglycerides and cholesterol. We further suggest that part of this effect is due to an immune response to lipoprotein lipase which occurs in 50% of SLE patients and promotes hypertriglyceridemia. In addition, autoantibodies to apolipoprotein A-1, Apo B and Apo E may perturb lipid transport and promote decreased HDL cholesterol and increased LDL cholesterol. Our plan is to combine our expertise in autoantibody research with epidemiologic methods. We will conduct a prospective study of SLE patients and their matched controls to evaluate these immune responses on lipid levels, in the presence of conventional risk factors and confounders, and their association with premature atherosclerosis. Recognition of autoimmune mechanisms that promote elevated triglycerides could lead to specific interventions as therapy or even possibly prevention of premature atherosclerosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTIGEN SPECIFIC RESPONSES TO BORRELIA Principal Investigator & Institution: Benach, Jorge L.; Professor, Molecular Genetics and Microb; Molecular Genetics & Microbiol; State University New York Stony Brook Stony Brook, Ny 11794 Timing: Fiscal Year 2002; Project Start 01-DEC-1993; Project End 31-MAY-2003 Summary: (Adapted from the applicant's abstract): The main and long term goal of this application is to understand the mechanism of action of bactericidal antibodies in Borrelia infections. A number of monoclonal antibodies have been discovered that can kill Borrelia burgdorferi without the assistance of complement, and the Fab fragments of the antibodies have the same bactericidal activity. Earlier studies showed that these antibodies function by lysis of the outer membrane in a Ca++ dependent medium process. This application is based on the hypothesis that complement independent bactericidal antibodies represent a novel and fundamental mechanism of host resistance in infections with Borrelia, and possibly in infections with other bacteria. The Research Plan is based on three underlying hypotheses that support the main goal of this application to characterize the mechanisms by which bactericidal antibodies can destroy Borrelia spp. The first approach will be to examine the antibodies themselves for possible catalytic properties which could result in a breakdown of the antigen leading to changes in the physical association of the antigen with other outer membrane molecules. The possibility that the antibodies could induce unique conformational changes in their antigens, which in turn could affect the topology and integrity of the outer membrane will also be evaluated. The second approach will be to test the hypothesis that the antibody-antigen complex induces the activation of lytic enzymes through an outer membrane signal transduction mechanism. Specifically, the identification and role of lipases and phospholipases in Borrelia will be evaluated. Such enzymes exist in these organisms and should be involved in the lysis of the outer membrane. If this mechanism of killing Borrelia is found to occur, it will represent a novel, and overlooked form of host defense. The third approach will be to test the possibility that bactericidal antibodies are a major form of host defense in Borrelia infections. Passive immunization studies will be conducted with the bactericidal antibodies in complement deficient (transgenic) mice to determine their role in preventing infection in a complement independent manner. Other studies will be involved in raising targeted bactericidal antibodies to antigens expressed in vivo. The possibility that the bactericidal antibodies may select more invasive phenotypes will also be evaluated.
8
Lipase
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: APO E GENOTYPE AND HDL CHANGES WITH EXERCISE TRAINING Principal Investigator & Institution: Hagberg, James M.; Professor; Kinesiology; University of Maryland College Pk Campus College Park, Md 20742 Timing: Fiscal Year 2002; Project Start 01-JUN-1998; Project End 31-MAY-2004 Summary: (Adapted from the Applicant's Abstract): Abnormal plasma lipids are a major modifiable risk factor for cardiovascular (CV) disease in older persons. Polymorphic variation at numerous gene loci independently and via interactions with environmental factors affect plasma lipid levels. A cross-sectional study and preliminary data suggest that apolipoprotein E (APO E) genotype affects the HDL-C and HDL2-C increases that occur with exercise training. Thus, in healthy, sedentary, middle-aged and older subjects, the investigators will test their primary hypothesis: HDL-C and HDL2-C levels increase more with exercise training in APO E2/3 than in APO E3/4 genotype individuals. Preliminary data also indicate that lipoprotein lipase (LPL) Pvull genotype affects HDL-C and HDL2-C increases resulting from exercise training. Thus, they will test their secondary hypothesis: HDL-C and HDL2-C levels increase more with exercise training in LPL Pvull -/- than in LPL Pvull +/+ or +/- genotype individuals. Exploratory analyses will determine if variations at another LPL and 3 hepatic lipase (HL) gene loci affect the exercise training-induced HDL-C and HDL2-C increases and if, as with preliminary data, LPL and HL activities change differently with exercise training among genotype groups. After screening subjects for APO E genotype, they will be stabilized on an AHA Step I diet. Subjects then complete Baseline Testing, 6 months of exercise training and Final Testing. If VO2max, body composition, or intra-abdominal fat change differently among genotype groups with exercise training, they will be included in linear regression models to assess the independent effects of genetic and non-genetic variables on lipid changes with exercise training. Results consistent with the hypotheses will identify persons who obtain the greatest CV disease risk reductions, resulting in the optimal stratifying of exercise training to those benefiting the most. Conversely, identifying persons who will improve their lipoprotein lipids the least with exercise training would allow them to focus on interventions that might be more efficacious for them. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BEHAVIOR MODIFICATION AND PHARMACOTHERAPY FOR OBESITY Principal Investigator & Institution: Wadden, Thomas A.; Professor; Psychiatry; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 01-AUG-1999; Project End 31-JUL-2003 Summary: Obesity is one of our nation's most serious health problems. The treatment of this disorder experienced a serious setback last year when two popular weight loss medications -- fenfluramine and dexfenfluramine -- were withdrawn from the market because of concerns that they were associated with valvular heart disease. Despite this unfortunate occurrence, it appears that pharmacotherapy will play an increasingly important role in the management of obesity in the next decade. In November 1997, the Food and Drug Administration approved sibutramine, a serotonin and norepinepherine re-uptake inhibitor, for "weight loss and maintenance of weight loss". Orlistat, a gastric and pancreatic lipase inhibitor, is now being considered for similar approval, with
Studies
9
several other medications likely to follow. Previous studies indicate that optimal weight losses and improvements in health are likely to be obtained when behavioral and pharmacologic interventions are combined. Behavior therapy facilitates adherence to exercise and medication recommendations, whereas pharmacotherapy, by reducing hunger and increasing satiety, aids efforts to consume a reduced calorie diet. Long-term pharmacotherapy also holds promise of improving the maintenance of weight loss, a shortcoming of behavioral treatment. The proposed study will examine, in an 18-month trial, the separate and combined effects of behavior therapy and pharmacotherapy for obesity. A total of 296 obese men and women (BMI greater than 32 kg/m2) will be randomly assigned to one of four conditions: 1) Medication (i.e., sibutramine) Plus Standard Care; 2) Medication Plus Individual Behavior Modification (provided by a physician in brief visits); 3) Medication Plus Group Behavior Modification; or 4) Group Behavior Modification Alone. We predict that subjects treated by medication, combined with either individual or group behavior modification, will achieve significantly greater weight losses and improvements in health than those treated by Medication Plus Standard Care. This will result from the latter subjects' significantly better adherence to diet, exercise, and medication recommendations. We also predict that subjects treated by medication plus behavior modification (in individual or group sessions) will achieve significantly greater weight losses (particularly during the last 9 months) than persons who receive Group Behavior Modification Alone. If confirmed, the above findings will have important implications for treating obesity in primary care. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL SIGNALING: MACROVASCULAR COMPLICATIONS OF DIABETES Principal Investigator & Institution: Bornfeldt, Karin E.; Pathology; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 30-SEP-1998; Project End 30-NOV-2005 Summary: (provided by applicant): A majority of people with diabetes die of cardiovascular disease caused by atherosclerosis that is accelerated by diabetes. The factors that drive diabetes-accelerated atherosclerosis are still poorly understood. Our recent studies on a new porcine model show that diabetes in combination with elevated lipid intake causes increased accumulation and proliferation of arterial smooth muscle cells (SMCs) in lesions of atherosclerosis. The increased SMC proliferation occurs concomitant with hyperglycemia and elevated levels of plasma triglycerides. High glucose levels are not sufficient to induce SMC proliferation, but certain fatty acids common in triglycerides (oleate and linoleate) stimulate SMC proliferation in the presence of insulin-like growth factor I (IGF-I). We propose that diabetes leads to an increased amount of IGF-I and of lipoprotein lipase in lesion macrophages, and that lipoprotein lipase degrades triglycerides into free fatty acids that act in synergy with IGF-I to stimulate SMC proliferation. Our goal for the next five years is to address the following questions: 1. Do oleate and linoleate enhance the growth-promoting effects of IGF-I on SMCs? 2. How do oleate and linoleate synergize with the growth-promoting action of IGF-I in SMCs? 3. Does lipoprotein lipase produced by lipid loaded macrophages increase SMC proliferation by generating oleate and linoleate? 4. Does glucose or lipids associated with diabetes stimulate SMC proliferation, lipoprotein lipase and IGF-I in lesions of atherosclerosis and does lack of macrophage-derived lipoprotein lipase result in reduced SMC proliferation? We will use several animal models of diabetes-associated atherosclerosis, isolated arterial SMCs for signal transduction studies as well as a co-culture model of monocyte derived macrophages
10
Lipase
and SMCs. Increased understanding of the regulation of SMC proliferation and accumulation in diabetic lesions of atherosclerosis may provide the basis information necessary for development of highly specific drugs that can prevent lesion progression and formation of vulnerable lesions that are likely to cause the clinical symptoms of cardiovascular complications in diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL SURFACE ACTIVITIES IN LIPOPROTEIN CATABOLISM Principal Investigator & Institution: Orlando, Robert A.; Assistant Professor; Biochem and Molecular Biology; University of New Mexico Albuquerque Controller's Office Albuquerque, Nm 87131 Timing: Fiscal Year 2002; Project Start 18-SEP-2000; Project End 30-NOV-2003 Summary: adapted from applicant's abstract): Studies in this application propose to investigate this apparent synergistic relationship between HSPG and LRP or megalin, that is necessary for lipoprotein/lipase clearance by cells. Using quantitative biochemical procedures we will determine if ligands are 1) transferred to the endocytic receptors for internalization following their initial binding to HSPG, or 2) if the HSPG and endocytic receptors are cointernalized with bound ligand. These studies will aid in determining if LRP and megalin can regulate ligand sequestration or lipolytic enzyme activities by controlling the amount of HSPG that is present on the cell surface through endocytosis. We also plan to identify the proteoglycan-like molecule that coprecipitates with megalin and LRP, and determine if disrupting its interactions with LRP and megalin prevents the uptake of lipoproteins by cells. As a second goal, studies are proposed to quantitatively evaluate the changes in LRP and megalin expression during adipocyte differentiation, and assess the functional role of these receptors in intracellular lipid accumulation. Supporting data have found that expression of LRP and megalin in differentiating adipocytes is responsive to glucocorticoid- and cAMPdependent signaling pathways. Based on this observation the applicant plans to identify and characterize the cis- and trans-activating elements in the promoters of LRP and megalin that are responsible for regulating their expression levels during adipocyte development. Together, these studies will help 1) better define the functional roles of LRP and megalin in lipoprotein clearance, 2) begin to understand the molecular basis of their tissue-specific expression, and 3) advance our knowledge of cardiovascular health and disease such as atherosclerosis and obesity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CENTRAL OOBESITY SYNDROME IN A SUBSET OF TYPE 1 DIABETES Principal Investigator & Institution: Brunzell, John D.; Prpfessor of Medicine; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-SEP-1976; Project End 31-MAR-2007 Summary: (provided by applicant): Project 2 started as an ancillary study of lipoprotein metabolism to the NIH sponsored clinical trial of intensive diabetes therapy in type 1 diabetics to prevent microvascular disease called the Diabetes Control and Complication Trial (DCCT). The Epidemiology of Diabetes Intervention and Complications (EDIC) is a ten year non-interventional follow-up of DCCT to evaluate the natural history of macrovascular and nephropathy complications in type 1 diabetes. In DCCT, we found that atherogenic small dense LDL were increased with hyperglycemia, microalbuminuria and were increased in that subset of subjects who gained excess
Studies
11
weight as a complication of intensive diabetes therapy during DCCT. Those who gained weight with intensive diabetes therapy were centrally obese, insulin resistant, hypertensive, dyslipidemic and had type 2 diabetic parents. This suggests they had inherited the metabolic-central obesity syndrome in addition to type 1 diabetes. This new proposal will use the phenotypes of 1) excessive weight gain with intensive diabetes therapy and 2) the presence of small dense LDL particles as markers of the central obesity-insulin resistance metabolic syndrome that occurred in this subset of type 1 subjects during intensive diabetes therapy. These markers of the central obesity syndrome will be used to predict the occurrence of cardiovascular events and the development or progression of microalbuminuria during the course of EDIC. Candidate genes for development of the central obesity syndrome and for the interaction of excess weight gain with the development of hypertension will be examined. Intraabdominal fat by CT scan and postheparin plasma hepatic lipase will be measured to further develop the phenotype associated with the excessive weight gain with intensive therapy and with development of nephropathy in the Seattle cohort and three Minnesota cohorts of EDIC. The development of the central obesity syndrome with intensive diabetes therapy in type 1 diabetic patients may predispose them to increased risk of cardiovascular disease and nephropathy. If so, modifications of clinical therapy will need to be made in this subset of individuals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHARACTERIZATION OF A NOVEL LYSOPHOSPHOLIPASE Principal Investigator & Institution: Huang, Ying; Pharmacology; Upstate Medical University Research Administration Syracuse, Ny 13210 Timing: Fiscal Year 2002; Project Start 02-AUG-2002; Project End 31-JUL-2004 Summary: (provided by applicant): Numerous studies have demonstrated that phospholipids and lysophospholipids act as lipid mitogens that affect cell proliferation and survival by altering various cell signaling pathways. Intracellular levels of phospholipids and lysophospholips are tightly regulated by their respective lipases and thus, the expression and activity of these enzymes is critical for cellular homeostasis. We have cloned a cDNA that encodes a novel putative lysophospohlipase. In view of its predicted molecular mass of 34 kDa, we have named it LPL34 (lysophospholipase 34). Our preliminary results indicate that the LPL34 mRNA is highly expressed in normal colon mucosa but absent or reduced in established colon cancer cell lines. Analysis of primary colon tumors and their matching normal tissues also revealed that the expression of LPL34 is absent or reduced in 4/4 tumor tissues. Consistent with these results, expression of exogenous LPL34 in cancer cells lacking endogenous LPL34 results in growth inhibition. We have proposed studies to further examine the role of LPL34 in digestive diseases such as colon cancer. We will analyze a larger pool of fresh-frozen and paraffin-embedded tissue specimens for the expression of LPL34 at both mRNA and protein levels. We will also investigate a correlation between LPL34 status and clinicopathological features. To investigate the molecular basis of LFL34-mediated growth suppression, we will study the effect of LPL34 on PI3-K/Akt and ERKdependent mitogenic and survival signaling pathways. To determine whether lipase activity is critical LPL34-mediated growth suppressive effect, site-directed mutagenesis approach will be used to mutate the conserved lipase motif 'GHSMG' and effects of mutated LPL34 on cell growth and mitogenic signaling pathways will be investigated. These are exploratory /developmental studies that, upon conclusion, will provide us with sufficient new data and reagents that will form the basis of future in-depth studies
12
Lipase
investigating the molecular mechanism(s) of action of this novel lysophospholipase in general and its role in the digestive diseases in particular. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COMMON VARIANTS IN CANDIDATE GENES AND PREMATURE MI RISK Principal Investigator & Institution: Schwartz, Stephen Marc.; Assistant Professor; Epidemiology; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2001; Project Start 15-SEP-1998; Project End 31-AUG-2004 Summary: (Adapted from Investigator's Abstract) Inherited factors play a role in the pathogenesis of myocardial infarction (MI), and there is growing interest in identifying common genetic susceptibility markers that interact with common environmental exposures to contribute to the occurrence of MI in the population. The preliminary data address the contribution of common genetic and environmental factors to the risk of MI among women under 45 years of age. Those data show that common polymorphisms in genes coding for two clotting factors, coagulation Factor V and coagulation Factor II, are risk factors for MI only among cigarette smokers in this sample. These relationships, and others observed, provide strong evidence of gene-environment interactions between thrombotic and atherosclerotic factors in early-onset MI. The plan is to extend this work to investigate the relationship of common putative susceptibility genotypes to the occurrence of early-onset MI in both men and women. One intent is to determine whether the risk of early-onset MI is related to interactions between environmental factors (e.g., cigarette smoking, exercise, alcohol consumption) and common polymorphisms in genes coding for thrombotic factors (coagulation Factor V, coagulation Factor II, plasminogen activator inhibitor-1, and beta-fibrinogen) and atherosclerotic factors (the adhesion molecule E-selectin and metalloproteinase stromelysin-1; the lipid metabolism enzymes paraoxinase, lipoprotein lipase, cholesterol ester transfer protein; and the apolipoproteins apolipoprotein E and apolipoprotein B). Additionally, there are plans to determine whether the risk of early-onset MI is related to interactions between plasma lipoprotein(a) levels (which are largely genetically determined) and environmental risk factors and/or polymorphisms in the candidate genes. Interactions among candidate polymorphisms will also be assessed. Cases will be all 18-49 year old male (n=386) and 18-59 female (n=386) residents of King, Pierce and Snohomish counties, Washington State, newly diagnosed with a first, non-fatal MI during a 3.25 year period. Demographically similar controls (n=772) will be ascertained and recruited through random digit telephone dialing. Cases and controls will be interviewed in person to assess medical and behavioral characteristics related to MI risk. A venous blood sample will be obtained and processed into aliquots of plasma and white cells. DNA extracted from the white cells will be tested using the polymerase chain reaction (PCR), PCR/restriction fragment length polymorphisms (RFLP), and oligonucleotide ligation assays to determine the genotypes of interest. Plasma will be tested for lipid, lipoprotein, and homocysteine concentrations. Analyses will address both the overall association between the genotypes and MI risk, along with posited gene-environment and gene-gene interactions. In addition to providing powerful tests of the Specific Aims, this large study will provide a unique resource for testing future hypotheses regarding the role of common genetic susceptibility factors in the pathogenesis of early-onset MI among both men and women. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
13
Project Title: CORTISOL, CENTRAL OBESITY, AND INSULIN RESISTANCE Principal Investigator & Institution: Purnell, Jonathan Q.; Associate Professor; Medicine; Oregon Health & Science University Portland, or 972393098 Timing: Fiscal Year 2002; Project Start 15-AUG-2000; Project End 31-JUL-2004 Summary: (adapted from the application) Central (visceral) obesity contributes to an excess risk of diabetes, dyslipidemia, hypertension, and premature death from coronary heart disease. A feed-back loop model of weight regulation has emerged from recent studies of animals and humans: afferent hormones signal amount of fat mass to the central nervous system; weight regulation centers in the hypothalamus interpret these signals and control efferent systems including appetite, energy expenditure, and enzymes in the fat cell, such as lipoprotein lipase, that facilitate partitioning of energy into lipid storage. It is proposed in this grant that the hypothalamic-pituitary-adrenal axis is an effector system of hypothalamic weight regulatory centers and that increased cortisol production rates in the obese state directly regulate enzyme transcription in the fat cell to promote lipid uptake and central fat distribution. Cross sectional data from lean and obese humans using stable isotope enrichment determined by mass spectroscopy demonstrate that increases in cortisol production rates across the physiological range are associated with increased adipocyte lipoprotein lipase activity, accumulation of fat mass independent of non-fat mass, increased visceral fat, and increased insulin resistance. These findings, however, do not establish whether increased cortisol production causes, or is simply associated with these variables. To directly test whether cortisol enhances lipid uptake, fat mass accumulation, increased visceral fat mass, and insulin resistance, it is proposed to study the effect of administration of increasing doses of hydrocortisone (including doses within the physiological replacement range) in subjects with complete adrenal failure on these parameters. Finally, leading cellular candidates for the regulation of adipocyte lipoprotein lipase gene expression and fat cell differentiation, including PPAR-gamma and C/EBP, will be measured in adipose samples from the subjects in these studies to provide a mechanistic link between peripheral signaling systems such as cortisol and the adipocyte enzymes involved with fat partitioning. These studies will not only provide insight into the mechanisms of central obesity and its metabolic consequences, they also have great importance to clinicians who care for subjects with adrenal insufficiency as to the consequences of recommended replacement doses of cortisol on risk factors for heart disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ENDOCANNABINOID SITES AS THERAPEUTIC TARGETS Principal Investigator & Institution: Makriyannis, Alexandros; Board of Trustees' Distinguished Profess; None; University of Connecticut Storrs Unit 1133 StorrsMansfield, Ct 06269 Timing: Fiscal Year 2003; Project Start 30-SEP-1994; Project End 31-MAR-2006 Summary: (provided by applicant): Marijuana is the most widespread illegal drug of abuse in Western societies. Its main active ingredient, delta-9-tetrahydrocannabinol, acts by binding to specific membrane receptors called cannabinoid receptors. Activation of these receptors exerts intense effects in humans, suggesting that endogenous cannabinoid (endocannabinoid) substances may contribute in important ways to brain functions such as cognition, mood and pain sensation. Several endocannabinoid substances have been identified, including anandamide and 2-arachidonylglycerol (2AG). Anandamide and 2-AG are released from neuronal and non-neuronal cells and
14
Lipase
activate cannabinoid receptors with high affinity. After release, anandamide and 2-AG undergo a rapid inactivation process, which may play an important role in terminating their biological actions. They may be taken up by cells via high-affinity transport system(s) and then broken down by distinct enzymatic activities: anandamide by fatty acid amide hydrolase (FAAH) and 2-AG by monoacylglycerol lipase (MGL). In initial studies, we have molecularly cloned a cDNA encoding for rat brain MGL and provided evidence that this enzyme may serve an important function in 2-AG inactivation. Based on these results, we propose to develop novel chemical probes that act as substrates or inhibitors for brain MGL. The first aim of the proposed research is to define the structural requirements involved in the recognition and hydrolysis of 2-AG by MGL, and develop a pharmacophore profile for MGL inhibition. In initial experiments we have molecularly cloned a cDNA encoding for rat brain MGL and developed an adenovirus-mediated MGL over-expression system in mammalian HeLa cells. Using this system, we will explore the structure-activity relationships of 2-AG hydrolysis by rat brain MGL. Specifically, we will design and synthesize novel 2-AG analogs and test them for their ability to serve as substrates or inhibitors for MGL and enhance 2-AG signaling in intact cells. The second aim of the proposed research is to develop chemically reactive 2-AG analogs, which may serve as covalent MGL ligands. Covalent, radioactively labeled ligands for MGL may be useful tools in molecular studies of this enzyme. We will design and synthesize potential covalent ligands for MGL based on the structure of 2-AG, and test them for their ability to interact irreversibly with MGL. These studies will set the stage for the elaboration of potent and selective inhibitors that target either 2-AG or anandamide deactivation and may open novel therapeutic avenues for the treatment of neuropsychiatric and substance abuse disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENZYMATIC TOOLS FOR DEGRADING TISSUE AND PRESERVING RNA Principal Investigator & Institution: Latham, Gary J.; Senior Scientist; Ambion, Inc. Austin, Tx 787441832 Timing: Fiscal Year 2002; Project Start 27-SEP-2002; Project End 31-AUG-2003 Summary: (provided by applicant): Intact RNA is an obligate starting material for expression profiling technologies that can link specific molecular events with disease phenotypes. RNA isolations from tissue currently require invasive mechanical force to disrupt the cellular architecture. Such mechanical approaches are tedious and potentially inefficient. They also expose the operator to possible biohazards. As a result, the development of a "closed system" for RNA isolation is needed to enable the highthroughput recovery of RNA from tissues such as biopsies using a safeguarded platform that can process dozens or hundreds of tissues at once. We proposed to achieve this goal through the use of "MELT" (Multi-Enzymatic Liquefaction of Tissue) technology. This technology will harness the degrading power of enzymes that have evolved together as a biological tool set for the decomposition of complex food sources. We refer to this tool set as an "enzyme community." Since some enzyme communities (e.g., the secreted enzymes of bacterial pathogens) mimic the spectrum of activities needed to digest tissue, these collections are an ideal repository for tissue-degrading enzymes. We propose to characterize and blend enzyme activities to create a MELT reagent that can rapidly degrade tissues, "freeze" mRNA expression profiles, and stabilize the RNA for downstream analyses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
15
Project Title: ETIOLOGY OF NEPHROPATHY AND HYPERTENSION IN AASK PATIENT Principal Investigator & Institution: Lipkowitz, Michael S.; Medicine; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2002; Project Start 01-AUG-2000; Project End 31-JUL-2005 Summary: (adapted from the application) We will study the etiology of hypertension and nephropathy in the majority of the 1094 African-American patients in the AfricanAmerican Study of Kidney Disease in Hypertension (AASK). The AASK study is an NIH sponsored clinical multicenter trial comparing the effect of two levels of blood pressure control and three antihypertensive regimens on progression of hypertensive nephropathy in African Americans. There is a disproportionate number of African Americans with hypertensive target organ damage, suggesting a genetic susceptibility in this population; paradoxically, few studies have been performed to evaluate such genetic predisposition to disease in this high risk population. The patients of the AASK study offer a unique opportunity to prospectively determine the genetic factors involved in hypertension and hypertensive target organ damage within a high risk and understudied population. The proposed studies will immortalize white blood cells from patients to provide a renewable source of tissue and DNA from this unique study group, and follow two approaches in assessing the etiology of hypertension, nephropathy, and their sequelae: 1. Studies are proposed to determine whether polymorphisms in candidate genes for hypertension, renal failure, and cardiac disease, including renin-angiotensin system genes, insulin resistance (beta3-adrenergic receptor and lipoprotein lipase) genes, Liddle's syndrome (beta and gammaENaC) genes, and others are related to hypertension or renal failure, severity/rate of progression of renal disease, severity/refractoriness of hypertension, electrocardiographic left ventricular hypertrophy, cardiovascular morbidity and mortality, and overall morbidity and mortality. 2. Additional studies will employ a new technique, mapping by admixture linkage disequilibrium (MALD), which uses the linkage disequilibrium caused by recent admixture of founder populations to localize genes linked to a particular phenotype within a 5-20 centiMorgan region in a genome-wide screen. By utilizing microsatellite markers from the carefully phenotyped patients of the AASK Study it should be possible to identify regions of interest containing genes associated with hypertension, renal failure, and the outcomes described above for candidate genes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EVASION OF NADPH OXIDASE BY SALMONELLA LIPASES Principal Investigator & Institution: Mccollister, Bruce D.; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2004; Project Start 01-JUL-2004; Project End 31-MAR-2009 Summary: (provided by applicant): The ability of Salmonella to survive within professional phagocytes is paramount to its pathogenicity, as strains incapable of survival in mononuclear phagocytes are severely attenuated in mice. Survival of Salmonella within phagocytes is tightly associated with its ability to halt maturation of the phagosome along the endocytic pathway. We have recently discovered that Salmonella pathogenicity island 2 (SPI2)-encoded effector proteins remodel the phagosome by interfering with the TNFalpha/TNFRp55 signaling cascade that directs delivery ofNADPH oxidase-containing vesicles to the vicinity of the Salmonella phagosome. I plan to test the hypothesis that, by cleaving glucosylceramide, glucosylceramidase interferes with TNFRp55 signaling and blocks migration of NADPH
16
Lipase
oxidase-harboring vesicles to the vicinity of the Salmonella phagosome. The specific aims are: 1) To determine the role of glucosylceramidase in the pathogenesis of Salmonella infections. Glucosylceramidase mutants will be constructed to examine the effect on both survival of Salmonella in macrophages and inhibition NADPH oxidase trafficking. 2) To examine the effect of Salmonella-encoded glucosylceramidase on macrophage lipid metabolism. Wildtype and glucosylceramidase-deficient Salmonella will be used to infect macrophages to assess global changes in the sphingomyelin pathway. Purified glucosylceramidase will be tested for lipid metabolizing activity, and immunocytochemistry will be used to visualize the effect of glycosylceramidase on trafficking of NADPH oxidase-containing vesicles. 3) To determine the role of glucosylceramidase on avoiding IFN( activated trafficking of NADPH oxidase. In this section, I will elucidate the mechanisms by which IFN\gamma stimulates antiSalmonella activity dependent upon the NADPH oxidase. The ability of IFNgamma to stimulate glucosylceramide synthesis will be examined as well. These studies will not only enhance our understanding of Salmonella pathogenesis but will also identify potential targets for the development of new therapeutic strategies against intracellular pathogens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MENOPAUSE
EXCERCISE
AND
REGIONAL
FAT
METABOLISM
AFTER
Principal Investigator & Institution: Nicklas, Barbara J.; Associate Professor; Internal Medicine; Wake Forest University Health Sciences Winston-Salem, Nc 27157 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant) Aerobic exercise (AEX) intensity may be an important factor affecting the selective loss of abdominal fat when combined with a hypocaloric diet (DIET). The goal of this study is to determine the cellular mechanisms by which AEX intensity affects the loss of abdominal (both subcutaneous and visceral) adipose tissue under conditions of equal energy deficit in postmenopausal women with abdominal obesity. The hypothesis is that, compared to DIET alone or DIET with lowintensity AEX, DIET with high-intensity AEX will augment the loss of abdominal fat and improvements in metabolic cardiovascular disease (CVD) risk factors due to greater reductions in lipoprotein lipase (LPL) activity, and to greater increases in lipolysis, in abdominal, relative to gluteal, adipose tissue. The specific aims are: 1) to determine the cellular mechanisms by which DIET alone, or DIET combined with low- or highintensity AEX, affects region-specific fat loss by measuring changes in abdominal and gluteal adipose tissue LPL activity and lipolysis in postmenopausal women with abdominal obesity; and 2) to determine the effects of DIET alone, or DIET combined with low- or high-intensity AEX on lipoprotein lipids, glucose tolerance, and insulin levels in these women. We also will measure messenger ribonucleic acid (mRNA) levels of genes that may be involved in the regulation of regional fat storage to begin to determine how DIET with and without AEX of different intensities affects gene expression to alter body fat distribution. Body composition and fat distribution (DXA and computed tomography), LPL activity, lipolysis, mRNA expression of genes from gluteal and abdominal adipose tissue, and lipoprotein lipids and glucose tolerance will be measured before and after six months of DIET with high-intensity AEX, DIET with low-intensity AEX, or DIET alone in 120 (40 per treatment group) overweight (BMI=2535 kg/m2), postmenopausal women with abdominal obesity (waist circumference greater than 88 cm). The degree of caloric restriction during DIET will be adjusted so that total caloric deficit (about 2800 kcals/wk) will be similar between treatments. Both
Studies
17
AEX groups will expend 400 kcal/wk in exercise energy expenditure and will reduce dietary intake by about 2400 kcal/wk (about 340 kcal/day). Identification of the mechanisms by which DIET with and without AEX of different intensities affects regional uptake and mobilization of triglyceride to alter body fat distribution will have important clinical implications for the development of the most effective treatment to promote the preferential loss of abdominal fat and improve CVD metabolic risk factors in older women with abdominal obesity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXTRACELLULAR REGULATION OF LIPOPROTEIN LIPASE ACTIVITY Principal Investigator & Institution: Goldberg, Ira J.; Professor of Medicine; Medicine; Columbia University Health Sciences Po Box 49 New York, Ny 10032 Timing: Fiscal Year 2002; Project Start 01-APR-1991; Project End 31-MAR-2005 Summary: Lipoprotein lipase (LpL) is the principal enzyme responsible for hydrolysis of triglyceride in circulating lipoproteins. Changes in LpL activity are a basic mechanism used to modulate uptake of free fatty acids and perhaps fat-soluble vitamins by tissues. Regulation of LpL involves a number of post-secretory processes. By investigating these processes basic biological insights into the interaction of proteins with heparan sulfate proteoglycans (HSPGs) have been obtained. In this renewal, a series of experiments are proposed to understand how LpL is transferred from its sites of synthesis, principally adipocytes and myocytes, to the luminal surface of endothelial cells. Aim 1 is to determine the pathways required for LPL transport across endothelial cell monolayers. We have observed that LpL transcytosis across endothelial monolayers is reduced by RAP, the 39 kDa inhibitor of the LDL receptor related protein and other receptors in this family. In this Aim we will assess the role of these receptors and HSPGs in the transcytosis of normal and mutant LpL. The importance of this pathway and the association of LpL with proteoglycans will also be studied in vivo. Aim 2 proposes to study how LPL interaction with HSPGs regulates HSPG binding. Using these mice and new mice expressing a tethered dimer of mutated LpL, the importance of LpL-HSPG interactions will be studied. Aim 3 will study how the VLDL receptor and other RAPsensitive receptor, and LpL monomizerization participate in the physiological regulation of LPL actions. We will assess the importance of LpL transcytosis pathways in wildtype and heterozygous LpL transcytosis pathways in wild type and heterozygous LpL knockout mice, the role of RAP-sensitive receptors in regulation of LpL activity with feeding/fasting, and modulation of tissue LpL in mice that cannot covert dimeric LpL to inactive monomers. These experiments will provide information about how a secreted protein transfers from the subendothelial space into the bloodstream and the importance of protein dimerization and HSPG binding in this process. Moreover by understanding the regulation of LpL activity, these investigations will may means to change human caloric and vitamin disposal; processes that are often abnormal in humans with lipoprotein disorders and diabetes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EYE IN GRAVES DISEASE--ROLE OF ORBITAL FIBROBLASTS Principal Investigator & Institution: Bahn, Rebecca S.; Professor; Mayo Clinic Coll of Medicine, Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2002; Project Start 01-AUG-1991; Project End 31-JUL-2004
18
Lipase
Summary: Graves' ophthalmopathy (GO) is an autoimmune eye disorder closed associated with Graves' hyperthyroidsim. There is convincing experimental evidence that the orbital fibroblast (including the preadipocyte fibroblast subpopulation) is the target cell in GO. However, the autoantigen against which the immune response is directed is unknown. The thyrotropin receptor (TSHr) is a prime candidate to be the orbital autoantigen because its involvement would help to explain the close clinical and laboratory associations between GO and hyperthyroidism. In recent studies, the PI has demonstrated the present of TSHr mRNA and protein in orbital adipose/connective tissues from patients with GO, wile TSHr expression was not apparent in normal orbital tissues. In addition, she showed that orbital preadipocyte fibroblasts, cells lacking fucntional TSHr, can be differentiated in vitro into mature TSHr-bearing adipocytes. These and other findings led to hypothesize that: 1)expression of TSHr in the orbit in GO is linked to the induction of adipogenesis in orbital preadipocyte fibroblasts, and that; 2) the adipocyte TSHr is the orbital autoantigen recognized by orbital-infiltrating lymphocytes in GO. The PI plans to examine these hypotheses using our system of cultured orbital preadipocyte fibroblasts derived from pateints with GO. In specific aim I, she will define the fibroblast-like cells present in the orbit in GO and identify factors that modulate adipogenesis in these cells. Experiments in Aim II are designed to characterize the obital TSHr and to clarify the link between TSHr expression and adipogenesis in the orbi. In Aim III, she will determine whether cloned orbitalinfiltrating lymphocytes from patients with GO recognize TSHr, or other antigens that are processed "naturally" by autologous antigen-presenting cells. The main goal of the research program is to increase understanding of the orbital immune response in GO in order that novel and more specific therapeutic and preventive strategies for this condition might be developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FATTY PRODUCTION
ACID
REGULATION
OF
LIVER
LIPOPROTEIN
Principal Investigator & Institution: Ginsberg, Henry N.; Professor; Medicine; Columbia University Health Sciences Po Box 49 New York, Ny 10032 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: (provided by applicant): Lipotoxicity involves the excess delivery of fatty acids (FA) to sites other than adipose tissue. In vivo, fatty acids (FA) can arrive at the liver bound to albumin or as components of TG (TG)-enriched remnant lipoproteins (chylomicron and VLDL). In the latter instances, FA can be liberated from remnants by the action of hepatic lipase bound to capillaries in the hepatic vascular bed or released from lysosomes after receptor-mediated internalization of remnant lipoproteins. In addition to exogenously derived FA, increased availability of FA may result form their synthesis in the liver from acetylCoA via lipogenesis. The latter pathway has been linked recently to insulin resistance and hyperinsulinemia. The liver is unique in that it is able to "unload" excess FA in bulk form by assembling and secreting apoBlipoproteins. There are few data, however, concerning the effects of FA from each of the sources described above on the two-step process of apoB-lipoprotein assembly: the first step involves the targeting of nascent apoB across the ER membrane and assembly of a lipid-poor primordial lipoprotein, while the second step involves the bulk addition of core lipid to the primordial particle and the formation of the mature TG-rich apoBlipoprotein. Importantly, it is not known if each of the pathways involved in providing increased FA within the hepatocyte impacts equally on FA synthesis and oxidation, genes involved in TG synthesis, or genes involved in the assembly and secretion of
Studies
19
apoB-lipoproteins. The link between insulin resistance/hyperinsulinemia and increased VLDL secretion is also incompletely defined. In particular, the relative importance of hepatic lipogenesis versus plasma FA uptake by the liver in the increased apoBlipoprotein secretion observed in insulin resistant animal models and humans has not been studied. The experiments proposed in this project are directed at unanswered questions related to FA regulation of apoB-lipoprotein assembly and secretion, including: (1) the effects of plasma albumin-delivered FA on each of the steps in apoBlipoprotein assembly and the expression of genes involved in maintaining hepatic lipid homeostasis; (2) the effects TG-rich remnant-like particle-delivered FA on apoBlipoprotein assembly and gene expression; and (3) the relative importance of insulin resistance/hyperinsulinemia versus increased plasma FA availability in the reaulation of apoB-lipoprotein assemblv and secretion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MUTATIONS
FUNCTIONAL
CHARACTERIZATION-LIPOPROTEIN
LIPASE
Principal Investigator & Institution: Kamboh, M Ilyas.; Professor; Human Genetics; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2003; Project Start 24-JAN-2003; Project End 31-DEC-2006 Summary: (provided by applicant): Lipoprotein lipase (LPL) enzyme plays a pivitol role in lipid metabolism by hydrolyzing triglyceride (TG) rich lipoprotein particles. Many diseases, including coronary heart disease (CHD), atherosclerosis and obesity seem to be directly or indirectly related to abnormalities in LPL function. A Hind lll polymorphism in intron 8 of the LPL gene has been shown to be associated with plasma TG and HDLcholesterol levels and with the risk of CHD. However, the biological mechanism behind this association is unknown. Previous studies have suggested that the intron 8 sequence, which encompasses the Hind lll site as well as intron 9 and non-coding exon 10 of the LPL gene, contain regulatory elements important for LPL transcription and translation. In this proposal we will determine if the nucleotide change in intron 8 by itself is responsible for the effect by disrupting an intronic enhancer element (Aim 1) and what is the role of the 3' region (intron 8, intron 9, exon 10) in regulating LPL transcription (Aim 2). In addition, we have identified a putative insulin response element (IRE) in non-coding exon 10 of the human LPL gene following sequence comparison of LPL genes from various species. The putative IRE sequence was targeted for mutation detection and we identified a 5 bp deletion mutation. We propose to characterize this new mutation further by performing functional and molecular studies (Aim 3). The proposed molecular and functional studies will characterize the functional significance of the LPL Hind lll and exon 10 mutations and may lead to identification and characterization of LPL regulatory elements in intragenic and 3 untranslated region of the gene. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONS OF LIPOPROTEIN RECEPTORS IN ALZHEIMER DISEASE Principal Investigator & Institution: Rebeck, G. William.; Assistant Professor; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2002; Project Start 05-AUG-1996; Project End 31-DEC-2002 Summary: (provided by the applicant): This application is a competing renewal of an R29 grant, "ApoE and its receptors in normal and Alzheimer's brain." ApoE
20
Lipase
(apolipoprotein E) remains the best-defined genetic risk factor for late onset Alzheimer disease (AD). ApoE is involved in cholesterol transport and, in AD, is associated with Abeta deposits. A number of in vitro and invivo studies have shown that apoE binds to the Abeta peptide, and affects both its clearance and its aggregation. ApoE is cleared by a family of cell surface receptors, members of the low-density lipoprotein (LDL) receptor family. We found expression of these receptors in subsets of cells in the CNS, focusing our attention primarily on the LDL receptor related protein, LRP. Polymorphisms in LRP may also affect the risk of AD, and in vitro, LRP can promote endocytosis of Abeta complexed to LRP ligands. In this proposal, we will continue to focus on endocytosis of apoE and Abeta via this family of receptors, but we will also expand our studies to look at other members of the LDL receptor family, including the VLDL receptor and apoE receptor 2. In addition, we will address newly identified functions of these receptors as signal transduction molecules. For example, in response to ligand binding, these receptors have been shown to affect calcium influx, protein phosphorylation, and glial activation. We propose that the deposition of apoE and related molecules on Abeta deposits in the AD brain affects the function of surrounding neurons and glia via these receptors. These ligand-receptor interactions could help explain the connection between amyloid deposits and formation of phospho-tau positive neurites in the AD brain. Aim 1. We hypothesize that clearance of apoE and lipoprotein-associated molecules interact with the VLDL receptor and apoEr2. A) We will test whether apoE isoforms, apolipoprotein J (apoJ) and lipoprotein lipase (LPL) are cleared by the VLDL receptor or apoEr2. B) We will test whether these receptors, present on microglia and neurons, act as clearance mechanisms for Abeta. C) We will measure the presence of apoJ and LPL in the AD brain, testing whether either affects the processes of amyloid deposition and dystrophic neurite formation. D) We will determine if polymorphisms in these genes may also affect the risk of AD. Aim 2. We hypothesize that the signaling functions of apoEr2 and the VLDL receptor cause neuronal dysfunction seen in AD. A) We will test whether these receptors interact with several hypothesized signal transduction molecules (including disabled) invivo. B) We will test whether these molecules are important for calcium influx and neurite outgrowth in neurons and activation of glia. C) We will test whether these molecules are involved in the phosphorylation of tau observed in neurofibrillary tangles of AD brains. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENERAL CLINICAL RESEARCH CENTER Principal Investigator & Institution: Pak, Charles Yc.; Professor of Internal Medicine; Internal Medicine; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 01-DEC-1978; Project End 30-NOV-2003 Summary: The overall goal of the General Clinical Research Center (GCRC) at Dallas is to provide an optimal environment for patient-oriented investigation which leads to an improved understanding of the disease process, allows better methods of diagnosis and treatment, foster interdisciplinary collaboration, and offers training in clinical investigation. Major activities of the GCRC include; to study efficacy and safety of adding a bisphosphonate to sustained-release sodium fluoride (Neosten) and to evaluate a new formulation of sustained-release sodium fluoride combined with calcium citrate (Caflor) for postmenopausal osteoporosis; to utilize newer techniques for assessment of bone quality in osteoporosis such as nuclear magnetic resonance (NMR) microscopy, critical angle reflection ultrasound and strut analysis; determination of the pathophysiology, particularly relate to insulin resistance in gouty diathesis (renal stone formation associated with gout), its molecular genetic basis and the effects of improving
Studies
21
insulin sensitivity in reversing the biochemical defects; elucidation of the genetic basis of low levels of high density lipoprotein (HDL) as related to the polymorphisms in hepatic lipase gene; characterization of phenotype and metabolic abnormalities, and elucidation of genetic defects in patients with congenital generalized and familial partial lipodystrophies; to study efficacy and safety of adding methotrexate therapy to ursodeoxycholic acid for therapy of primary billiary cirrhosis in a randomized, blinded, placebo-controlled trial; comparison of innovative and conventional treatments for management of or develop surrogate biologic markers predicting predisposition to specific skin diseases and response to therapy; to study neural mechanisms of obesityrelated hypertension in African-Americans utilizing microelectrode recordings of postganglionic sympathetic nerve activity; and development of new and reliable techniques to assess renal functions and to perform safety and dose-ranging studies of alpha- melanocyte stimulating hormone (MSH) for subsequent clinical trials of alphaMSH to treat or prevent acute renal failure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENES CAUSING SPONTANEOUS OBESITY Principal Investigator & Institution: Warden, Craig H.; Associate Professor; Pediatrics; University of California Davis Sponsored Programs, 118 Everson Hall Davis, Ca 956165200 Timing: Fiscal Year 2002; Project Start 01-JUN-1998; Project End 31-MAY-2003 Summary: The long-term goal of this research is to investigate the mechanisms of spontaneous obesity in mice. Previous work has identified 4 chromosomal regions (mouse chr. 6,7,12,and 15) or loci (QTLs) that contribute to obesity in spontaneously obese BSB mice. BSB mice were produced by a backcross of (Mus spretus x C57BL/6J) F1 x B6. Preliminary data on an available congenic mouse strains confirm that the locus on chr. 7 affects adiposity. The objective of this present proposal is to identify the genes underlying these obesity loci. Congenic mouse strains carrying the spretus chromosomal regions as donor DNA on the B6 background will be created. As co-incident QTLs for obesity, plasma cholesterol and hepatic lipase (HL) activity on mouse chr. 7 were found, the already constructed B6 HL knockout will used to test the hypothesis that alterations of HL activity determine these cholesterol and/obesity loci. BSB backcrosses with the HL KO B6 mouse will yield animals both homozygous and heterozygous for the HL knock-out. QTLs at chromosome 7; will be compared and contrasted in these two groups. The mouse chr. 6,7, and 1 loci include within their 90 percent confidence intervals, respectively, the obese, tubby, and uncoupling protein 2-genes. Molecular and biochemical studies of these candidate genes will be performed to test whether differences are likely to explain the observed effect on the trait. If there are differences in the coding portion of the spretus and B6 leptin, then the biological consequence of the differences will be tested. The chromosome 6 locus was linked to just one of the four fat pads measured in BSB mice. Leptin mRNA levels in the four fat pads will be determined to examine their correlations with plasma leptin and fat pad sizes. They have already found that spretus and B6 UCP2 differ for 2 amino acids, so uncoupling activity of UCP2 from these strains will be examined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC DETERMINANTS OF PLASMA LIPOPROTEINS Principal Investigator & Institution: Cohen, Jonathan C.; Associate Professor of Internal Medicin; Internal Medicine; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105
22
Lipase
Timing: Fiscal Year 2002; Project Start 30-SEP-1994; Project End 31-AUG-2004 Summary: Hepatic lipase is a 476 amino acid glycoprotein that catalyzes phospholipid and triglyceride hydrolysis in circulating lipoproteins. Hepatic lipase activity varies widely among individuals, and this variation has been associated with inter-individual differences in the plasma concentrations of high density lipoproteins (HDL), particularly the HDL2 subfraction, the rates of low density lipoprotein (LDL) synthesis and catabolism, and in the size distribution of LDL. Preliminary data from our laboratory suggest that ethnic differences in hepatic lipase activity may also be responsible for the well known differences in plasma HDL concentrations between African American and white American men. Since these studies are based on correlations between phenotypes, however, they are subject to confounding by secondary factors such as obesity and plasma triglyceride concentrations that may have independent effects on hepatic lipase activity and lipoprotein metabolism. Therefore it is difficult to infer from these studies whether or not the relationship between hepatic lipase activity and plasma lipoprotein concentrations is causal. Thus a key question that remains unanswered by these studies is "does primary variation in hepatic lipase activity cause variation in plasma lipoprotein metabolism in humans?" A second question that remains unanswered is what causes the wide variation in hepatic lipase activity observed in otherwise healthy individuals? These two questions provide the focus of this competing continuation. In the first two Specific Aims, we will compare individuals with genetically defined hepatic lipase activities to determine: i) whether genetic variation in hepatic lipase activity accounts for the well known differences in plasma HDL-C concentrations between African American and white men, and ii) whether primary differences in hepatic lipase activity cause differences in plasma lipoproteins. In the third Specific Aim, we will determine whether genetic polymoprhism in hepatic lipase contributes to the very high hepatic lipase activities commonly seen in white Men. These studies will help to determine the role of variation in hepatic lipase activity in determining plasma HDL concentrations, and LDL size distribution, two important risk factors for coronary artery disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETICS AND REGULATION OF HEPATIC LIPASE Principal Investigator & Institution: Deeb, Samir; Research Professor; Medicine; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 30-SEP-1999; Project End 31-AUG-2006 Summary: (provided by applicant): The long-term goals of this proposal are to define mechanisms of regulation of hepatic lipase (HL) levels in humans and to determine how genetic variation at the HL gene locus modulates these levels under a variety of physiological and pathological states. HL plays a key role in lipoprotein metabolism by catalyzing the hydrolysis of triglycerides and phospholipids. A high level of HL is associated with two important metabolic risk factors for atherosclerosis: diminished concentrations of plasma high density lipoprotein cholesterol (HDLC) and an increased prevalence of small, dense low density lipoprotein (LDL) particles. Various studies, including those of our group, have shown that a significant proportion (20-25%) of the variability in HL activity is explained by a common genetic variation in the regulatory sequences of the HL gene, and that ethnic/racial background, gender and intraabdominal fat accumulation are other important modulating factors. The underlying hypotheses of this proposal are: first, that additional variants in the HL gene are responsible for variation in HL activity and the associated lipoprotein profiles in different ethnic/racial groups. Second, that high hepatic lipase activity is a risk for the
Studies
23
development of cardiovascular disease. Third, that transcription factors whose activity is modulated by ligands would be excellent targets for drug design. Fourth, that HL activity is modulated by the commonly used drugs that modulated lipids. Our preliminary results support these hypotheses. The specific aims are to: 1) Identify a small set of genetic markers that would predict levels of HL activity and the associated lipoprotein phenotypes. 2) Define all hepatic lipase gene variants that are associated with risk for cardiovascular disease. 3) Identify and characterize transcription factors that regulate hepatic lipase gene expression. 4) Determine in human subjects the impact of perturbation of lipid metabolism and insulin resistance on HL activity. The results of these studies will provide insights into the metabolic and molecular bases of interindividual variation in HL activity and the associated plasma lipoprotein profiles. Key transcription factors that regulate HL activity could serve as targets for novel pharmaceutical for inducing a favorable lipoprotein profile. The genetic markers would be valuable in predicting cardiovascular risk as well as response to therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESISTANCE
GENETICS
OF
ATHEROSCLEROSIS--ROLE
OF
INSULIN
Principal Investigator & Institution: Hsueh, Willa A.; Professor of Medicine and Chief; Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-AUG-1999; Project End 31-JUL-2004 Summary: The theme of this investigation is the hypothesis that insulin resistance (IR), hyperinsulinemia and a subset of components of the IR syndrome promote changes in the vasculature leading to atherosclerosis, and that there are common genes linking these factors and coronary artery disease (CAD). We have developed a multidisciplinary approach incorporating gene mapping in animals and in man with human and animal physiologic analyses that involve extensive phenotyping of traits related to IR and atherosclerosis to test this hypothesis, Because of their family structure and the high prevalence of IR, Mexican American (MA) families with CAD represent an ideal ethnic group in which to identify genes linking to both IR and CAD and to determine the critical physiologic relationships of IR and hyperinsulinemia and its associated metabolic changes to vascular structural alterations leading to atherosclerosis. Exciting preliminary data in MA families supports both our hypothesis and the overall feasibility of completing the goals outlined in this grant application. Three experienced teams of senior research investigators and three supportive cores constitute a highly focused, collaborative, integrated investigation that features expertly designed and performed phenotyping; innovative methods of mathematical genetic analysis pioneered and successfully applied by members of our team; state of the art genetic mapping technology through the newly created UCLA Human Genetics Department; and physiologic investigation of the role of hyperinsulinemia and IR in atherosclerosis through novel mechanisms leading to vascular damage including the role of paraoxonase, hepatic lipase and alterations in lipid turnover, as well as lipid oxidation. An important theme of this program project is gene->cell->tissue->animal- >human>gene translation. The combination of detailed human and animal phenotyping, comprehensive genetic mapping, novel tissue investigations and lipid turnover studies outlined herein provides a powerful, multi- dimensional approach to identify genes and pathophysiologic mechanisms linked to atherosclerosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
24
•
Lipase
Project Title: TREATMENTS
GENHAT-GENETICS
OF
HYPERTENSION
ASSOCIATED
Principal Investigator & Institution: Arnett, Donna K.; Associate Professor; Epidemiology; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 01-SEP-1999; Project End 31-AUG-2004 Summary: The Genetics of Hypertension Associated Treatments (GenHAT) is proposed as a prospective study to examine whether the association between selected hypertensive genes and combined fatal coronary heart disease and nonfatal myocardial infarction in high-risk hypertensives is modified by the type of antihypertensive treatment, leading to differential risks of coronary heart disease (CHD). Such genetreatment interactions might shed important light On the variation in patient response to antihypertensive agents, and improve our ability to pick the right antihypertensive for specific patients. GenHAT will be an ancillary study to ALLHAT (the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). ALLHAT recruited 42,515 hypertensives and randomized them to one of four antihypertensive agents (lisinopril, chlorthalidone, amlodipine, and doxazosin); followup will be completed in March, 2002. GenHAT will characterize hypertension genetic variants and determine their interaction with antihypertensive treatments in relation to CHD. DNA from frozen clots stored at the ALLHAT Central Laboratory will be used to genotype variants of hypertension genes (angiotensinogen -6, angiotensin converting enzyme insertion/deletion, angiotensin type- 1 receptor, alpha-adducin, beta2 adrenergic receptor, lipoprotein lipase, and 10 new hypertension variants expected to be discovered during the course of the study). In addition to the primary aim, a number of secondary aims will be undertaken to evaluate gene- treatment interactions in relation to other endpoints, including all-cause mortality, stroke, heart failure, left ventricular hypertrophy, decreased renal function, peripheral arterial disease, and blood pressure lowering. Because of the ethnic and gender diversity of ALLHAT, we will also assess effects of these variants on outcomes in key subgroups (age >65 years, women, African Americans, Type II diabetics), and whether the gene-treatment interactions in relation to outcomes are consistent across subgroups. This proposal has the advantages of (1) incorporation into an already funded clinical trial, and (2) collaboration with experienced investigators in genetic analysis (Drs. Boerwinkle and Eckfeldt) and clinical trials (Drs. Davis and Ford). It will, therefore, provide an important and cost-efficient contribution to the knowledge and understanding of the treatment of hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HDL GENE DISCOVERY--GENOME WIDE EXPRESSION SCREENS Principal Investigator & Institution: Rubin, Edward M.; Director, Joint Genome Institute; Division of Life Sciences; University of Calif-Lawrenc Berkeley Lab Lawrence Berkeley National Laboratory Berkeley, Ca 94720 Timing: Fiscal Year 2002; Project Start 05-FEB-2000; Project End 31-JAN-2004 Summary: Based on the incompleteness of our understanding of High Density Lipoprotein (HDL) metabolism the focus of this proposal is the identification of new genes involved in the metabolism of this lipoprotein through genome-wide expression screens. Mouse cDNA arrays containing >5000 mouse genes will be used to identify genes whose expression is altered in the liver and adrenals of several transgenic and knockout lines of mice chosen based on their characterized abnormalities in HDL metabolism. This will initially include transgenic and knockout mice for apolipoprotein
Studies
25
A-I (apo A-I), Scavenger Receptor class b1 (sr- bi), Hepatic lipase (HL), and Lecithin Cholesterol Acyl Transferase (LCAT). A basic assumption in these studies is that alterations in the expression of genes known to be involved in HDL metabolism will affect the expression of other genes also participating in the metabolism of this lipoprotein. The novel genes identified from these studies will be prioritized for further biological characterization based on a variety of parameters including: level of expression change, clustering of expression patterns between mice of different HDL mutant genotypes, and sequence or expression pattern similarities to other genes known to participate in lipoprotein metabolism. The function of a limited number of novel "HDL candidate" genes (approximately 10) will be assessed each year through their over-expression in transgenic mice coupled with careful analysis of the consequence of transgene over-expression over-expression on lipoprotein metabolism. In these studies we will be utilizing a combination of new technologies and previously developed experimental substrates to address the fundamental question of what genes are directly or indirectly involved in the metabolism of HDL in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HDL PHOSPHOLIPASES
METABOLISM
INFLUENCE
OF
EXTRACELLULAR
Principal Investigator & Institution: Rader, Daniel J.; Director, Preventive Cardiology; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2004; Project Start 01-MAR-1996; Project End 31-MAR-2009 Summary: (provided by applicant): Plasma levels of high-density lipoprotein (HDL) cholesterol and its major HDL apolipoprotein, apoA-I, are inversely associated with atherosclerotic cardiovascular disease. Plasma HDL cholesterol and apoA-I levels are determined in part by the rate at which they are catabolized, but the mechanisms that modulate their catabolism in vivo remain incompletely understood. Both acute inflammatory states, such as sepsis, and chronic inflammatory states, such as the metabolic syndrome, are associated with low levels of HDL cholesterol and apoA-I, primarily due to increased catabolism. A major underlying hypothesis of this project has been that extracellular phospholipases are upregulated in response to inflammation and modulate systemic HDL metabolism through hydrolysis of HDL phospholipids. We cloned and characterized a new member of the lipase gene family that we termed endothelial lipase (EL). In the current cycle of this project, we have demonstrated that overexpression of EL in mice causes markedly reduced HDL due to increased catabolism, and antibody inhibition of EL in mice causes increased HDL due to reduced catabolism. In this competing renewal proposal, we will focus our efforts on EL toward achieving a greater understanding of its structure-function relationships, metabolic interactions with other genes that influence HDL, association with atherosclerosis, and its relationship to human physiology and pathophysiology. Specific Aim 1: To investigate the differences between EL and its highly homologous relatives LPL and HL with regard to the molecular basis of the lipid and lipoprotein preferences of EL compared with LPL and HL. Specific Aim 2: To test the hypothesis that in the liver, EL interacts with HL and SR-BI to influence HDL metabolism, selective uptake of cholesterol, and reverse cholesterol transport. Specific Aim 3: To determine the effects of chronic hepatic-specific EL expression on atherogenesis in mice. To compare these results with the effects of endothelial-specific EL expression on atherosclerosis. To test the hypotheses that endothelial EL expression influences endothelial physiology. Specific Aim 4: To test the hypothesis that EL is increased in inflammatory conditions in humans and may contribute to the reduced HDL-C levels associated with these
26
Lipase
conditions. A recent editorial stated: "Perhaps the most important questions concerning endothelial lipase are: a) does it play an important role in HDL metabolism in humans, and b) does it play a significant role in atherogenesis?" This proposal addresses both of these issues and also addresses key structure-function questions and potential genegene interactions with regard to EL and its effects on HDL metabolism. The results of these studies should provide important new insight into the role of EL in HDL metabolism and atherogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEPATIC METABOLISM OF DIET DERIVED LIPOPROTIENS Principal Investigator & Institution: Cooper, Allen D.; Professor; Palo Alto Medical Foundation Res Inst 795 El Camino Real Palo Alto, Ca 94301 Timing: Fiscal Year 2002; Project Start 01-JUL-1986; Project End 30-NOV-2003 Summary: The overall objective is to understand how chylomicron remnants contribute to atherosclerosis. The goal of the current proposal is to elucidate the mechanisms of the hepatic removal of these particles. Remnants accumulate in the blood during the postprandial period implying that there are times when their removal becomes limiting. The hypothesis to be tested is that the initial rate of chylomicron remnant removal is determined by the number of LDL receptors, and the capacity of the liver to sequester the particles before internalizing them (sequestration space). The size of the sequestration space is defined by heparan-sulfate-proteoglycans, and the affinity of the space for remnants is modified by the presence of hepatic lipase. The steady state rate of removal is determined by transfer from sequestration to LDL receptors and the LRP. The latter, is determined in part, by co-factors, particularly hepatic apoE. Three specific aims are proposed. First, to complete studies utilizing the isolated perfused mouse liver to characterize the remnant removal process. Isolated mouse liver perfusion was validated as a technique for studying remnant removal. Data demonstrates that both the LDL receptor and the LRP are saturable components of this process, and that there may be an additional mechanism for removal; apoE is absolutely required for rapid remnant removal, but the hepatic secretion of apoE is required for only one component of the process. Mice deficient in LDL receptors and the LRP, as well as apoE, will be utilized to complete these studies. Second, methodologies will be developed to determine the size of the sequestration space and the rate of egress from this space. The use of confocal microscopy with fluorescent labeled remnants and fluorescent markers for both endothelial cells and hepatocytes will allow determination of where remnants are accumulating, what fraction of the accumulated remnants are in the space of Disse, and the rate at which they leave this space. A multi-compartment model for analysis of the isotope removal data is being developed to determine the affinities and capacities of the components of the removal process. Using the animals of the third specific aim, this will identify which molecules contribute to these components. As a back up strategy, cell separation techniques can be used to accomplish the goals of the first two methods. The third specific aim will examine the nature of the determinants of the process. Mice that express varying fixed levels of LDL receptors will be used to study the role of this molecule in initial removal, as well as egress from sequestration. A similar strategy will be utilized for the LRP by creating truncated but functional, LRP-like molecule. Mice with different isoforms of apoE will be studied to evaluate how this affects its function as a co- factor, and as a portion of the capture mechanism. This group of studies will also evaluate the role of LPL in remnant removal in the liver. In the last group, the amount, location and enzymatic activity of hepatic lipase in the liver will be varied, to learn whether it serves as a co-factor for the LRP, or whether it serves as a determinant
Studies
27
for the sequestration space, or both. In addition, attempts will be made to vary the syndecan content of the liver to test the role of this HSPG as a major determinant of the sequestration space. Together, it is anticipated that these studies will provide a concrete model for remnant removal, as well as identify the key elements in this mechanism, at which therapeutic intervention might be directed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIGH-DENSITY LIPOPROTEIN SPECIES--STRUCTURES AND ROLES Principal Investigator & Institution: Kane, John P.; Cardiovascular Research Inst; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002; Project Start 01-JUL-1984; Project End 31-AUG-2006 Summary: (Provided by applicant): This project is directed at understanding the native molecular speciation of high density lipoproteins, the functional roles of individual HDL species, and the processes by which they are generated and catabolized. It also includes study of the influence of mutations and polymorphisms in key genes involved in HDL metabolism with the objective of identifying genomic determinants of HDL speciation and the genetic basis of HDL deficiency disorders. Specific Aims: 1) To complete the isolation and characterization of the native molecular species of human HDL using selected affinity immunosorption. The stoichiometry of constituent proteins and lipids in those species will be established by immunochemical methods and mass spectroscopic analysis. 2) To continue to isolate novel proteins from human HDL and elucidate their gene structures. Candidates are proteins discovered by mass spectroscopic analysis that are not present in sequence databases. 3) To characterize the HDL species that are substrates and products of SR-Bl, -hepatic lipase (HL), phospholipid transfer protein (PLTP), and - mediated reactions. 4) To develop methods for quantitative measurement of individual HDL species in plasma. 5) To study the composition and distribution of plasma HDL species of HDL deficient subjects. 6) To determine the impact of mutations andpolymorphisms in the HL, PLTP, SR-BI, the ABCA1 transporter, and apolipoprotein L genes on the metabolism of individual molecular species of HDL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IDENTIFICATION OF LIPOPROTEIN AND OBESITY RELATATED QTLS Principal Investigator & Institution: Blangero, John C.; Scientist; Southwest Foundation for Biomedical Res San Antonio, Tx 782450549 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 31-MAY-2007 Summary: (provided by the applicant): The overall goal of Project 5 is to identify genes and functional polymorphisms that affect quantitative measures of atherosclerosis, NIDDM, and obesity in Mexican American families. The particular focus of Project 3 is on following up significant evidence of linkage and association that has been detected in the current grant period. Two chromosomal regions will be the primary targets of this effort, a region on chromosome 2 that has shown linkage to a quantitative trait locus (QTL) for leptin levels (LOD=7.5) and association between leptin levels and polymorphisms in the pro-opiomelanocortin gene (p<0.005) and a region on chromosome 15 that has shown linkage to a QTL for a variety of HDL size phenotypes (LODs 2.1 to 3.8) and association between these traits and a variant in the promoter region of the hepatic lipase gene (p<0.001). The previously detected associations with
28
Lipase
strong candidate genes in these two regions will be exploited to focus the initial search on polymorphism in or near these genes. To identify single nucleotide polymorphism (SAPS) in these genes, 20 kb in and around pro-opiomelanocortin and hepatic lipase will be sequenced in 48 individuals from the families that show linkage to these regions and associations with previously typed markers in these genes. All SAPS will be genotyped that have a frequency of at least 5% in the set of 500 individuals in 10 large polymorphism will be initially assessed using combined linkage/disequilibrium and conditional measured genotype methods. When all polymorphism in a given region have been genotype in the 10 large pedigrees, newly developed statistical functional gnomic methods will be applied that are designed to identify functional polymorphism by teasing apart variants which affect the trait from those in linkage disequilibrium with them. SAPS showing evidence of association will be typed in a second set of 500 individuals for replication. Finally, Project 3 will also genotype 50 micro satellite markers in new regions of interest identified by Projects 1 and 2 for purposes of finemapping as well as 20 SAPS in positional candidate genes in these new regions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INNER CITY TOXICANTS, CHILD GROWTH AND DEVELOPMENT Principal Investigator & Institution: Wolff, Mary S.; Professor; Community and Preventive Med; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2004; Project Start 01-NOV-1998; Project End 31-OCT-2008 Summary: (provided by applicant) Two classes of industrial chemicals with endocrinedisrupting capability-the phthalates and the alkylphenols-have become widely dispersed in the urban built environment, and significant levels of phthalates are now nearly ubiquitous in the bodies of Americans. Highest exposures occur in children and in minorities. Infants and children appear especially susceptible to disruptors, because of their disproportionately heavy exposures and the vulnerability of their still forming organs to any disruption of the hormonal signaling that irreversibly shapes early development. Yet little is known, either of children's pathways of exposure, or of the human developmental toxicity of EDs. To address these gaps, the Mount Sinai Center for Children's Environmental Health and Disease Prevention Research proposes, 1) to characterize the levels and sources of children's exposures to contemporary-use EDs in the urban built environment; 2) to study relationships between EDs and neurobehavioral development; 3) to study relationships among ED exposures, diet, physical activity, and somatic growth; 4) to characterize previously unexplored enzymatic polymorphisms that may modulate individual susceptibility to EDs; and 5) to develop and deploy culturally appropriate, evidence-based strategies in East Harlem to improve children's diets, increase physical activity, reduce obesity, reduce ED exposures, and promote good health. Project 1, the Community-based Prevention Research Project (CBPR), Growing Up Healthy in East Harlem, is built on a longstanding partnership with the East Harlem community. It will study levels and sources of urban children's exposures to EDs and assess relationships among ED exposures, diet, physical activity, obesity, and use of personal care products. Project 2, an ongoing prospective epidemiological study, will analyze new and previously banked biological samples to examine associations between pre- and postnatal exposures to EDs and growth and development in a cohort study of urban children. This project will also continue to assess the developmental effects in this cohort of early exposures to neurotoxicants-organophosphates, pyrethroids, PCBs, and lead-that have been its focus for the past 5 years. Project 3, a molecular genetic study, will assess gene-environment
Studies
29
interactions that may influence individual susceptibility to EDs by identifying and characterizing polymorphisms and variations in expression levels of PON1, lipase, and UGT-glucuronyltransferase enzymes involved in ED metabolism. A new Community Outreach and Translation Core (COTC) will use scientific information from the Center to educate and empower community leaders in East Harlem and to inform policy makers and health professionals regionally and nationally about links between the urban environment and children's health. The Center will contain an Exposure Assessment Core that collaborates with the laboratories of the Center for Disease Control and Prevention (CDC) National Center for Environmental Health, a Biostatistics and Data Management Core and an Administration Core. The Center will support two new investigators in children's environmental research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIPID BINDING PROTEINS IN OBESITY/DIABETES SYNDROMES Principal Investigator & Institution: Bernlohr, David A.; Professor and Head; Biochem/Mole Biol/Biophysics; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 12-AUG-1998; Project End 30-JUN-2006 Summary: (provided by applicant): In the United States, one in every three individuals is considered very overweight or obese. More than a cosmetic issue, obesity is a positive correlate to cardiovascular disease, hypertension, atherosclerosis and diabetes. The discovery of leptin as an adipocyte-derived secreted cytokine has expanded our view of the fat cell beyond being a repository for caloric excess to a dynamic cell type functioning in the assessment and integration of overall energy homeostasis. The focus of the laboratory is on the linkage between obesity, fatty acid metabolism and lipolysis with an emphasis on fatty acid trafficking in the adipocyte and NIDDM. The laboratory studies fatty acid carriers of the adipocyte, specifically the products of the FABP4 and FABP5 genes. In fat cells, these proteins form 1:1 non-covalent complexes with fatty acids and other hydrophobic monoacyl lipids. aP2 (FABP4) and KLBP (FABP5) each form a physical complex with the hormone-sensitive lipase (HSL), the key rate-limiting enzyme of lipolysis that hydrolyzes triacylglycerol to fatty acids. Consistent with the association of aP2 with the HSL, FABP4 null mice exhibit reduced basal and hormonestimulated lipolysis suggesting fatty acid binding proteins affect the process by removing end-product fatty acids from the lipase reaction and facilitating their efflux from the cell. FABP4 null mice exhibit protection from obesity-linked insulin resistance without reduction in fat mass or leptin levels. Double FABP4-FABP5 null mice have lower fat mass and leptin levels. Conversely, transgenic mice that overexpress KLBP in fat cells under the aP2 promoter, have elevated fat cell mass and are more insulin resistant than are wild type animals. We hypothesize that FABPs stimulate lipolysis via interaction with HSL and that the disruption of the interaction results in a quantitative difference in both the molecular species and abundance of fatty acids that are lipolyzed from the fat cell. Such changes in lipolysis-derived fatty acids affect the availability of fatty acids linked to the development of insulin resistance. To test this hypothesis we propose to: Specific Aim A: Evaluate lipolysis in vivo and in situ from low and high fat fed mice harboring either disrupted FABP genes or the aP2-KLBP transgene. Correlate the rate and extent of lipolysis to insulin resistance in such animal models. Specific Aim B: Examine the physical interaction of FABPs with HSL in vitro. Assess the role of FABPs in regulating the activity of HSL and map the interaction domains of the two proteins. Specific Aim C: Assess the association of FABPs with HSL in 293 cells and 3T3-
30
Lipase
L1 adipocytes using fluorescence resonance energy transfer. Examine phosphorylation/translocation of HSL and its relationship to FABP association.
the
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIPID SIGNAL TRANSDUCTION /OSCILLATORY INSULIN SECRETION Principal Investigator & Institution: Corkey, Barbara E.; Professor; Boston Medical Center Gambro Bldg, 2Nd Fl, 660 Harrison Ave, Ste a Boston, Ma 02118 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): Insulin secretion oscillates, possibly due to oscillatory metabolism of glycolysis, mitochondrial energy production, anaplerosis and lipolysis. These oscillations generate important signals underlying oscillations in electrical activity, ion fluxes and, ultimately, secretion. We hypothesize that FFA may participate as coupling factors to synchronize islet metabolic signal transduction and insulin secretion and to provide communication between peripheral fat cells and islets. This may be achieved by recruiting beta cells, increasing synchrony among beta cells or enhancing responsiveness of beta-cells to glucose. We further presume that FFA and their release by hormone sensitive lipase (HSL) generate important signals that regulate insulin secretion in response to fuel stimuli and elevation of cAMP. We predict that animal models deficient in PFK-M (phosphofructokinase-M) or HSL will demonstrate the critical importance of glycolytic and lipolytic pathways in insulin secretion. Aim 1 will determine the effect of FFA on glucose-induced mitochondrial metabolic oscillations of individual cells within the intact islet. The role of endogenous FFA as a signaling molecule will be studied by monitoring the synchronized metabolic activity in the intact HSL deficient islet. Aim 2 will determine the relationship between oscillatory changes in lipid partitioning and lipolysis in beta cells and islets and GSIS and the effect of FFA on these parameters. Intracellular distribution and movement in real time of fluorescent FFA will be monitored using confocal imaging of beta cells and islets. In addition FFA and glycerol release from stimulated cells will be temporally correlated with insulin secretion and measurements made in Aim 1. Aim 3 will test the hypothesis that FFA promote secretion via direct modulation of voltage-gated L-type calcium channels. Aim 4 will test the hypothesis that oscillatory FFA release from fat cells via HSL-mediated lipolysis plays a role in synchronized insulin secretion from islets. Sequential co-perifusion of isolated fat cells and pancreatic islets will be undertaken. Aim 5 will test the hypothesis that regulation of HSL in the R-cell occurs via oscillatory inhibition by long chain-CoA. Aim 6 will study the mechanism whereby HSL-deficiency in beta-cell results in altered GSIS. Aim 7 will test mechanisms of secretory and electrical synchronization in the intact perfused pancreas and its relationship to islet and single cell studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LIPOLYTIC MECHANISMS OF PPAR ACTIVATION Principal Investigator & Institution: Plutzky, Jorge; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2004; Project Start 01-JAN-2004; Project End 31-DEC-2007 Summary: (provided by applicant): Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated nuclear receptors central to the transcriptional regulation of adipogenesis, glucose control and lipid metabolism. More recent work establishes PPAR expression and effects in the vasculature, including endothelial cells (EC). Despite
Studies
31
these advances, major unresolved issues persist. One central unanswered question in the PPAR field is the nature of endogenous PPAR ligands, which might recapitulate the effects of synthetic PPAR agonists, or how such natural mediators are produced under physiologic conditions. Similarly, despite extensive studies implicating PPARs in lipid biology, little data exists regarding the links between pathways of lipid metabolism and subsequent PPAR activation. Such insight could have major implications for metabolic disorders and atherosclerosis. Data is presented establishing lipoprotein lipase (LPL), the central enzyme in triglyceride-rich lipoprotein metabolism, as an endogenous mechanism for PPARalpha activation. In vitro and in vivo evidence, using both gain of function (LPL overexpression) and loss of function (PPARalpha-deficiency) models, support this claim. LPL-mediated PPAR-alpha activation is independent of LPL's known non-enzymatic effects and is selective as to PPAR (PPARalpha>>PPARdelta> PPARgamma), lipoprotein substrate (VLDL>>LDL>HDL), and lipase- absent with other fatty acid-releasing lipases tested. Furthermore, monoacylglycerol (MAG), a LPLspecific product, is identified as a novel PPARalpha activator contributing to these LPL responses. Our central hypothesis is that lipolysis is a major pathway for endogenous PPAR activation, with distal effects determined by the varying nature of lipoprotein substrate, lipase, and targeted PPAR. This proposal outlines experiments to define lipolytic mechanisms for PPAR activation across these same parameters. Unique contributors to LPL-mediated PPARalpha activation, as suggested by preliminary data, will be studied, including MAG as a little studied signaling molecule and mechanisms of ligand delivery. Key lipolytic variables of lipoprotein substrate and other tiglyceride lipases will be examined in terms of their PPARalpha, -delta, and -gamma effects. These studies include measures of lipolytic PPAR responses on available well-characterized VLDL and plasma samples from both mice and humans. The existence of genetic LPL variants in mouse models and in humans, which have a range of LPL activity, will be utilized in vitro and in vivo to determine how graded LPL function alters wellestablished PPAR responses. These LPL models include the otherwise lethal LPLdeficient mice rescued by transient LPL expression. Through these programmatic efforts, insight will be gained into lipolysis as a mechanism for selective endogenous PPAR activation, and its distal transcriptional effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIPOPROTEIN LIPASE AND PREECLAMPSIA Principal Investigator & Institution: Hubel, Carl A.; Assistant Professor of Ob/Gyn; Magee-Women's Health Corporation 204 Craft Ave Pittsburgh, Pa 152133180 Timing: Fiscal Year 2002; Project Start 15-FEB-2000; Project End 31-JAN-2005 Summary: Preeclampsia is a leading cause of maternal death and increases perinatal death five-fold. There is compelling evidence that maternal endothelial dysfunction contributes to the pathogenesis of preeclampsia. Hypertriglyceridemia, decreases in high density lipoprotein (HDL) cholesterol, and abnormally small-sized low density lipoprotein (LDL) particles are characteristic features of preeclampsia. We have proposed that these lipid abnormalities promote endothelial dysfunction in preeclampsia through the generation of oxidative stress. Lipoprotein lipase (LPL) plays a vital role in the clearance of triglycerides from the circulation. The importance of LPL defects in the development of cardiovascular disease is increasingly recognized. Several common variations in the LPL gene promote the triad of increased triglyceride, decreased HDL cholesterol, and small-sized LDL. The dyslipidemic effects of these functional variants are accentuated by pregnancy. In our Caucasian population, a sum total of 18.8% of preeclamptics are heterozygous for either the N291S or D9N coding
32
Lipase
sequence variants of the LPL gene, compared with 4.6% of normal pregnancy controls. Accordingly, Aim 1 is to test whether these observations can be generalized to other populations. We will compare the prevalence of the four most common, functional variants in the LPL gene in Caucasians and African-Americans from western Pennsylvania, and in Icelandic women. Aim 2 is to sequence the coding and promoter regions of the LPL gene to identify other functional variants, which will then be genotyped in cases and controls. We posit that variations in the LPL gene the predispose to dyslipidemia are over-represented in women with preeclampsia. Aim 3 is to compare plasma lipids, lipid peroxidation products, and markers of endothelial dysfunction in women with preeclampsia stratified by genotype. We hypothesize that, among women with preeclampsia, those carrying LPL variants with reduced enzymatic activity will display an especially adverse blood profile. In Aim 4, we will measure plasma LPL enzyme activity in women 12 weeks postpartum to further test the hypothesis that a constitutional deficiency in LPL (hormonally and/or genetically mediated) is associated with preeclampsia. In Aim 5, we will explore the effects of heterozygous LPL deficiency on endothelial regulation of vascular function during pregnancy, using the LPL knockout mouse. This systematic approach will help to clarify the link between dyslipidemia and the pathogenesis of preeclampsia and could provide clues to prevention or treatment of the disorder. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIPOPROTEIN LIPASE, NUTRITION AND NERVE MYELINATION Principal Investigator & Institution: Eckel, Robert H.; Professor of Medicine,; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 01-JAN-1990; Project End 30-NOV-2003 Summary: Lipoprotein lipase (LPL) is a hydrolytic enzyme which releases fatty acids and monoacylglyerol from nutrient-dependent triglyceride-rich lipoproteins [chylomicrons and very low density lipoproteins (VLDL)] and regulates the partitioning of these lipid fuels to tissues. This process has been studied most extensively in adipose tissue and muscle. However, LPL is also made in other sites including the nervous system, where the lipase is found in the brain, spinal cord and peripheral nerve. In the peripheral nerve, in vitro experiments have suggested, but not yet proven, that function of LPL is to enhance the uptake of chylomicron and VLDL triglyceride fatty acids to Schwann cells for myelin phospholipid synthesis. The studies outlined in this proposal will further this understanding by: 1) determining the sites of LPL expression within the peripheral nerve and defining the role of LPL in myelin synthesis nd peripheral nerve regeneration; 2) assessing the expression and regulation of peripheral nerve LPL in animal models of diabetic peripheral neuropathy; and 3) evaluating the efficacy of retroand adenovirally mediated human LPL (hLPL) gene delivery to augment myelination following peripheral nerve injury, and reverse and/or retard the neuropathy of diabetes mellitus. A combination of experiments in rodents and cultured Schwann cells will be utilized. To more specifically determine the role of the LPL in peripheral nerve in rodents (Specific Aim #1), the cells of origin and response of LPL to crush injury will be examined in normal rats and mice, and in transgenic mice without LPL in the peripheral nerve. In Specific Aim #2, several models of diabetic mellitus with already characterize peripheral neuropathy will determine if LPL expression in the peripheral nerve injury is impaired +/- crush injury. Finally, in Specific Aim #3, an important series of experiments will determine the efficacy of the delivery of LPL to augment myelination in regenerating nerves and in rodents with diabetic peripheral neuropathy. Two viral
Studies
33
gene delivery systems will be evaluated for their ability to deliver hLPL to rat sciatic nerve: retrovirus-mediated gene delivery, which targets dividing cells, and adenovirusmediated gene delivery, which introduces genes into non-dividing cells. The method that better facilitates sciatic nerve recovery from crush injury will then be administered to rodent models of diabetic neuropathy in an attempt to improve peripheral nerve myelination. Overall, these studies should provide a comprehensive understanding of the role of LPL in the peripheral nerve. Moreover, we are hopeful that new insights into the treatment of peripheral neuropathies will also ensue. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MACROPHAGE MECHANISMS
CHYLOMICRON/B48
RECEPTOR,
BINDING
Principal Investigator & Institution: Bradley, William A.; Professor of Medicine; Medicine; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 01-FEB-2000; Project End 31-JAN-2005 Summary: ApoB is essential to life yet excess apoB100 or apoB48 is atherogenic and associated with increased risk of cardiovascular disease. We identified and cloned a new, unique receptor (R) for dietary triglyceride-rich lipoproteins (TGRLP), the apoB48 R. It is constitutively expressed on monocyte-macrophages (MM), including human atherosclerotic foam cells and bone marrow precursors, and endothelial cells (ECs), cells intimately involved in hemostasis and atherothrombogenesis as well as hemopoiesis, immune function and tissue nutrition. Although we have documented that the apoB48 R binds to apoB48, major questions remain on the precise mechanism(s) of binding and why normal VLDL and LDL have low affinity for this R--which microdomain of apoB48 is necessary for R binding and how the other apoB regions, apoproteins, and lipid constituents modulate binding of lipoproteins to this R. Our published and preliminary data support the hypotheses that (1) an apoB48 microdomain that is required for binding is at or near the lipoprotein lipase binding site, is not releaseable by trypsin, is not in a heparin binding domain, and is masked in normal VLDL and LDL; (2) apoB48 R binding affinity is greater in large particles (Sf greater than 100) than in small particles (Sf less than 100); and (3) apoE inhibits binding to the apoB48 R. This ensures sufficient uptake of larger nutrient-rich (lipids and lipid-soluble vitamins) dietary particles by cells responsible for tissue nutrition, immune function and hemopoiesis, cells with high nutritional requirements, and directs smaller apoB lipoproteins to the liver, as observed in vivo. We propose multiple approaches to define the R-binding apoB48 microdomain (Aim 1) and to define modulators of this interaction (Aim 2), using native, modified, and model lipoproteins, monoclonal antibodies, C-terminal truncated apoB, molecularly engineered apoB mutant constructs, and cell and ligand blotting studies. Knowledge of the basic biochemical determinants and molecular mechanisms that govern the interactions of TGRLP with the apoB48 R are crucial to meaningful intervention to prevent excess, atherothrombogenic uptake by this route while preserving sufficient nutrient uptake or, conversely, to enhance uptake in subjects with multiple pathologies due to defective or deficient apoB. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF METHYLMERCURY INDUCED NEURONAL TOXICITY Principal Investigator & Institution: Aschner, Michael; Professor; Physiology and Pharmacology; Wake Forest University Health Sciences Winston-Salem, Nc 27157
34
Lipase
Timing: Fiscal Year 2002; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: (Adapted from the Investigator's Abstract) Methylmercury (MeHg) is a significant environmental contaminant that continues to pose a great risk to human health. Considerable attention in the scientific and health policy fora is focused on the question of whether MeHg intake from a diet high in fish is associated with aberrant CNS function. A number of recent studies (Kjellstrom et al., 1986, 1989; McKeon-Eyssen et al., 1983; Grandjean et al., 1997) suggest that fetal exposure at levels attained by mothers eating fish regularly during pregnancy are associated with neurological deficits in their offspring. Astrocytes play a key role in MeHg-induced excitotoxicity. [1] MeHg preferentially accumulates in astrocytes. [2] MeHg potently and specifically inhibits glutamate uptake in astrocytes. [3] Neuronal function is secondary to disturbances in astrocytes. [4] co-application of nontoxic concentrations of mercury and glutamate leads to the typical appearance of neuronal lesions associated with excitotoxic stimulation. [5] MeHg induces swelling in astrocytes. These observations are fully consistent with MeHg-induced dysregulation of excitatory amino acid homeostasis, and indicate that a glutamate-mediated excitotoxic mechanism is involved. The working hypotheses of the proposal outline a number of critical target sites for MeHg-induced neurotoxicity. In Specific Aim 1.0 we will test the hypothesis that activation of the astrocyte-specific enzyme, cytosolic phospholipase A2 (cPLA2) and the ensuing hydrolysis and release of arachidonic acid (AA) are mediators of glutamate release upon exposure to MeHg. We will investigate the lipase(s) involved, and determine the relationship between cPLA2 activation, regulatory volume decrease (RVD), and glutamate release. In specific Aim 2.0, we will test the hypothesis that MeHg-induced increased extracellular glutamate concentrations will competitively inhibit cystine transport into astrocytes, leading to diminished supply of cysteine for neuronal glutathione (GSH) synthesis. In Specific Aim 3.0, we will test the hypothesis that modification of cysteine residues by MeHg is associated with altered glutamate transport, and that it is regulated by the chemical redox-state of reactive cysteine residues in the astrocyte-specific glutamate transporters, GLAST and GLT1. The studies will be carried out in rat primary cultures of neurons and astrocytes, as well as Chinese hamster ovary (CHO-K1) cells (where transporters can be over expressed in cells that lack the endogenous glutamate transporter). Our approach will encompass a broad array of methods, including molecular biology, electrophysiology, radiolabel trans-membrane fluxes, and electrical impedance measurements of cell volume. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MEMBRANE STRUCTURE AND ENZYME ACTIVITY Principal Investigator & Institution: Brockman, Howard L.; Professor; Hormel Institute; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 01-MAR-1992; Project End 31-MAY-2006 Summary: (provided by applicant): Translocation of proteins to phospholipid membranes involves specific protein structures and can be triggered by the presence in the interface of a non-phospholipid lipid "second messenger," like diacylglycerol The long-range goal of this research is to understand how interactions between phospholipids and non-phospholipid second messengers regulate peripheral protein binding to interfaces and the subsequent expression of catalytic activity. Its focus is pancreatic triacylglycerol lipase (PTL) and its cofactor protein, colipase (COL), for which lipids like diacylglycerols are activators as well as lipase substrates. PTL and two other members of its gene family, lipoprotein lipase and hepatic lipase, are the primary regulators of the distribution of lipids to and from peripheral tissues. Hence, they are
Studies
35
highly relevant targets in the treatment of diseases of lipid homeostasis like obesity and atherosclerosis. To function properly, the lipid-binding motif of the N-terminal domain of PTL must bind to the lipid-water interface in its catalytically-efficient or 'open' conformation. The role of the C-terminal domain of PTL in this is unclear. In the fluid lipid interfaces at which PTL functions, phospholipids and lipase substrates form dynamic complexes that mix with uncomplexed lipids. We hypothesize that complexes inhibit the rate of protein adsorption and, hence, lipolysis. We further hypothesize that once PTL and COL bind, they rearrange lipid species in the interface to help overcome the inhibition. Apolipoprotein C-II, the cofactor for lipoprotein lipase, appears to act similarly to COL despite its lack of structural homology. To test these hypotheses, we propose 1) to define the role of lipid complexes in regulating the association of PTL's domains and COL to interfaces. To accomplish this we will use radiometric and fluorometric methods to measure initial rates of COL and PTL domain binding as a function of interfacial composition and packing; 2) to determine the ability of each of the three lipid associating motifs of PTL and COL to perturb lipid lateral organization. To accomplish this we will fluorimetrically determine the extent to which each bound protein motif is able to laterally redistribute lipid species in interfaces; 3) to determine the interfacial requirements for the binding of PTL's catalytic domain in the catalyticallyefficient conformation. To accomplish this we will chemically and spectroscopically determine how PTL catalytic domain binding and conformation are regulated; 4) to define the functional similarities of the PTL-COL lipolytic system with the serum lipoprotein lipase-apolipoprotein C-II system. To accomplish this the techniques used in aims 1-3 will be applied to these proteins. With its unique focus on the role of lipid interfacial structure in regulating protein binding, this research will provide a specific mechanistic understanding of how cofactor proteins enable lipolysis to occur at physiologically relevant interfaces. More broadly, it will help to explain how lipid second messengers regulate protein translocation associated with signaling events in cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MENOPAUSE, LPL GENOTYPE AND METABOLISM AFTER WEIGHT LOSS Principal Investigator & Institution: Goldberg, Andrew P.; Professor; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-JUL-2005 Summary: This research is designed to determine whether obese postmenopausal women with a common polymorphism in the lipoprotein lipase (LPL) PvuII gene, i.e. the (+) allele have less favorable metabolic responses to weight loss (WL) treatment than women without the LPL PvuII cut-site (-/-). The hypothesis is that the LPL PvuII genotype affects fasting muscle and adipose tissue and LPL activity and the metabolic responses to hypocaloric feeding-induced WL in a dose-dependent manner to affect the magnitude of the reduction of total and visceral fat, and improvements in glucose/insulin and lipoprotein lipid metabolism following WL in postmenopausal women. Specific aims determine whether obese women who are homozygous for the LPL PvuII (+) cut-site, i.e. the (+/+) genotype, have greater increases in adipose tissue LPL and decreases in muscle LPL activity and larger decreases in resting metabolic rate (RMR) and fat oxidation than heterozygotes during hypocaloric diets, that are associated with: 1) the loss of less total body and visceral fat; and 2) smaller improvements in lipid and glucose metabolism than women without the cut-site, i.e., (/-). We will study healthy, obese (Body Mass Index, 30-40 kg/m2) 50-60 year old
36
Lipase
women within 5 years of menopause. The statistical power to test our hypothesis is based on preliminary data showing differences in adipose tissue LPL responses to WL between LPL PvuII (+/+) and (-/-) genotypes, and requires 27 women/genotype. Subjects will be entered prospectively based on their LPL genotype to ensure a homogeneous group of obese menopausal women are studied to eliminate confounding factors of gender, age, duration from menopause and body composition on the metabolic responses to WL treatment. Metabolic studies are performed on prepared calculated weight maintaining eucaloric diets for 2-3 weeks at baseline and after 6-mo WL to ensure metabolic stability, and on hypocaloric diets after the short-term study to assess metabolic responses to negative energy balance. We will measure muscle and adipose tissue LPL activity, RMR, fat oxidation, total and visceral body fat (DXA and CT scans) lipoprotein lipids and. glucose/insulin responses during an oral glucose tolerance test. Following the post-WL metabolic evaluations, subjects enter a 6- mo follow-up period followed by metabolic testing to assess long- term metabolic adaptations and weight regain by genotype. Collectively, these findings will enhance our understanding of obesity by assessing the gene-metabolic mechanisms underlying the predisposition of some obese women to more favorable metabolic health benefits from WL. This would allow the targeting of WL treatments to women more likely to respond, and pharmacologic and other treatments to those less likely to respond to WL. This optimistic outcome would reduce prevalence of obesity and risk for CVD in older women. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METABOLIC REGULATION OF LIPOPROTEIN LIPASE IN ADIPOCYTES Principal Investigator & Institution: Currie, Richard A.; Scientific Review Administrator; Wheeler Institute for Biomedical Res Jhu Bayview, Alpha Center Baltimore, Md 21224 Timing: Fiscal Year 2002; Project Start 01-MAR-1993; Project End 31-JUL-2003 Summary: (adapted from the applicant's abstract): In this application Dr. Currie plans to extend studies from the previous funding period on the role and mode of action of Nuclear Factor Y (NF-Y) in the transcriptional regulation of the lipoprotein lipase (LPL) gene during adipocyte differentiation. Five hypotheses are proposed: 1) Reiterated AThook motifs in HMG-I(Y) both bind AT-rich DNA sequences as well as stabilize the CCAAT-box complex; 2)Reversible phosphorylation of PC4 regulates the stability of NFY subunit interaction, and indirectly the CCAAT-box complex; 3)HMG-I(Y) and PC4 provide functional links between NF-Y, Oct-1 and components of the Pol II complex in the assembly of the pre-initiation complex; 4)The NF-Y complex is associated with additional, currently unidentified protein which modulate transactivation potential; and 5) The histone acetyltransferases GCN5 and P/CAF remodel the chromatin around the LPL promoter CCAAT-box through their interaction with NF-Y. In order to eventually test these hypotheses, three specific aims will be pursued: I) The functional roles of PC4, HMG-I(Y), GCN5, and P/CAF in modulation NF-Y mediated transcription will be studied. II) Additional NF-Y subunit associated components will be identified and purified and their functional properties in the native NF-Y complex studied. III) An in vitro cell-free transcription system based on purified components will be established in order to study the biochemical roles of NF-Y, Oct-1, and their associated cofactors in the transcriptional regulation of the human LPL gene. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
37
Project Title: METABOLISM OF INTRAVENOUS LIPID EMULSIONS Principal Investigator & Institution: Deckelbaum, Richard J.; Director, Professor of Pediatrics; Institute of Human Nutrition; Columbia University Health Sciences Po Box 49 New York, Ny 10032 Timing: Fiscal Year 2003; Project Start 30-SEP-1992; Project End 31-AUG-2007 Summary: (provided by applicant): Our objective is to characterize pathways whereby intravenous (IV) lipid emulsions, commonly used clinically as nutritional support, deliver specific types of triglyceride (TG) to tissues and cells. With increasing recognition of the importance of omega-3 (omega-3) very long chain fatty acids (FA) (omega3-VLC FA) in multiple biological pathways, our major goal is to delineate mechanisms for delivery of these omega3 FA to different tissues, and to define the effects of this delivery on selected cellular endpoints related to cell TG and cholesterol metabolism. Recent evidence indicates that routes for blood clearance and tissue uptake of fish oil omega3 TG are very different from those of omega6 soy oil long chain TG (LCT). For example, removal of (omega3 VLCT) emulsions from blood seems to depend far less on intravascular lipolysis than does LCT emulsions. While substantial amounts of both emulsions are delivered to tissues as intact TG, this pathway is likely more important for omega3 TG particles. Omega3 TG particles are less dependent on "classical" lipoprotein receptor related clearance pathways, than are LCT. FA derived from omega3 TG appear to act as stronger inhibitors than LCT in sterol regulatory element (SRE) dependent gene expression-genes that are involved in both TG and cholesterol syntheses. The proposed research will systematically define mechanisms whereby TG composition, particle size, and specific ligand related pathways contribute to LCT vs. omega3-VLCT clearance and metabolism in different tissues and cell types. Aim 1 will use physical-chemical approaches (e.g., 13C-NMR) to clarify how omega3-TG and FA affect the properties of the emulsion particle surface, and how this in turn affects lipoprotein lipase and apoprotein E binding, structure, and function. Aim 2 utilizes in vitro cell culture experiments and Aim 3 in vivo mouse models to differentiate metabolic pathways for omega3-VLCT/FA and omega6 TG/FA, and how these differences affect expression of genes related to TG and cholesterol homeostasis. Studies in Aim 4 will test if hypotheses generated from cell and mouse models are likely to occur in humans -- by protocols whereby omega3-VLCT and LCT emulsions are infused in healthy volunteers. Our analyses will differentiate between mechanisms for clearance and metabolism omega3 vs. omega6 TG and FA. Our studies will allow new insight as to how fish oil derived emulsions reach different tissue, undergo metabolic processing, and regulate expression of certain genes, and will also provide carefully characterized models for the study of human lipid and lipoprotein metabolism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOBILIZATION OF TRIACYLGLYCEROL STORES IN INSECTS Principal Investigator & Institution: Arrese, Estela L.; Biochem and Molecular Biology; Oklahoma State University Stillwater Stillwater, Ok 74078 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2007 Summary: (provided by the applicant): Unlike vertebrates, where the stored fatty acids are mobilized as free fatty acids, a great number of insects, mobilizes fatty acids as an-1, 2-diacylglycerol (DG). The mobilization of TG stores requires the action of a TG-lipase, whose activity is hormonally regulated. The substrate of the lipase (TG) is found in large intracellular lipid droplets, which are constituted by a core of TG surrounded by a complex surface layer of phospholipids and proteins. On the other hand, the TG-lipase
38
Lipase
localizes in the cytosol of lipolytically unstimulated fat body cells. Lipolysis involves the interaction of the lipase with the surface of the lipid droplet. It is known that activation of lipolysis promotes both an increase of intracellular calcium concentration and activation of amp-dependent protein kinase (A-kinase) but the basic mechanisms involved in how phosphorylation-dephosphorylation reactions modulate the rate of lipolysis is unknown. Moreover, little is known about the relevance and nature of the structural and compositional changes that affect the lipid droplet when lipolysis is hormonally activated. These changes must ultimately affect the interaction of the lipase with the lipid substrate and the concomitant activation of lipolysis. DG moves from the lipid droplet to the plasma membrane by an uncharacterized mechanism. It appears that after the conversion of TG into DG on the surface of the lipid droplets, DG would be transferred to a cytosolic carrier, which in turn would target the delivery of DG across the plasma membrane. The overall goals of this project are to establish the mechanisms regulating lipolysis by determining the factors that promotes the interaction between TG-lipase and its substrate, the lipid droplet and to define the mechanism of intracellular transport of DG. Clearly the elucidation of these mechanisms is of fundamental importance in insect biochemistry and physiology. These studies will provide comprehensive information on the lipolytic process in insects and this knowledge could also contribute to the broad field of lipid metabolism and transport in vertebrates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODIFICATION OF HELICOBACTER PYLORI LIPID A Principal Investigator & Institution: Trent, Michael S.; Microbiology; East Tennessee State University Box 70565 Johnson City, Tn 37601 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): The outer membrane of Gram-negative bacteria consists of a unique molecule known as lipid A that serves as the membrane anchor for lipopolysaccharide (LPS). Lipid A (endotoxin) is the component of LPS responsible for the stimulation of the host innate immune system involved in Gram- negative sepsis. The lipid A of Escherchia coli is a hexa-acylated disaccharide of glucosamine that is substituted at the 1- and 4'- positions with phosphate and glycosylated at the 6' position with two Kdo (3-deoxy-D-manno-octulosonic acid) moieties. Nine enzymes are required for biosynthesis of Kdo2- lipid A, the minimal LPS required for E. coli growth under normal laboratory conditions. Since lipid A is required for bacterial growth, it has become an interesting target for the design of novel antibacterial agents. Although single copies of the lipid A biosynthetic genes are found in nearly all Gram-negative bacterial genomes including those of Helicobacter pylori, the lipid A of the latter is underacylated with the phosphate groups either absent or modified. The primary focus of the present study is the identification of novel enzymes required for the modification of H. plyori lipid A and initial studies to evaluate the importance of such modifications during infection. Secondly, the lipid A structure of Helicobacter heilmannii will be investigated. H. pylori is now considered the causative agent of gastric and duodenal ulcers and H. heilmannii has recently been found associated with human gastritis. The specific aims of the current proposal are: (I) characterization and cloning of lipid A deacylases of H. pylori; (II) characterization and cloning of genes required for modification of the phosphates of H. pylori lipid A; (III) relevance of H. pylori lipid A modifications during infection; and (IV) isolation, purification, and structural characterization of key lipid A species of H. heilmannii. The completion of these aims will not only further the understanding of the lipid A biosynthetic pathway in H. pylori
Studies
39
and H. heihnannii but also lay the foundation for new molecular insights into the pathogenesis of these unique organisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR MYCOBACTERIA
BIOLOGY
OF
UNIQUE
WALL
LIPIDS
OF
Principal Investigator & Institution: Kolattukudy, Pappachan E.; Professor and Directpr; None; University of Central Florida 12443 Research Pky, Ste 207 Orlando, Fl 328283252 Timing: Fiscal Year 2003; Project Start 30-SEP-1993; Project End 31-DEC-2007 Summary: (provided by applicant): Tuberculosis remains the leading cause of preventable deaths. Natural spread of multidrug resistant tuberculosis and the potential use of such strains by terrorists make discovery of new targets for antimycobacterial therapy a very critical need. Cell wall lipids constitute a major physical and chemical defensive barrier that helps the pathogen evade the host defenses and antimycobacterial drugs. Therefore, synthesis of such unique lipids that are critical for infection can be suitable targets for new antimycobacterial drugs. Multiple methyl branched lipids such as dimycocerosyl phthiocerol (DIM) have been shown to be virulence factors. Elucidation of the biochemical reactions and the nature of the enzymes involved in the biosynthesis of such virulence factors is required for developing novel drags. To this end we propose to: 1. Elucidate the functions of lipase genes and their possible role in pathogenesis, a) Express and characterize the catalytic capabilities of lip gene products and determine whether disruption of specific lip genes will result in the absence of a specific class of acyl-lipids or absence of a specific group of esterified fatty acids, and determine whether the mutations affect virulence, b) Directly test whether the expressed lip gene products can release the acyl chains from the expressed synthases in vitro. 2. Elucidate the biological function of tes genes and their possible role in virulence, a) Express tes genes and characterize the catalytic capabilities of their products, b). Disrupt the three tes genes, determine the effects on lipid metabolism by using 14C-labeled acetate and 14C-labeled propionate as radiotracers and determine the effect of the mutations on virulence of the pathogen in the murine model. 3. Elucidate the function of wes genes, a) Express the wes genes and test whether these gene products are involved in the esterification of the methyl branched acids generated by the large synthases to the hydroxyl groups in the ultimate acceptors, b) Determine the consequences of disrupting the wes genes on lipid metabolism and test the virulence of mutants that show novel biochemical phenotypes. 4. a) Elucidate the role of the novel ( subunit in the enzyme that catalyzes the synthesis of methylmalonyl-CoA, the building block for the multiple methyl branched virulence factors, b) Determine whether disruption of accD4 and accD5 affect propionyl-CoA carboxylation, and methyl branched lipid synthesis in M. tuberculosis and its virulence. c) Determine the possible role of succinate as a source for methylmalonyl-CoA. The results of this study are likely to give information and tools for screening chemical libraries to discover new types of drug candidates directed at novel targets in M. tuberculosis and thus help in combating multidrug resistant tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR GENETIC APPROCHES IN ATHEROSCLEROSIS RESEARCH Principal Investigator & Institution: Lusis, Aldons J.; Professor; Molecular Biology Institute; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024
40
Lipase
Timing: Fiscal Year 2002; Project Start 01-JUL-1984; Project End 31-DEC-2005 Summary: The theme of this proposal is the examination of altered states of triglyceride metabolism contributing to coronary artery disease. The program addresses this theme using the mouse and human homology at the pathological, physiological, biochemical, genomic and molecular levels. Of the 5 projects in this proposal, Projects 3 will mostly involve studies in mice while 2 projects principally involve studies in humans, with 5 cores providing phenotyping, genotyping, sequencing, positional cloning, biostatistical and administrative support. Our major approach will be use genetic defects in mice and humans to identify underlying genes that contribute to altered states of triglyceride metabolism. We will emphasize familial combined hyperlipidemia (FCHL), a genetically complex disease characterized by increased plasma triglyceride metabolism. We will emphasize familial combined hyperlipidemia (FCHL), a genetically complex disease characterized by increased plasma triglyceride and/or cholesterol levels which accounts for up to 20% of premature coronary artery disease. Dr. Lusis' project will extend previous genetic studies in mice to systematically delineate genetic factors contributing to triglyceride metabolisms. Notably, will combine forces with Dr. Peltonen's Project to identify the gene affected by Hyplip1, a mutation in the mouse that causes combined hyperlipidemia and co- localizes with a homologous FCHL locus in humans. Dr. Wong's Project will focus on the structure-function properties of lipoprotein lipase (LPL), an enzyme central to triglyceride metabolism, as well as identifying genetic loci that affect LPL expression and may contribute to the LPL deficiency observed in FCHL. Dr. Reve's Project will isolate the genes, and characterize the function of the corresponding gene products, for two mouse mutations affecting triglyceride metabolism, fatty liver dystrophy (fld) and combined lipase deficiency (cld); these mutations are characterized by insulin resistance (fld) and LPL deficiency (cld) that often associated with FCHL. Dr. Rotter's project will use a combination of genome wide linkage and candidate gene association approaches to characterize genetic risk factors for coronary artery disease in human populations by identifying genes for lipid and lipoprotein variation in FCHL. Dr. Peltonen's project, using the power of a discrete population isolate (the Finn's) will perform fine mapping of a recently identified FCHL locus to isolate the predisposing FCHL gene by a positional cloning approach. Importantly, the Finnish FCHL locus is syntenic with mouse Hyplip1, and Project V will assist in isolating the mouse gene to complement and aid in the identification of the homologous human FCHL gene. Thus, the 5 projects provide a coordinated approach to identifying major genes affecting triglyceride metabolism and predisposing to coronary artery disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR REGULATION OF LPL IN SKELETAL MUSCLE Principal Investigator & Institution: Neufer, Peter Darrell.; Associate Fellow; John B. Pierce Laboratory, Inc. 290 Congress Ave New Haven, Ct 06519 Timing: Fiscal Year 2002; Project Start 23-APR-1999; Project End 31-MAR-2004 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NOVEL BRAIN CANNABINOID LIGAND Principal Investigator & Institution: Piomelli, Daniele; Professor of Pharmacology; Pharmacology; University of California Irvine Irvine, Ca 926977600 Timing: Fiscal Year 2002; Project Start 14-AUG-1998; Project End 31-JUL-2004
Studies
41
Summary: Marijuana is the most widespread illegal drug of abuse in Western societies. The main active ingredient of marijuana, Delta9- tetrahydrocannabinol (THC), binds to selective G protein-coupled receptors, called cannabinoid receptors. Activation of these receptors by THC exerts profound behavioral effects in humans. This suggests that endogenous neurotransmitter substances that engage cannabinoid receptors may serve important physiological and pathological functions. Although an endogenous cannabinoid ligand, anandamide, was recently identified, evidence indicates that additional ligands may exist. On the basis of our preliminary results, we propose to test the hypothesis that 2- arachidonylglycerol (2-AG), a product of phospholipid metabolism, constitutes a second endogenous ligand for brain cannabinoid receptors. To test this hypothesis it will be necessary to show that the enzymatic machinery for the formation and inactivation of 2-AG is present in neurons. Moreover, it will be necessary to demonstrate that 2-AG binds to and activates neuronal cannabinoid receptors. The first aim of the proposed research is to investigate the mechanisms responsible for 2-AG production, using rat brain neurons in primary culture. Preliminary experiments have shown that these neurons produce substantial amounts of 2-AG. The proposed studies will identify the transmembrane signalling systems and enzyme pathways underlying 2AG production. The second aim of our proposed research is to determine whether neural activity is necessary for the formation of 2-AG. Preliminary experiments have demonstrated that, in superfused slices of rat hippocampus, high-frequency electrical stimulation of an identified excitatory pathway (the Schaffer collaterals) results in the marked accumulation of 2-AG. We will examine whether 2-AG formation is stimulated by levels of neural activity that are likely to occur in vivo, and investigate the ion channels and neurotransmitter receptors involved in this response. The third aim of our proposal is to characterize the pharmacological properties of 2-AG in cortical neurons in culture. Initial experiments have indicated that 2-AG activates neuronal cannabinoid receptors. We will determine the potency, efficacy and selectivity of 2-AG in eliciting such response. The fourth aim of the proposed research is to identify the biochemical mechanisms involved in the biological inactivation of 2-AG. Preliminary results suggest that 2-AG is hydrolyzed enzymatically to arachidonate and glycerol, two products that do not activate cannabinoid receptors. We will use subcellular fractions of rat brain tissue to identify and characterize the enzyme activity that mediates 2-AG hydrolysis. In conclusion, by demonstrating that 2-AG meets the necessary criteria of an endogenous cannabinoid ligand, our studies will shed new light on the mechanisms of marijuana abuse and help develop new strategies in the treatment of neurological, psychiatric and substance abuse disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL PROTEASE FORMULATION BASED ON CROSSLINKED CRYSTALS Principal Investigator & Institution: Shenoy, Bhami C.; Altus Biologics, Inc. 625 Putnam Ave Cambridge, Ma 021394807 Timing: Fiscal Year 2003; Project Start 01-JUL-2000; Project End 31-MAR-2005 Summary: (provided by applicant): Design of stable and efficient formulation of proteins for therapeutic use as drugs has been a major focus of biotechnology and pharmaceutical companies. In the Phase I grant, we developed a stable, active formulation of protease from Aspergillus melleus, TheraCLEC-Protease, for use in the treatment of chronic abdominal pain in chronic pancreatitis and also along with TheraCLEC-Lipase and amylase for the treatment of malabsorption as a result of pancreatic insufficiency in cystic fibrosis and chronic pancreatitis. TheraCLEC-Protease
42
Lipase
exhibited product characteristics superior to commercially available pancreatic enzyme products. TheraCLEC-Protease exhibited a very high level of activity against casein and stability under low pH and towards various proteases present in the intestine. Moreover, in the preliminary investigations, the TheraCLEC-Protease did not show any toxicity. Based on these results in Phase II, we will prepare a drug product prototype for use in the treatment of abdominal pain in chronic pancreatitis and along with TheraCLEC-Lipase for use in the treatment of pancreatic insufficiency, azotorrhea and steatorrhea in cystic fibrosis and chronic pancreatitis patients. As a first step, we will crystallize and crosslink the protease with methods developed in Phase I Subsequently, we will mix TheraCLEC-Protease with TheraCLEC-Lipase and amylase for use in a final formulation or alone depending on the disease and type of treatment. The final formulation will be tested for efficacy in digesting proteins and fats in dogs with ligated pancreatic ducts. Using radiolabeled TheraCLEC-Protease, we will follow the lack of absorption into the systemic circulation. In addition, we will test the subacute, subchronic and long-term effects of feeding TheraCLEC-Protease in two species. If successful, a TheraCLEC-Protease prototype will provide an efficient treatment for abdominal pain. TheraCLEC-Protease will be ready to enter clinical trials, and will provide a novel treatment for pancreatic insufficiency in chronic pancreatitis and cystic fibrosis along with TheraCLECLipase. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NUCLEAR ATHEROGENESIS
RECEPTOR
SIGNALING
PATHWAYS
IN
Principal Investigator & Institution: Tontonoz, Peter J.; Associate Professor; Pathology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-FEB-2001; Project End 31-JAN-2006 Summary: The long-term goal is to understand the mechanisms by which lipids regulate gene expression in vascular cells and thereby influence the development cardiovascular disease. The interaction of oxidized low-density lipoprotein with cells of the artery wall is central to the pathogenesis of atherosclerosis. Oxidized lipids not only serve as the substrate for macrophage lipid accumulation, but are also thought to contribute to lesion development through regulation of adhesion molecules and cytokines. This proposal is focused on defining the role of the nuclear receptor PPARgamma in regulating macrophage gene expression and function in response to oxidized lipids. PPARgamma is expressed at high levels in macrophage-derived foam cells of atherosclerotic lesions and is transcriptionally activated by oxidized fatty acid components of oxLDL. Multiple functions have been proposed for this receptor in macrophages, including promotion of cell differentiation, modulation of cytokine expression, and regulation of lipid uptake and metabolism. However, the true role of this transcription factor in macrophage physiology and vascular disease remains unclear. The first aim is to identify target genes of PPARgamma in monocytic cells. The identity of these genes should provide valuable insight into the nature of the processes controlled by this receptor. Preliminary data has identified the nuclear oxysterol receptor LXRa and lipoprotein lipase as regulatory targets for PPARgamma. The second aim is to characterize gene expression and function in genetically defined macrophages that over express or lack PPARgamma. The importance of PPARgamma in regulating lipid metabolism, cytokine production and mediating the biological effects of oxidized lipids on macrophage gene expression will be tested. The third aim is to analyze the role of PPARgamma in macrophage function and atherogenesis in vivo through creation of a macrophage-specific deletion of the
Studies
43
PPARgamma gene. These aims are expected not only to advance our understanding of the biologic function of PPARgamma but also to clarify mechanisms by which lipid mediators regulate gene expression during pathologic processes such as inflammation and atherosclerosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OBESITY--NEURAL CONTROL OF METABOLISM AND WEIGHT GAIN Principal Investigator & Institution: Levin, Barry E.; Professor and Acting Chair; Neurology and Neurosciences; Univ of Med/Dent Nj Newark Newark, Nj 07107 Timing: Fiscal Year 2002; Project Start 01-APR-1982; Project End 31-MAR-2004 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ORGANOPHOSPHORUS PESTICIDE TOXICOLOGY Principal Investigator & Institution: Casida, John E.; Professor of Entomology; Environmntl Sci Policy & Mgmt; University of California Berkeley Berkeley, Ca 947205940 Timing: Fiscal Year 2003; Project Start 01-DEC-1997; Project End 30-JUN-2007 Summary: (provided by applicant): Organophosphorus (OP) insecticides are the principal cause of pesticide-related human poisonings. Recent restrictions on the use of chlorpyrifos and diazinon reflect continuing concern for human health, particularly children. The two principal targets of OP toxicant action are acetylcholinesterase (AChE) for acute toxicity and neuropathy target esterase (NTE) for OP-induced delayed neuropathy (OPIDN). This research focuses on noncholinergic effects, based in part on findings with collaborators on nullizygous AChE-knockout mice (AChE -/-) and heterozygous NTE-knockout mice (NTE ). AChE -/- mice are extremely sensitive to chlorpyrifos oxen (CPO) (intraperitoneal LD50 0.45 mg/kg) compared with their wildtype littermates (LD30 3 mg/kg), establishing the importance of an unidentified nonAChE target for acute lethality. The first specific aim is to identify this non-AChE target in mammals. Mouse brain proteins from AChE -/- and wild-type mice will be radiolabeled in vitro and ex vivo with [3H-ethyl]CPO. Differential protein labeling in the AChE -/- and wild-type mice with very low levels of [3H]CPO will allow selection, purification and identification of the candidate alternate target of OP acute poisoning. The second aim is to establish the function of NTE in OPIDN using mice as the model. The NTE mice have a 40% reduction in NTE activity, making them ideal for toxicological investigations. The studies will focus on the association of NTE levels with behavioral and neuropathological changes, the sensitivity of NTE and wild-type mice to ethyl octylphosphonofluoridate and other OP delayed toxicants, validation of the mouse model for OPIDN and the mechanism by which lowered NTE induces hyperactivity and delayed toxicity. The third aim is to define the mechanisms of toxicity from disruption of signal transduction pathways, and more specifically those mediated by lysophospholipase, diacylglycerol lipase, and the muscarinic acetylcholine receptor. The last goal is to define the mechanisms and significance of two secondary targets of OP pesticides: altered endocannabinoid action by OP phosphorylation at a nucleophilic site coupled to the cannabinoid receptor-1 (CB1) agonist site; kynurenine formamidase (KFase) structure and function relative to teratogenesis and diazinon oxen action in the brain. Knowledge gained on OP pesticide toxicology is also applicable to OP nerve gases as chemical warfare and terrorism agents.
44
Lipase
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PERILIPIIN AND LIPOLYSIS Principal Investigator & Institution: Greenberg, Andrew S.; None; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2004; Project Start 15-JAN-1999; Project End 31-MAR-2008 Summary: (provided by applicant): Adipocyte lipolysis contributes significantly to the pathogenesis of obesity-associated diseases by increasing levels of circulating free fatty acids (FFA). FFA promote insulin resistance and type 2 diabetes. My laboratory's longterm goal is to elucidate molecular mechanisms of lipolysis regulation. The proposed studies will investigate structure / function relationships of Perilipin A (Peri A), a lipid droplet- associated phosphoprotein that regulates lipolysis mediated by hormone sensitive lipase (HSL) and non-HSL lipase(s). Peri A acts dually as a suppressor of basal lipolysis (in the absence of hormonal stimulation) and as a potent enhancer of protein kinase A (PKA)-stimulated lipolysis (in the presence of hormonal stimulation). Despite its important regulatory role, the primary sequences and the mechanism(s) by which Peri A regulates lipase actions have not been determined. Our preliminary studies indicate that Perilipin regulates lipolysis via multiple regulatory domains, which exhibit surprising lipase specificity. The proposed studies will 1) identify the minimal domains of Peri A that modulate basal and PKA-stimulated lipolysis by HSL and non-HSL lipase(s), 2) determine the relative role of PKA phosphorylation sites in PKA- stimulated lipolysis by HSL and non-HSL lipase, and 3) define the in vivo effects of altered Peri A expression, Peri A truncations and Peri A PKA site mutants using Peri A transgenic and Peri null mice. Our adipocyte and systemic studies will measure basal lipolysis, lipolytic response to beta-adrenergic agents, and antilipolytic response to insulin. These studies will provide in vivo proof of concept tests of how Peri A expression levels, regulatory domains, and phosphorylation sites regulate basal and stimulated lipolysis. These data will be directed to the prevention and treatment of diabetes, hyperlipidemia and other obesity - associated disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PERILIPINS AND CELLULAR TRIACYLGLYCEROL METABOLISM Principal Investigator & Institution: Brasaemle, Dawn L.; Nutritional Sciences; Rutgers the St Univ of Nj New Brunswick Asb Iii New Brunswick, Nj 08901 Timing: Fiscal Year 2002; Project Start 15-AUG-2000; Project End 31-JUL-2004 Summary: (Adapted from the Investigator's Abstract): Obesity is a health problem that is reaching epidemic proportions in the United States and has become a major and growing factor contributing to an increased prevalence of Type II diabetes and an increased risk of premature death from cardiovascular disease. Despite the need for therapeutic options to control obesity, little is known about the intracellular mechanisms that regulate fat storage and release in adipose tissue. Fatty acids, the body's major energy currency, are stored as triacylglycerols in large intracellular lipid droplets in adipocytes. The perilipins are the most abundant proteins on the surfaces of lipid droplets in adipocytes and are also found in steroidogenic cells. The proposed studies test the hypotheses that 1) perilipins facilitate triacylglycerol storage by forming a protective barrier against cytosolic lipases, and 2) phosphorylation of perilipins facilitates lipolysis in lipolytically stimulated adipocytes by attenuating the barrier to facilitate lipase access to stored triacylglycerols. The Specific Aims of the proposed research are to 1) define the structural domains of perilipin A required for its targeting
Studies
45
to and embedding into lipid droplets, 2) to study how perilipin A protects stored triacylglycerols from hormone-sensitive lipase, and 3) to elucidate the role of the phosphorylation of perilipin A in the promotion of lipolysis. These aims will be tested by the expression of intact and mutant perilipin A in cultured cells that lack perilipins followed by assays for lipid storage and release, and the presence of the mutant perilipins on lipid droplets. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHARMACOGENETICS OF THE STATIN RESPONSE Principal Investigator & Institution: Schaefer, Ernst J.; Professor; None; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2003; Project Start 29-SEP-2003; Project End 31-AUG-2007 Summary: (provided by applicant): Coronary heart disease (CHD) is the leading cause of death and disability in our society. Most CHD deaths occur in subjects over 70 years of age. Significant independent CHD risk factors are age, gender, elevated low density lipoprotein (LDL) cholesterol (C), decreased high density lipoprotein (HDL) C, hypertension, smoking, diabetes, elevated lipoprotein (a) or Lp(a) (LDL C> 50% reduction), and elevated C-reactive protein. In this response to RFA HL-03-001 (ancillary pharmacogenetic studies), we propose to study 2804 male and 3000 female participants in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), who were selected for age 70-82 years, having vascular disease coronary, cerebral or peripheral) or increased CHD risk due to smoking, hypertension or diabetes and total cholesterol levels between 4.0 and 9.0 mml/L or 151 and 340 mg/dl. In this randomized controlled trial pravastatin decreased LDL C 34% and triglyceride 12% and raised HDL C 5%. Creactive protein and Lp(a) values have already been measured. Fatal and nonfatal myocardial infarction (MI) were decreased by 19%, and fatal MI 24%, but increased risk of new cancer were noted in the pravastatin group over 3.2 years as compared to the placebo group (all p<0.01) (Lancet 360: 1623-30, 2002). Benefit was greatest in subjects with low HDL C (<1.1 lmml/L or 43 mg/dl). No benefit of pravastatin versus placebo on cognitive function or stroke was noted. We and others have shown that statins increase large alpha 1 migrating apolipoprotein A-I containing HDL, decrease plasma lathosterol, a marker of cholesterol synthesis, and increase plasma betasitosterol, a marker of cholesterol absorption as well as decrease cholesterol ester transfer protein (CETP) mass. We propose to measure HDL subspecies, CETP mass, lathosterol, and beta-sitosterol in the 292 subjects who developed CHD while on pravastatin and in a control group (n=292) who did not develop CHD on pravastatin. We propose to isolate DNA in all subjects, carry out sequencing for single nucleotide polymorphism detection in 5 male and 5 female hyper-responders and the same number of hypo-responders (LDL C <10% reduction) and then genotyping at all SNPs on the two 292 patients groups, and the informative SNP detection on the entire 5804 cohort at the following gene loci: ATP binding cassette transporters G5 and G8 (ABCG5, ABCG8), CETP; HMG CoA reductase, apolipoprotein E, lipoprotein and hepatic lipase, microsomal transfer protein, C-reactive protein, connexin, plasminogen activator type I inhibitor and stromelysin I. These genes have been selected because of our own preliminary studies, and their known key role in cholesterol absorption and lipoprotein metabolism or CHD. We hypothesize that response to pravastatin in terms of lowering of LDL C, triglycerides and C-reactive protein, and HDL C raising will be related to specific genotypes and haplotypes. We also hypothesize that subjects with the greatest LDL Cand C-reactive protein-lowering, the greatest increase in large alpha HDL particles, the greatest reduction in lathosterol and the least increase in beta-sitosterol will have the
46
Lipase
greatest benefit in CHD risk reduction, and that these changes will be related to specific genotypes and haplotypes of the candidate genes being examined. These results can be used to formulate guidelines for identifying elderly subjects for statin treatment to prevent future CHD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEMEOSTASIS
PHOSPHODIESTERASE
REGULATION
OF
GLUCOSE
Principal Investigator & Institution: Michaeli, Tamar H.; Developmtl & Molecular Biology; Yeshiva University 500 W 185Th St New York, Ny 10033 Timing: Fiscal Year 2003; Project Start 15-MAR-2003; Project End 31-DEC-2006 Summary: (provided by applicant): The objective of the proposed research is to elucidate the contribution of the camp phosphodiesterase, PDE7A, to the regulation of glucose homeostasis. Since cAMP antagonizes insulin action, cAMP phosphodiesterases can augment insulin signaling by reducing levels of cAMP pools relevant to insulin action. In particular, PDE3B augments insulin signaling in fat and liver. PDE3B, however, is not expressed in skeletal muscle. Our studies established PDE7A as a cAMP specific phosphodiesterase expressed to high levels in skeletal muscle as the particulate PDE7A2 splice variant. Our targeted disruption of the PDE7A gene in mice yielded PDE7KO mice with defects in glucose homeostasis - glucose intolerance and insulin resistance. PDE7KO mice, however, are not hyperinsulinemic and their insulin secretion in response to injected glucose is indistinguishable from that of wild type mice. Consistent with the abundant expression of PDE7A2 in skeletal muscle, and with the strong contribution of skeletal muscle to whole body glucose disposal, PDE7KO mice are impaired in insulin stimulated glucose uptake by skeletal muscle, but not by adipose tissue. Based on these observations, we hypothesize that a primary defect in PDE7KO mice is the disposal of glucose by skeletal muscle. The experimental program will examine in vivo defects of PDE7KO mice in glucose disposal, glucose and lipid metabolism, cAMP and insulin signaling, in skeletal muscle, and in liver and adipocytes. The contribution of pancreatic beta-cells to PDE7KO phenotypes will also be assessed. Thus, the aim of the proposal is to at understand the cross talk between the insulin and the cAMP signaling pathways and mechanisms underlying diabetogenic, metabolic perturbations in glucose homeostasis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHOSPHOLIPID SYNTHESIS BY GIARDIA LAMBLIA Principal Investigator & Institution: Das, Siddhartha; Associate Professor; University of Texas El Paso El Paso, Tx 79968 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2007 Summary: (provided by applicant): The ancient protist, Giardia lamblia colonizes the small intestine of humans and animals. This protozoan parasite lacks mitochondria, highly evolved Golgi structures, and other organelles typical of higher eukaryotes. Nonetheless, it has developed unique metabolic pathways that allow this parasite to survive and multiply in the small intestine by scavenging lipid molecules from the host. Various investigators have shown that Giardia trophozoites are unable to synthesize the majority of their own lipids and cholesterol de novo; rather, they depend mostly on supplies from outside sources. Naturally, the questions of how they scavenge and utilize exogenous lipids for metabolic purposes are extremely important. Earlier we have shown that exogenous phospholipids, once internalized, can be remodeled via
Studies
47
deacylation/reacylation and headgroup exchange reactions, which allow Giardia to alter lipids and generate parasite-specific phospho and glycophospholipid molecules. In addition, recent results from our laboratory suggest that transbilayer/ cellular movement of fluorescent-conjugated sphingolipids is dependent on actin filaments and the microtubule network, suggesting the presence of sophisticated lipid transport machinery in Giardia. The major goal of this proposal is to investigate the underlying mechanisms of lipid transport and metabolism in this early-diverging protozoan cell. Therefore, the specific aims are: Aim-1 to investigate the transbilayer lipid transport and trafficking, and the possible role of giardial actin/microtubule cytoskeleton in these processes; Aim-2 to investigate and characterize the regulatory enzyme(s) of phospholipid deacylation/reacylation reactions (i.e., phospholipase/lysophospholipase) by molecular/biochemical methodologies; Aim-3 to study the key enzymes of headgroup exchange pathways, and finally Aim-4 to test the effects of various inhibitors/analogs of lipid metabolic enzymes on in vitro growth of this water-borne pathogen. These studies will yield valuable information regarding lipid synthesis/remodeling by mucosal protozoa, and will lay the foundation for future investigations on novel chemotherapies against Giardia and other related protozoan parasites. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLEIOTROPIC EFFECTS ON OBESITY AND LIPOPROTEINS Principal Investigator & Institution: Comuzzie, Anthony G.; Associate Scientist; Southwest Foundation for Biomedical Res San Antonio, Tx 782450549 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: Obesity is an important risk factor for atherosclerosis. However, the reasons for the relationship between these disorders are still poorly understood. Evidence from body composition studies suggests that adiposity is highly correlated with several important endocrine measures including phenotypes related to glucose and lipoprotein metabolism. Little is known regarding the genes that influence adiposity and their pleiotropic effects on these endocrine parameters and on correlated risk factors for atherosclerosis such as lipoprotein phenotypes. In this Project, we will measure several adiposity-related phenotypes including total body fat (estimated using bioimpedance), and serum concentrations of several adipocyte derived endocrine factors (e.g., leptin, adiponectin, acylation stimulating protein, and TNFalpha) in pedigreed baboons. To better examine the underlying genetic determinants of variable gene expression, we will also continue to measure quantitative mRNA levels of several candidate genes (the leptin, lipoprotein lipase, and glucose transporter 4 genes) as well as three additional genes (the leptin receptor, adiponectin, and resistin genes) in biopsied omental fat tissue. We will detect and localize quantitative trait loci (QTLs) influencing adiposityrelated phenotypes and test hypotheses regarding their pleiotropic effects on lipoprotein traits and genotype ? age interaction. Localization of quantitative trait loci will be accomplished via a genomic screen using candidate gene and STR polymorphisms in a single pedigree of 750 non-inbred baboons. Statistical linkage analyses will be performed using the multipoint variance component method which makes efficient use of all available information and which we have extended to accommodate the complications of inbred pedigrees. When a quantitative trait locus is found, we will utilize multivariate linkage analysis to determine if adiposity-related genes have pleiotropic effects on lipoprotein phenotypes. Finally we will attempt to identify strong positional candidate genes in the regions of promising QTLs and will use combined linkage/disequilibrium analyses and a novel Bayesian quantitative trait nucleotide
48
Lipase
analysis method to assess whether polymorphisms in these genes account for the observed linkage signal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POLYMORPHISMS OF B1 AND B2 RECEPTOR GENES AND OBESITY Principal Investigator & Institution: Lima, John J.; Professor; Nemours Children's Clinic 807 Children's Way Jacksonville, Fl 322078482 Timing: Fiscal Year 2002; Project Start 15-JUN-2001; Project End 31-MAY-2004 Summary: Obesity has been associated with insulin resistance, hyperinsulinemia, noninsulin-dependent diabetes mellitus, hypertension and a higher risk of cardiovascular disease and death. Genetic, metabolic and environmental factors are known to contribute to obesity. Genes that are involved in the regulation of catecholamine function may be important because of the role catecholamines play in energy expenditure and lipolysis. Ninety percent of fat in the body is stored in white adipose tissue as triglycerides, which are broken to free fatty acids and glycerol through the action of hormone-sensitive lipase. Lipolysis is stimulated by beta1, beta2 and beta3 adrenergic receptors in human adipocytes, with the beta1 and beta2 adrenergic receptors (beta1 and beta2 AR) being the most dominant subtypes. Catecholaminestimulated lipolysis is reduced in obesity, which is thought to be due to defects in the beta2 AR-signaling pathway. Mis-sense mutations in the beta1 AR gene results in polymorphisms at nucleic acid 145 (A->G), which results in a substitution of Ser for Gly at position 49, and at nucleic acid 1165 (G- >C, which results in a substitution of Gly for Arg and position 389. Beta1 AR polymorphisms have functional significance; whether or not they associate with obesity is unknown. Mutations in the 5' leader and coding regions of the human beta2 AR gene give rise to several polymorphisms, which can after receptor density and function. The working hypotheses of this submission are that polymorphisms at position 389 and haplotypes of beta2 AR polymorphisms in the 5' leader and coding regions associate with obesity. Specific Aim #1: to compare the beta1 AR allele frequencies and genotypes in healthy obese and non- obese subjects. The hypothesis driving this specific aim is that obesity associates with the Gly 389 beta1 AR allele. Specific Aims #2: to compare the distribution of beta2 AR haplotypes in healthy obese (Body Mass Indexes > 30) and non-obese (BMI < 25) subjects. Beta2 AR haplotypes will be determined by PCR and direct sequencing. The thesis driving this specific aim is that obesity associates with the Arg19-Gly16- Glu27 beta2 AR haplotype. The distribution of beta2 AR haplotypes in 118 non-obese and 118 otherwise healthy obese subjects will be compared. The results of this study will determine whether polymorphisms in beta1 and beta2 AR allels associate with obesity. The information obtained from our studies are important in designing clinical trials of interventions designed to reduce body weight. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: POSTPRANDIAL VITAMIN A Principal Investigator & Institution: Blaner, William S.; Professor; Medicine; Columbia University Health Sciences Po Box 49 New York, Ny 10032 Timing: Fiscal Year 2004; Project Start 01-AUG-2004; Project End 30-JUN-2009 Summary: (provided by applicant): Dietary vitamin A is absorbed in the intestine where it is converted to retinyl ester. This retinyl ester is packaged along with other dietary lipids into nascent chylomicrons and secreted into the lymphatic system. Upon entering
Studies
49
the general circulation the chyiomicrons undergo metabolism that gives dse to chylomicron remnants that are cleared from the circulation by liver and other tissues. Approximately 66-75% of chylomicron remnant retinyl ester is taken up by the liver where it is either resecreted into the circulation as retinol bound to retinol-binding protein (RBP) or stored in hepatic stellate cells. The remaining postprandial vitamin A is cleared by extrahepatic tissues. At present, there is only very limited understanding of the biochemistry that underlies the uptake and processing of postprandial vitamin A, either by the liver or by other tissues. Our studies will provide new biochemical understanding of these processes. We are proposing to identify factors and to investigate mechanisms responsible for the uptake and processing of postprandial vitamin A within the liver and in extrahepatic tissues, especially focusing on heart and mammary tissue. All of our studies will be carried out in knockout and transgenic mice. In Aim 1, we propose to investigate how chylomicron remnant retinyl ester is taken up by hepatocytes and how the newly absorbed vitamin A is transferred from hepatocytes to hepatic stellate cells for storage. We will investigate the roles that RBP and cellular retinol-binding protein, type I (CRBPI) have in this process. Uptake of postprandial vitamin A into the heart will be examined in Aim 2. Unlike the liver, the heart does not store vitamin A. However, the heart has a relatively high need for retinoic acid for maintaining cellular health. In Aim 2, we will examine the roles that RBP and cellular retinol-binding protein, type III (CRBPIII) have in facilitating cardiac retinoic acid synthesis from postprandial vitamin A and in retinol resecretion from the heart. In Aim 3 we plan to explore how postprandial vitamin A is taken up and processed by mammary tissue for incorporation into milk. Our preliminary data indicate that postprandial vitamin A is an important source of the vitamin A present in milk. Here, we will focus on the roles that RBP, CRBPI, CRBPIII and lipoprotein lipase have in facilitating postprandial vitamin A incorporation into milk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PPAR-GAMMA REDISTRIBUTION
AGONISTS,
WEIGHT
GAIN
AND
FAT
Principal Investigator & Institution: Johnson, Julia A.; St. Luke's-Roosevelt Inst for Hlth Scis New York, Ny 10019 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 30-NOV-2005 Summary: (provided by applicant): The candidate for this Research Career Award (K01) plans through this application to receive additional training in conducting animal and clinical research, with a special emphasis in learning cell and molecular biology techniques commonly employed in studying adipocyte biology. Her ultimate goal is to attain independent funding to continue her research in adipose tissue metabolism and development as it relates to obesity and the metabolic syndrome. The New York Obesity Research Center is well-equipped to offer her further instruction and training in these areas. Thiazolidinediones, drugs commonly used in the treatment of type 2 diabetes mellitus, improve insulin sensitivity and hyperlipidemia partly through inducing repartitioning of lipid towards adipose tissue storage. These drugs are ligands for the transcription factor peroxisome proliferator activated receptor gamma (PPAR gamma), which is a regulator of adipocyte differentiation. Weight gain is a common side effect of these drugs, but it is unclear which individuals are most susceptible to gaining weight during treatment. These PPAR gamma agonists also have been shown to redistribute adipose tissue from visceral to subcutaneous compartments in type 2 diabetic subjects. It is not known which PPAR gamma agonist-induced changes in adipose tissue metabolism are responsible for the fat redistribution and improvement in insulin
50
Lipase
sensitivity. The Specific Aims of this application are as follows: (1) To determine changes in adipose tissue metabolism and respiratory quotient that accompany PPAR gamma agonist-mediated increased insulin sensitivity in nondiabetic obese insulinresistant human subjects. (2) To examine regional variation in PPAR gamma agonistmediated effects in vitro on metabolism and gene expression, in different subcutaneous abdominal and visceral fat depots from morbidly obese human subjects. (3) To examine whether PPAR gamma agonists mediate changes in adipose tissue that may alter susceptibility to weight gain in rodents when exposed to a high fat diet, post-treatment. The results of these studies will assist physicians in predicting which patients will best respond to thiazolidinedione therapy, and will help to develop strategies to minimize weight gain during and after treatment with PPAR gamma agonists. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRENATAL EXPOSURES AND PREECLAMPSIA PREVENTION Principal Investigator & Institution: Roberts, James M.; Director, Magee-Womens Research Institut; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2002 Summary: In this proposal we test the role of oxidative stress in the pathophysiology of preeclampsia. Oxidative stress generates free radicals that injure tissues, especially vascular endothelial cell function as components of oxidized LDL (ox-LDL), alter endothelial cell structure and function. Data from our lab and others support alterations of endothelial cell function as a component of the pathophysiology of preeclampsia. In addition, preliminary data from our group indicates potential generation of pro oxidants by preeclamptic placenta. We demonstrated increased xanthine oxidase/dehydrogenase, an enzyme which can generate superoxide, in invasive cytotrophoblast from preeclamptic women. We recently demonstrated material in the blood or plasma of preeclamptic women that increases ascorbate oxidation in vitro. We propose to characterize the activity. Whether these findings indicate cause or effect or are an epiphenomenon cannot be answered by available data. We propose definitively testing a causal role. We will study circulating markers of oxidative stress before, during and after preeclampsia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROTEASE INHIBITOR RELATED ADIPOGENESIS IN HIV INFECTION Principal Investigator & Institution: Agrawal, Krishna C.; Regents Professor and Chairperson; Pharmacology; Tulane University of Louisiana New Orleans, La New Orleans, La 70112 Timing: Fiscal Year 2002; Project Start 01-AUG-2001; Project End 31-MAY-2004 Summary: (Provided by applicant) The clinical use of HIV-1 protease inhibitors (PIs) in highly active anti-retroviral therapy (HART) has led to significant improvements in the prognosis and quality of life in HIV-1 infected patients. However, long-term use of PIs has resulted in side effects such as peripheral lipodystrophy, hyperlipidemia, insulin resistance, and disruption of the adipogenic process. Our preliminary studies have shown that PIs suppress adipogenic differentiation in 3T3-L1 cells and the addition of TNFalpha further suppressed the rate of adipogenesis. In contrast, the insulin sensitizing agent, troglitazone, blocked this suppression even in TNFalpha sensitized cells. The primary goal of the proposed research is to investigate the molecular
Studies
51
mechanisms involved in the PI-induced modulation of adipogenesis and to test the hypothesis that preadipocytes are sensitized by HIV-1 induced inflammatory cytokine TNFalpha and/or HIV-1 Tat protein, to PI-induced disruption of adipogenesis. This will be achieved by the following specific aims: 1.) To determine the in vitro effects of PIs on adipogenic differentiation in human bone marrow stromal progenitor cells. Transcripts of early, middle and late genetic markers i.e., pref-1, lipoprotein lipase (LPL) and GAPDH, respectively will be determined. Levels of nuclear transcription factors, PPARgamma and C/EBP-alpha will be determined by transient transfection assays and gel mobility shift assays. 2.) to determine the sensitizing effect of the HIV-1 induced inflammatory cytokine, TNFalpha and/or HIV-1 Tat protein on PI-induced inhibition of adipogenic differentiation in human bone marrow stromal progenitor cells. 3.) To determine the in vitro effects of PIs on the activity of ECM degrading proteases in human stromal adipogenic progenitor cells. Fibrinolytic activity in undifferentiated and differentiated cells will be monitored by using a chromogenic plasmin substrate. The ECM production at different stages of differentiation will be determined by SDS-PAGE electrophoresis and the activation of ECM degrading proteolytic enzymes (MMPs) will be monitored by gelatin zymography. Real time RT-PCR studies will monitor gene expression of tPA, PAI-1/2 and MMPs/TIMPs which are involved in the fibrinolytic cascade. 4.) To investigate the ameliorative effects of insulin sensitizers on PI-induced lipodystrophy. We will investigate the efficacy of thiazolidinediones (rosiglitazone and pioglitazone) and biguanides (metformin) in suppressing the effects of PI-induced inhibition of adipogenic differentiation. These studies will delineate the molecular mechanisms that may be responsible for the adipogenic side effects induced by the PIs in the presence of HIV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF CYTIDYLYTRANSFERASE IN FETAL RAT LUNG Principal Investigator & Institution: Mallampalli, Rama K.; Professor; Internal Medicine; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2002; Project Start 01-APR-1996; Project End 31-DEC-2005 Summary: (provided by applicant): Surfactant deficiency plays an integral role in the pathogenesis of neonatal lung diseases such as RDS and acute lung injury. Although surfactant replacement therapy has made an impact in RDS, it is not totally effective. An alternative strategy to increase the alveolar surfactant pool is by stimulating biosynthesis. Surfactant synthesis is tightly controlled by the rate-limiting enzyme, cytidylyltransferase (CT). CT activity is inhibited by sphingolipids and stimulated by fatty acids. However, prior studies administering fatty acids in vivo to stimulate surfactant production have had mixed success with associated toxicity. Thus, the goal of this proposal is to develop a novel and safe approach to stimulating surfactant synthesis in fetal lung by the use of very low density lipoproteins (VLDL) and lipoprotein lipase (LPL). This revised competing renewal expands from recent advances in our laboratory made through support of the existing grant showing that 1) fatty acids carried within very low density lipoproteins (VLDL) are potent stimulators of CT activity in vitro in the presence of LPL and 2) oxidized lipoproteins inhibit surfactant synthesis,. These observations led to the hypothesis that native lipoprotein loading and oxidized lipoproteins differentially regulate the CT enzyme. We will investigate whether loading with native lipoproteins (VLDL) increases CT activity by altering fatty acids and sphingolipids associated with the enzyme (AIM 1). We will also investigate how modified (oxidized) lipoproteins acutely down-regulate surfactant synthesis by inducing CT proteolysis (AIM 2). Our hypothesis will be tested, in vivo, by maternal
52
Lipase
administration of lipoproteins in pregnant rats and with analysis conducted in primary fetal type II cells. These in vivo studies will be supplemented with use of a lipoproteinresponsive type II (MLE12) cell line. The unique contributions of this proposal impacting the field of surfactant metabolism include: 1) mechanistic studies with potential clinical application by which native lipoproteins control CT function posttranslationally (AIM 1) and 2) studies investigating CT regulation at the level of protein stability (AIM 2). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF EPITHELIAL CELL MOTILITY BY VILLIN Principal Investigator & Institution: Khurana, Seema; Associate Professor; Physiology; University of Tennessee Health Sci Ctr Memphis, Tn 38163 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2009 Summary: (provided by applicant): The PI proposes to determine and characterize the role of villin and its ligands (phosphatidylinositol 4,5- bisphosphate (PIP2) and actin) in epithelial cell motility. Active cell motility regulates many important intestinal epithelial cell functions, including: ion transport proteins via endocytosis and exocytosis, crucial for absorption of nutrients; intestinal restitution, important to maintain homeostasis in the presence of large osmotic and mechanical stress; the movement of cells along the crypt-villus axis; the invasion and propagation of enteropathogens; immune surveillance and inflammation; as well as neoplastic tumor cell dissemination and metastasis. Villin is an actin nucleating, capping, severing, and bundling protein. Villin binds and regulates two ligands that are known to regulate cell motility, phospholipase C-gamma1 (PLC-gamma1) as well as the substrate of the lipase namely, phosphatidylinositol 4,5-bisphosphate (PIP2). Recent studies with villin knock out mice have demonstrated that villin is necessary to regulate epithelial cell motility. In addition, villin shares sequence homology with other proteins of its family including gelsolin, which have been shown to regulate cell motility in vivo. Our working hypothesis is that villin's ability to regulate phosphoinositide-mediated signal transduction pathways and the actin cytoskeleton is important to epithelial cell physiology and pathophysiology involving changes in cell motility. To accomplish our overall study objectives we will characterize the villin-PIP2 interaction using the following approaches: reconstitution in vitro using recombinant villin proteins; endogenous villin expression in the intestinal epithelial cell line, Caco-2; and over expression of villin and enzymes that regulate intracellular PIP2 levels, in the villin null intestinal cell line, IEC-6 using a tetracyclineregulated system. To determine unequivocally the role of villin in the epithelial cell motility, we will use villin knock out mice. These studies promise the prospect of modifying motility for enhancement of normal physiology and for amelioration of disease. Inhibition of epithelial cell motility can be significant in several diseases, including inflammatory bowel disease, celiac disease, and colon cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REGULATION OF LIPOPROTEIN LIPASE IN ADIPOCYTES Principal Investigator & Institution: Kern, Phillip A.; Professor; Internal Medicine; University of Arkansas Med Scis Ltl Rock Little Rock, Ar 72205 Timing: Fiscal Year 2002; Project Start 01-SEP-1988; Project End 30-JUN-2006 Summary: (Scanned from the Applicant's Description): Lipoprotein lipase (LPL) is a central enzyme in lipid metabolism and adipocyte biology. Although the changes in LPL activity with diabetes and other conditions have been well described, the mechanism of
Studies
53
LPL regulation is complex. We have described regulation of LPL translation in response to catecholamines, thyroid hormone, and in diabetes. Our recent studies have described an RNA binding protein that inhibited translation through binding to the 3'UTR of the LPL mRNA. We have now identified a member of the RNA binding complex as the alpha catalytic subunit of cAMP dependent protein kinase (PKA). In addition, we have produced transgenic mice that express an LPL gene (LPLt) that lacks the RNA binding motif on the 3'UTR. Our future aims are to better characterize the role of PKA in LPL regulation, and to better understand the role of translation in the physiologic regulation of LPL. Hypothesis 1. Protein kinase A (PKA) is involved in the translational regulation of LPL. Aim 1. Characterize the binding of the PKA C subunit to LPL mRNA: tissue specificity and involvement of other proteins. Aim 2. Determine the sequence and kinase activity of the C subunit involved in translational regulation. Aim 3. Characterize the motif on the 3'UTR of LPL that is involved in C binding. Aim 4. Determine whether LPL translation is altered in PKA knockout mice. Hypothesis 2. Regulation of LPL translation is important physiologically. Aim 1. Examine the translational regulation of both LPLt and wild type LPL (LPLwt) in response to epinephrine, thyroid hormone, and phorbol ester in isolated adipocytes from transgenic mice. Aim 2. Examine the regulation of LPLt and LPLwt in adipose tissue of transgenic mice following the induction of streptozotocin-diabetes or hypothyroidism, and the in vivo administration of epinephrine. Aim 3. Examine the mechanism by which the expression of LPLt in transgenic mice is accompanied by a down regulation of wild type LPL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESOLUTIONS IN BRANCHED ALKANES USING LIPASE IN BEADS Principal Investigator & Institution: Neau, Steven H.; Pharmaceutical Sciences; University of Missouri Kansas City Kansas City, Mo 64110 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2005 Summary: (provided by applicant): The long-term goals of this research are to investigate and characterize fresh and freeze-dried macromolecule-loaded polysaccharide-based hydrogel beads for applications in chemical reactions, and their application in macromolecule delivery for therapeutic purposes. The use of these beads for therapeutic peptide and protein delivery will be pursued, in particular for site specific delivery of these agents to the colon following oral administration. Various chemical reactions can be investigated using entrapped enzymes. The long-term goals include applications of these beads in reactions where the catalysis is well characterized, such that the bead performance (and not the reaction) is studied. The proposed research incorporates lipase into these beads for easy recovery and subsequent delivery. The solvents are straight chain and methyl-branched alkanes to test the hypothesis that branching can enhance the activity and enantioselectivity of lipase. The short-term goal is the resolution of the pharmacologically active enantiomer of a drug that is a racemic mixture, ibuprofen, by enantioselective esterification by a lipase that is free or entrapped in the chitosan bead. Isolation of the active, enantiomer will become a regulatory requirement because administration of only the active enantiomer can reduce the toxicity and dose. Resolution using an entrapped lipase offers a rapid, enantioselective reaction; repeated applications since the enzyme can be recovered; and economical terminal resolution in the synthesis sequence. In the first study, the solvent system, consisting of water at a known activity in an alkane, will be optimized for the fastest reactions and the highest enantioselectivity. Michaelis-Menten parameters will be evaluated and compared. In the second study, lipase-loaded chitosan hydrogel beads
54
Lipase
are fabricated. The successful rugged, spherical matrix can entrap the enzyme, minimally interfere with activity, and allow substrate and product diffusion. Permeability of the bead will be investigated by measuring the substrate diffusion coefficient within the bead. Reaction parameters of the entrapped enzyme will be compared to those of the free enzyme in the third study. The stability of the bead, the efficiency of the lipase entrapment, and the reduction in lipase activity as a function of repeated applications will also be evaluated in the third study. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RETINOID METABOLISM IN HEPATITIC STELLATE CELLS Principal Investigator & Institution: Bosron, William F.; Professor; Biochem and Molecular Biology; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-JUL-2006 Summary: (provided by applicant): The overall goal of this proposal is to understand the role of specific rat retinoid metabolizing enzymes (especially retinyl ester hydrolases) in the regulation of retinoid metabolism in hepatic stellate cells. Hepatic stellate cells are the main reservoir of Vitamin A in the liver where it is stored mainly as retinyl palmitate in highly visible intracellular lipid droplets. When animals are exposed to hepatotoxins or humans chronically abuse alcohol, the stellate cells become activated and transform into myofibroblast-like cells. These transformed cells are the sites of collagen and extracellular matrix protein formation in alcohol-induced hepatic fibrosis. One of the earliest events in stellate cell activation is the hydrolysis of retinyl esters and the depletion of the intracellular lipid droplets. The most likely retinyl ester hydrolase candidates are the members of the families of broad substrate specificity lipases and carboxylesterases. The specific retinyl ester hydrolases expressed in hepatic stellate cells and the mechanisms for regulation of their activity during stellate cell activation is not known. In preliminary data, we show that the five most common rat liver carboxylesterases with retinyl palmitate activity are not highly expressed in stellate cells. However, the hormone-sensitive lipase gene is expressed in rat hepatic stellate cells and it has retinyl palmitate hydrolase activity in vitro. The goals of the grant are to identify the specific retinyl ester hydrolases (lipases and carboxylesterases) that are expressed in isolated rat liver cells (stellate cells, Kupffer cells, hepatocytes) by real-time, quantitative PCR of RNA and immunofluorescence microscopy of stellate cells with enzyme-specific antibodies. The expression of retinyl ester hydrolases and retinol dehydrogenases will be correlated with retinoid autofluorescence in lipid droplets and expression of cellspecific markers in cultured rat stellate cells as they undergo activation to myofibroblast-like cells. When feasible, we will measure retinyl palmitate hydrolase activity and perform protein gel electrophoresis of cellular extracts with esterase activity staining. We will examine the kinetics of purified rat stellate cell retinyl ester hydrolases and examine the effects of enzyme activators and inhibitors. Inhibitors of retinyl ester hydrolysis in stellate cells may be an effective therapeutic strategy for arresting stellate cell activation early in hepatic fibrosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE DEGENERATION
OF
CHOLESTEROL
HOMEOSTASIS
IN
MACULAR
Principal Investigator & Institution: Lakkaraju, Aparna; Ophthalmology; Weill Medical College of Cornell Univ New York, Ny 10021
Studies
55
Timing: Fiscal Year 2003; Project Start 01-DEC-2003; Project End 30-NOV-2005 Summary: (provided by applicant): The main objective of this proposal is to investigate the role of cholesterol homeostasis in the pathogenesis of age-related macular degeneration. Although several reports suggest that aberrant cholesterol metabolism may play a role in AMD pathogenesis, the underlying cell biology of this process is unclear. Published work from our laboratory demonstrates that the lipofuscin component A2E delays the degradation of rod outer segment lipids in retinal pigment epithelial (RPE) cells without affecting protein processing. The first specific aim of this proposal will extend this work by investigating the mechanistic aspects of A2E-induced phospholipid and cholesterol accumulation in the RPE. Lysosomal lipase activities, transcriptional activation and enzyme-substrate interactions will be studied in the presence and absence of A2E. The second specific aim will examine the roles of the LDL receptor, the scavenger receptor class B type l, caveolin-1 and the ATP-binding cassette transporter A1 in polarized lipoprotein internalization and cholesterol/phospholipid efflux pathways in the RPE and investigate how A2E affects these processes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF SPHINGOMYELIN IN LIPOPROTEIN METABOLISM Principal Investigator & Institution: Subbaiah, Papasani V.; Professor; Rush University Medical Center Chicago, Il 60612 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): The long term objective of this proposal is to investigate the physiological role of sphingomyeIin (SPH) in plasma, where it is the most abundant phospholipid next to phosphatidylcholine (PC). In contrast to its functions in membrane cholesterol metabolism and signal transduction, the role of SPH in the metabolism of plasma lipoproteins has received little attention, although its concentration is significantly increased in atherosclerosis and aging. Based on preliminary data, the PI proposes that SPH modulates plasma lipolytic activities, reverse cholesterol transport pathways, and lipid peroxidation reactions, thereby preventing excessive turnover and premature degradation of PC and cholesterol.The PI will test the hypothesis that SPH, by virtue of its structural similarities to PC, competitively inhibits not only LCAT, as he previously showed, but also other lipolytic enzymes that hydrolyze PC, such as hepatic lipase and secretory phospholipases A2. He will also investigate the mechanism(s) involved in the inhibition of these activities, by employing monolayer techniques, enzyme kinetics, and structural modifications of the SPH molecule. The role of SPH in the exchange of free cholesterol and cholesteryl ester (CE) between lipoproteins, and in the selective uptake of HDL CE by various cells in culture will be studied by manipulating the SPH concentration of native lipoproteins and recombinant HDL (rHDL) particles. Since the surface concentration of CE determines its transfer rate, the effect of SPH on the partitioning of CE into surface lipids of rHDL will be investigated by [13C] NMR. The possible role of membrane SPH in the function of SR-B1 receptor will also be investigated.The PI proposes to test the novel hypothesis that SPH inhibits lipid peroxidation by retarding the propagation of lipid peroxy radicals and that the increased oxidative susceptibility of small dense LDL, compared to buoyant LDL, is due to the low SPH/PC ratio in the former. He will correlate the oxidizability of various LDL subfractions and synthetic liposomes with their SPH/PC ratios. The mechanism by which SPH inhibits lipid peroxidation will be investigated by using structural analogs of SPH, by oxidizing fluorescent probes which are specifically localized in the surface or core of lipoproteins, and by studying the effects of SPH on membrane fluidity and lateral diffusion rates.The results from these studies should
56
Lipase
provide new insights into the physiological functions of SPH in lipoproteins, and its possible relevance to atherosclerosis and inflammation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SECRETION AND BIOSYNTHESIS OF INSULIN Principal Investigator & Institution: Mcdaniel, Michael L.; Professor; Pathology and Immunology; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2002; Project Start 01-MAY-1977; Project End 31-JAN-2007 Summary: (provided by applicant) Type 2 diabetes is associated with obesity and elevated plasma levels of free fatty acids (FFA) and triacylglycerides (TAG). Obesity is also associated with the development of insulin resistance in insulin-sensitive tissues that results in hyperglycemia and hyperinsulinemia. b-cell failure in obesity-associated type 2 diabetes is believed to correlate with the intracellular accumulation of lipids that contribute to defects in insulin secretion and/or insulin and growth factor signaling necessary to maintain sufficient b-ceIl mass. The overall goal of this proposal is to define the cellular mechanisms whereby FFA and TAG exert their inhibitory effects on b-cell function in obesity-associated type 2 diabetes. Our recent studies have identified lipoprotein lipase (LpL) in b-cells, a key enzyme for catalyzing the hydrolysis of lipoprotein-associated TAG, to produce FFA for local cellular uptake. Our overall hypothesis is that LpL serves as a gatekeeper for the physiological import of FFA into bcells analogous to that described for adipocytes. Furthermore, our new findings indicate that elevated concentrations of glucose and insulin enhance LpL enzyme activity in bcells that may explain how b-cells continue to accumulate lipids in the setting of hyperglycemia and hyperinsulinemia associated with type 2 diabetes. In specific aim 1, we will: 1) further characterize the ability of nutrients, glucose and amino acids, and insulin to regulate LpL activity, expression and intracellular localization in rodent and human islets and b-cell lines, 2) assess the role of rapamycin, an inhibitor of mTOR, to regulate LpL and: lipid levels, and 3) evaluate LpL function in vivo. In specific aim 2, we will 1) examine the effects of enhanced FFA uptake by overexpression of FATP1 and ACS1, 2) characterize lipid droplet associated proteins, ADRP, perilipins and HSL, and 3) determine the regulation of lipid droplet synthesis and breakdown by phosphorylation and overexpression of lipid droplet associated proteins. Mitochondria exert a major role in glucose-stimulated insulin secretion, and mitochondrial activation is required for normal signal transduction. Recent studies suggest that FFA up-regulate mitochondrial uncoupling proteins (UCP) proposed to dissipate the proton gradient across the mitochondrial inner membrane. In specific aim 3, we will: 1) determine the role of UCP in mediating b-cell function by overexpressing UCP-2 in islets and b-cell lines, 2) assess the modulation of UCP-2 by increased levels of FFA in vitro and in vivo as described in specific aims 1 and 2. This experimental approach will be used to delineate the link between FFA and b-cell mitochondrial dysfunction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SELECTIVE UPTAKE FROM LDL:ROLE OF THE PLASMA MEMBRANE Principal Investigator & Institution: Seo, Toru; Medicine; Columbia University Health Sciences Po Box 49 New York, Ny 10032 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-DEC-2004 Summary: (provided by applicant) The applicant's long-term goal is to determine the cholesterol delivery mechanisms and their regulation. Cholesterol delivery to cells and
Studies
57
tissues is a critical process in maintaining normal cell function. Specifically, regulatory roles of free cholesterol (FC) and free fatty acids (FFA) on cholesterol delivery have been of interest since they affect cell lipid metabolism at various levels; influx and efflux of lipoproteins as well as direct effects on cell receptors and lipogenic processes at genetic levels. The proposed studies will examine selective uptake (SU) as a mechanism for cell cholesterol delivery and its regulation by FC and FFA, and will allow the applicant to expand his research competition. New techniques such as fluorescent microscopy and use and generation of transgenic mice used in studies herein will provide new skills for future studies. Our previous studies demonstrated that J774 macrophages incubated with FFA increased not only LDL uptake by the LDL receptor (LDLR), but also markedly stimulated SU of cholesteryl esters (CE) from LDL. Although LDL uptake via LDLR is a primary cholesterol delivery pathway, other pathways such as SU are important in cells and tissues with little or no LDLR. Since an initial step of SU likely involves the CE transfer to the plasma membrane, the role of the plasma membrane, particularly FC and sphingolipid rich membrane rafts, as a CE acceptor will be determined by assessing transfer of (3H) cholesteryl ethers from LDL core to isolated membranes or large unilamellar vesicle (LUV) as model membranes. Moreover, since FC modulates membrane fluidity, changes in FC content in membranes on CE transfer from LDL will be examined (Aim 1). Similarly, potential roles of FFA on regulating SU will be examined by directly intercalating various FFA, or altering phospholipid content in the plasma membrane that occurs in cells incubated with FFA (Aim 2). The second step of SU, internalization of membrane CE, will be addressed by using fluorescently labeled LDL, where LDL-CE and apolipoprotein B (apoB) will be traced with fluorescent BODIPY and ALEXA, respectively. Studies will be performed to determine what cell organelles are required for CE internalization by disrupting various cell organelles with specific inhibitors. We will determine whether membrane rafts are required for CE internalization and whether FFA affect raft-mediated CE trafficking by in situ colocalization of CE and membrane rafts in the presence or absence of FFA. Also, two different SU pathways, mediated by lipoprotein lipase vs. FFA, will be compared to determine whether CE internalization by these pathways are different (Aim 3). Finally, the physiological relevance of LDL SU in tissues will be determined using mutant mice and whether dietary intakes of different fats modulate cholesterol delivery to tissues via SU from LDL and whether macrophage specific expression of LpL stimulates cholesterol delivery to extrahepatic tissues (Aim 4). Roles of SU and its regulation by FC and FFA will be delineated and results from these studies will provide further understanding on mechanisms of cholesterol delivery to cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURE-FUNCTION ANALYSIS OF COLIPASE AND LIPASE Principal Investigator & Institution: Lowe, Mark E.; Professor of Pediatrics and Director; Pediatrics; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2002; Project Start 01-AUG-1996; Project End 31-MAR-2006 Summary: The long-term goal of this project is to describe the biochemical mechanisms of the lipolytic enzymes responsible for dietary fat digestion. Dietary fats provide a major source of energy, essential fatty acids, a vehicle for fat-soluble vitamins, and components of cellular membranes. Fats eaten in excess adversely affect health increasing the risk of cardiovascular disease and obesity. Before fats can be absorbed, they must be digested. Lipases in the stomach and duodenum digest dietary fats. This proposal focuses on the lipase responsible for the majority of fat digestion, pancreatic triglyceride lipase, and another pancreatic protein, colipase, which is required, by
58
Lipase
pancreatic triglyceride lipase for activity. We propose that specific interactions among lipase, colipase, lipids, and bile salts, which are necessary for absorption of the fatty acids released by lipase, dictate the function of pancreatic triglyceride lipase. The first specific aim is to characterize the mechanisms that mediate specific interactions among lipase, colipase, bile salts, and lipids. We will substitute selected amino acids in lipase or colipase by site-specific mutagenesis to identify functionally important regions of both proteins. The second specific aim is to determine the mechanisms that trigger the conversion of lipase from an inactive to an active conformation. In aqueous solution lipase is inactive. When lipase encounters the lipid substrate its conformation changes and it becomes active. We will follow the conformational change by tryptophan fluorescence to determine the factors that influence this critical conformational change. The last specific aim is to develop an expression system for labeling recombinant colipase with stable isotopes. The ability to label colipase with stable isotopes will enable NMR studies of the conformation of colipase in aqueous solutions under different conditions. We will test various culture conditions to improve our current system for the production of 15N labeled colipase and we will develop a system for economically labeling colipase with 13C and 15N. These studies will determine the biochemical details of the interactions between lipase, colipase, lipids, and bile salts that impact lipase function. The results will ultimately permit us to manipulate these interactions for therapeutic purposes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STUDIES OF REGIONAL FAT DISTRIBUTION AND ENERGY BALANCE Principal Investigator & Institution: Weigle, David S.; Associate Professor of Medicine; Medicine; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-MAR-2001; Project End 31-JAN-2006 Summary: The studies in this application are designed to better understand the regulation of body fat mass and the mechanisms determining body fat distribution in humans. Three Specific Aims are proposed: 1. To determine whether experimentallyinduced or spontaneous variations in plasma leptin levels predict subsequent changes in body composition. The protocols employed will also elucidate the mechanism by which high carbohydrate diets induce satiety and weight loss, and the mechanism of involuntary weight loss in the elderly. 2. To examine the relationships among central body fat redistribution, changes in adipogenic gene expression, and atherogenic changes in plasma lipids and insulin sensitivity. The model for this work will be the body fat redistribution that occurs in subjects receiving aggressive antiretroviral therapy for HIV infection. 3. To determine whether changes in uncoupling protein (UCP) gene expression act to attenuate diet-induced changes in body fat mass. This study will use the technology developed for Specific Aim 2 to ascertain whether muscle and fat UCP expression change in parallel with energy expenditure following experimental weight gain and weight loss in human subjects. The applicant has successfully trained several young physician investigators in patient-oriented and basic research, and a plan to continue doing so is presented. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STUDY OF THE DYNAMIC BINDING, STRUCTURE-FUNCTION OF CIII Principal Investigator & Institution: Breyer, Emelita D.; Chemistry; Georgia State University University Plaza Atlanta, Ga 30303
Studies
59
Timing: Fiscal Year 2003; Project Start 15-JUL-2003; Project End 30-JUN-2008 Summary: (provided by applicant): Recent study shows that Apolipoprotein CIII (CIII) specifically binds and inhibits Lipoprotein Lipase (LpL) and Hepatic Lipase (HL) enzymes. The significance of the N-terminal domain in stabilizing the lipid-protein interaction and displacing Apolipoprotein E (E) was also identified (1). Our previous study that confirms the ability of CIII to displace E (2), sets up the stage for further structure-function studies evaluating the factors that enable CIII to displace E, and inhibits both HL and LpL. These functions should be investigated in correlation to CIIl's ability to bind to the lipoprotein particle (Lp) with varying size and composition. The cooperative and complex conformational modification of CIII binding to Lp and LpL/HL suggests that this study requires a factorial design experiment that can extract latent variable (factors) from collinear measurements of the protein's physico-chemical properties and structure (X-matrix), and relate these factors to the extracted latent variables from the Y-matrix consisting of the protein's functions. This study will be the first attempt to evaluate the structural factors in CIII that is responsible for the above functions in a systematic way using a factorial designed experiments. By using our model structure of CIII generated by homology with E crystal structure followed by molecular mechanics modeling, we are able to identify significant residues in CIII that may give us information regarding the difference in its function with respect to E and CII. Structural factors such as helix length, positive helix cap, loop flexibility, and hydrophobicity of side chains will be evaluated using different constructs in order to assess their contribution to the different functions of CIII. This approach is designed to give us a surface plot describing how the structural factors of CIII correlate with its functions. A more structured search and prediction of Clll analog that has a high lipid binding ability but with lipase inhibitory sites replaced by either the activating site of CII or E can be made using this approach. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE ROLE OF HEPATIC LIPASE IN CHOLESTEROL HOMEOSTATIS Principal Investigator & Institution: Dichek, Helen L.; Pediatrics; University of Washington Grant & Contract Services Seattle, Wa 98105 Timing: Fiscal Year 2002; Project Start 01-JUL-2001; Project End 31-MAY-2006 Summary: The enzyme hepatic lipase (HL) is central to cholesterol homeostasis. HL participates in the regulation of plasma cholesterol levels, a major risk factor for atherosclerosis. It also mediates steroid hormone production, by controlling access to exogenous cholesterol in steroid-producing tissues. In turn, increased production of the adrenal steroid cortisol (corticosterone in mice) as occurs in stress, depression and certain tumors of adrenal and pituitary origin, modulates the development of atherosclerosis: increased cortisol levels are linked to an increased risk for atherosclerosis. However, HL's precise role in atherosclerosis is unknown. HL exerts its role via at least two functions. Its catalytic function processes lipoproteins for both receptor-mediated endocytosis and selective cholesterol uptake. Its bridging function facilitates interactions between lipoproteins, receptors, and the plasma membrane, thereby modulating lipoprotein cholesterol flux. This proposal seeks to establish the respective contributions of the catalytic and bridging functions to the cellular uptake of lipoprotein cholesterol and atherosclerosis by generating transgenic mice that express wildtype HL and functional mutants of HL. These mice will be bred with mice deficient in endogenous HL(hl-/-) and with h1-/- mice that are also deficient in the low density lipoprotein (LDL) receptor to generate Ldlr-/-hl-/- mice. (The Ldlr-/- mice serves as a model for diet-induced atherosclerosis). Thus, we will determine the effect of the
60
Lipase
expression of wildtype and mutant HLs on plasma lipid and lipoprotein concentrations, composition and size, and lipoprotein turnover. The mechanisms of lipoprotein cholesterol uptake will be examined in primary hepatocyte cultures from the livers of these mice by determining the effects of wildtype and mutant HL on cellular binding and uptake of labeled lipoproteins in the presence of specific inhibitors of cellular receptors. The effect of expression of wildtype and mutant HL on atherosclerosis development will be established in high-fat diet fed wildtype and mutant HL expressing mice on the Ldlr-/-hl-/-background. In addition this proposal seeks to establish the role of HL in regulating the adrenal steroidogenic response to stress and to identify the contribution of the catalytic function of HL to the adrenal steroidogenic response to stress. This will be accomplished by determining plasma corticosterone response, adrenal cholesterol content and adrenal expression of receptors and enzymes involved in cholesterol metabolism, in response to chronic pharmacologic stimulation of corticosterone production in wildtype- and mutant HL-expressing mice and compared to nontransgenic mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “lipase” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for lipase in the PubMed Central database: •
A BglII RFLP at the lipoprotein lipase gene. by Hegele RA, Nakamura Y, Emi M, Lalouel JM, White R.; 1989 Nov 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=335091
•
A Cold-Adapted Lipase of an Alaskan Psychrotroph, Pseudomonas sp. Strain B11-1: Gene Cloning and Enzyme Purification and Characterization. by Choo DW, Kurihara T, Suzuki T, Soda K, Esaki N.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106070
•
A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. by Guerra R, Wang J, Grundy SM, Cohen JC.; 1997 Apr 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20757
•
A Lipase Isolated from the Silkworm Bombyx mori Shows Antiviral Activity against Nucleopolyhedrovirus. by Ponnuvel KM, Nakazawa H, Furukawa S, Asaoka A, Ishibashi J, Tanaka H, Yamakawa M.; 2003 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=228431
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
61
•
A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries. by Monsalve MV, Henderson H, Roederer G, Julien P, Deeb S, Kastelein JJ, Peritz L, Devlin R, Bruin T, Murthy MR, et al.; 1990 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296787
•
A Mutation in the Promoter of the Lipoprotein Lipase (LPL) Gene in a Patient with Familial Combined Hyperlipidemia and Low LPL Activity. by Yang W, Nevin DN, Peng R, Brunzell JD, Deeb SS.; 1995 May 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41964
•
A silencer element for the lipoprotein lipase gene promoter and cognate double- and single-stranded DNA-binding proteins. by Tanuma Y, Nakabayashi H, Esumi M, Endo H.; 1995 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=232003
•
A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease. by Klima H, Ullrich K, Aslanidis C, Fehringer P, Lackner KJ, Schmitz G.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=288469
•
Abnormal Lipoprotein Lipase in Familial Exogenous Hypertriglyceridemia. by Schreibman PH, Arons DL, Saudek CD, Arky RA.; 1973 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302490
•
Activation of a Bacterial Lipase by its Chaperone. by Hobson AH, Buckley CM, Aamand JL, Jorgensen ST, Diderichsen B, McConnell DJ.; 1993 Jun 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46785
•
Activation of hormone-sensitive lipase and phosphorylase kinase by purified cyclic GMP-dependent protein kinase. by Khoo JC, Sperry PJ, Gill GN, Steinberg D.; 1977 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=432052
•
Amino acid substitution (Ile194----Thr) in exon 5 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in three unrelated probands. Support for a multicentric origin. by Henderson HE, Ma Y, Hassan MF, Monsalve MV, Marais AD, Winkler F, Gubernator K, Peterson J, Brunzell JD, Hayden MR.; 1991 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296955
•
An additional MspI RFLP at the human hepatic lipase (HL) gene locus. by Van Eyk R, Chan L, Top B, Stalenhoef AF, Havekes LM, Frants RR.; 1990 May 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=330900
•
An ethylene-induced cDNA encoding a lipase expressed at the onset of senescence. by Hong Y, Wang TW, Hudak KA, Schade F, Froese CD, Thompson JE.; 2000 Jul 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27014
62
Lipase
•
Anaerobically controlled expression system derived from the arcDABC operon of Pseudomonas aeruginosa: application to lipase production. by Winteler HV, Schneidinger B, Jaeger KE, Haas D.; 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168137
•
Another hormone-sensitive triglyceride lipase in fat cells? by Saltiel AR.; 2000 Jan 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33961
•
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. by Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423815
•
Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. by Baggio G, Manzato E, Gabelli C, Fellin R, Martini S, Enzi GB, Verlato F, Baiocchi MR, Sprecher DL, Kashyap ML, et al.; 1986 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423374
•
Application of a Specific and Sensitive Radiometric Assay for Microbial Lipase Activities in Marine Water Samples from the Lagoon of Noumea. by Bourguet N, Torreton JP, Galy O, Arondel V, Goutx M.; 2003 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=309873
•
Association of plasma lipoproteins with postheparin lipase activities. by Goldberg IJ, Kandel JJ, Blum CB, Ginsberg HN.; 1986 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423910
•
ATP-Dependent and Cyclic AMP-Dependent Activation of Rat Adipose Tissue Lipase by Protein Kinase from Rabbit Skeletal Muscle. by Huttunen JK, Steinberg D, Mayer SE.; 1970 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=283201
•
Aut5/Cvt17p, a Putative Lipase Essential for Disintegration of Autophagic Bodies inside the Vacuole. by Epple UD, Suriapranata I, Eskelinen EL, Thumm M.; 2001 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99673
•
Ava-II RFLP at the human hepatic lipase (HL) gene locus. by Li SR, Chan L, Thorn J, Baroni M, Oelbaum R, Galton DJ, Stocks J.; 1989 Jun 26; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=318071
•
Bcl-1 RFLP at the human hepatic lipase gene locus (CIPC). by Li SR, Chan L, Thorn J, Galton DJ, Stocks J.; 1991 Jan 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=333569
Studies
63
•
Binding of diamine oxidase activity to rat and guinea pig microvascular endothelial cells. Comparisons with lipoprotein lipase binding. by Robinson-White A, Baylin SB, Olivecrona T, Beaven MA.; 1985 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423716
•
Biochemical properties of a novel metalloprotease from Staphylococcus hyicus subsp. hyicus involved in extracellular lipase processing. by Ayora S, Lindgren PE, Gotz F.; 1994 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205491
•
bldA-dependent expression of the Streptomyces exfoliatus M11 lipase gene (lipA) is mediated by the product of a contiguous gene, lipR, encoding a putative transcriptional activator. by Servin-Gonzalez L, Castro C, Perez C, Rubio M, Valdez F.; 1997 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=179747
•
Bovine milk lipoprotein lipase transfers tocopherol to human fibroblasts during triglyceride hydrolysis in vitro. by Traber MG, Olivecrona T, Kayden HJ.; 1985 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=425518
•
Brain monoglyceride lipase participating in endocannabinoid inactivation. by Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D.; 2002 Aug 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=125056
•
Bst NI (Eco RII) RFLP in the lipoprotein lipase gene (LPL). by Funke H, Reckwerth A, Stapenhorst D, Schulze Beiering M, Jansen M, Assmann G.; 1988 Mar 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=336422
•
Bst-1 RFLP at the human lipoprotein lipase (LPL) gene locus. by Li S, Oka K, Galton D, Stocks J.; 1988 Dec 23; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=339154
•
Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: Direct evidence that lipoprotein lipase bridging occurs in vivo. by Merkel M, Kako Y, Radner H, Cho IS, Ramasamy R, Brunzell JD, Goldberg IJ, Breslow JL.; 1998 Nov 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24920
•
Cell-Bound Lipase and Esterase of Brevibacterium linens. by Sorhaug T, Ordal ZJ.; 1974 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=380093
•
Characterization of an Extracellular Lipase Encoded by LIP2 in Yarrowia lipolytica. by Pignede G, Wang H, Fudalej F, Gaillardin C, Seman M, Nicaud JM.; 2000 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=101989
64
Lipase
•
Characterization of lipase activities in obese Pima indians. Decreases with weight reduction. by Reitman JS, Kosmakos FC, Howard BV, Taskinen MR, Kuusi T, Nikkila EA.; 1982 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370287
•
Characterization of lipase-deficient mutants of Acinetobacter calcoaceticus BD413: identification of a periplasmic lipase chaperone essential for the production of extracellular lipase. by Kok RG, van Thor JJ, Nugteren-Roodzant IM, Vosman B, Hellingwerf KJ.; 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=177023
•
Characterization of the human lipoprotein lipase (LPL) promoter: evidence of two cisregulatory regions, LP-alpha and LP-beta, of importance for the differentiation-linked induction of the LPL gene during adipogenesis. by Enerback S, Ohlsson BG, Samuelsson L, Bjursell G.; 1992 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=360389
•
Characterization of the Vibrio cholerae El Tor lipase operon lipAB and a protease gene downstream of the hly region. by Ogierman MA, Fallarino A, Riess T, Williams SG, Attridge SR, Manning PA.; 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=179649
•
Cloning of chlorophyllase, the key enzyme in chlorophyll degradation: Finding of a lipase motif and the induction by methyl jasmonate. by Tsuchiya T, Ohta H, Okawa K, Iwamatsu A, Shimada H, Masuda T, Takamiya KI.; 1999 Dec 21; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24824
•
Cloning of rat hepatic lipase cDNA: evidence for a lipase gene family. by Komaromy MC, Schotz MC.; 1987 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=304467
•
Cloning of the Pseudomonas glumae lipase gene and determination of the active site residues. by Frenken LG, Egmond MR, Batenburg AM, Bos JW, Visser C, Verrips CT.; 1992 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=183182
•
Cloning, expression, and nucleotide sequence of a lipase gene from Pseudomonas fluorescens B52. by Tan Y, Miller KJ.; 1992 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=195611
•
Cloning, sequence, and expression of a lipase gene from Pseudomonas cepacia: lipase production in heterologous hosts requires two Pseudomonas genes. by Jorgensen S, Skov KW, Diderichsen B.; 1991 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=207046
•
Colipase and maximally activated pancreatic lipase in normal subjects and patients with steatorrhea. by Gaskin KJ, Durie PR, Hill RE, Lee LM, Forstner GG.; 1982 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370992
Studies
65
•
Complete nucleotide sequence of the lipase gene from Staphylococcus hyicus cloned in Staphylococcus carnosus. by Gotz F, Popp F, Korn E, Schleifer KH.; 1985 Aug 26; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=321920
•
Construction of Yeast Strains with High Cell Surface Lipase Activity by Using Novel Display Systems Based on the Flo1p Flocculation Functional Domain. by Matsumoto T, Fukuda H, Ueda M, Tanaka A, Kondo A.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=124111
•
Development and analytic validation of an enzyme-linked immunosorbent assay for the measurement of canine pancreatic lipase immunoreactivity in serum. by Steiner JM, Teague SR, Williams DA.; 2003 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=227049
•
Development of a Lipase Fermentation Process That Uses a Recombinant Pseudomonas alcaligenes Strain. by Gerritse G, Hommes RW, Quax WJ.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106439
•
Direct detection and automated sequencing of individual alleles after electrophoretic strand separation: identification of a common nonsense mutation in exon 9 of the human lipoprotein lipase gene. by Hata A, Robertson M, Emi M, Lalouel JM.; 1990 Sep 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=332217
•
Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a). by Sandholzer C, Feussner G, Brunzell J, Utermann G.; 1992 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=443258
•
Disulfide Bond in Pseudomonas aeruginosa Lipase Stabilizes the Structure but Is Not Required for Interaction with Its Foldase. by Liebeton K, Zacharias A, Jaeger KE.; 2001 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=94915
•
DNA sequence of lipoprotein lipase cDNA cloned from human monocytic leukemia THP-1 cells. by Takagi A, Ikeda Y, Yamamoto A.; 1990 Nov 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=332549
•
Domain exchange: characterization of a chimeric lipase of hepatic lipase and lipoprotein lipase. by Wong H, Davis RC, Nikazy J, Seebart KE, Schotz MC.; 1991 Dec 15; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=53120
•
Effect of clindamycin, erythromycin, lincomycin, and tetracycline on growth and extracellular lipase production by propionibacteria in vitro. by Unkles SE, Gemmell CG.; 1982 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=181825
66
Lipase
•
Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. by Ong JM, Kern PA.; 1989 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=303983
•
Effect of Heparin on the Inactivation of Serum Lipoprotein Lipase by the Liver in Unanesthetized Dogs. by Whayne TF Jr, Felts JM, Harris PA.; 1969 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=322346
•
Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase. by Rubinstein A, Gibson JC, Paterniti JR Jr, Kakis G, Little A, Ginsberg HN, Brown WV.; 1985 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423564
•
Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNFinduced hyperlipidemia. by Feingold KR, Soued M, Staprans I, Gavin LA, Donahue ME, Huang BJ, Moser AH, Gulli R, Grunfeld C.; 1989 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=303797
•
Effects of insulin and exercise on muscle lipoprotein lipase activity in man and its relation to insulin action. by Kiens B, Lithell H, Mikines KJ, Richter EA.; 1989 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=329768
•
Endothelial lipase is a major determinant of HDL level. by Ishida T, Choi S, Kundu RK, Hirata KI, Rubin EM, Cooper AD, Quertermous T.; 2003 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151857
•
Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. by Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L.; 2003 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151412
•
Expression of the Staphylococcus hyicus Lipase in Lactococcus lactis. by Drouault S, Corthier G, Ehrlich SD, Renault P.; 2000 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91867
•
Extracellular lipase of Pseudomonas sp. strain ATCC 21808: purification, characterization, crystallization, and preliminary X-ray diffraction data. by Kordel M, Hofmann B, Schomburg D, Schmid RD.; 1991 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=208163
•
Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene. by Ameis D, Kobayashi J, Davis RC, Ben-Zeev O, Malloy MJ, Kane JP, Lee G, Wong H, Havel RJ, Schotz MC.; 1991 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=295125
Studies
67
•
Fat Digestion in the Newborn CHARACTERIZATION OF LIPASE IN GASTRIC ASPIRATES OF PREMATURE AND TERM INFANTS. by Hamosh M, Scanlon JW, Ganot D, Likel M, Scanlon KB, Hamosh P.; 1981 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370635
•
Gene cloning, sequence analysis, purification, and secretion by Escherichia coli of an extracellular lipase from Serratia marcescens. by Li X, Tetling S, Winkler UK, Jaeger KE, Benedik MJ.; 1995 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=167541
•
Gene Organization and Primary Structure of Human Hormone-Sensitive Lipase: Possible Significance of a Sequence Homology with a Lipase of Moraxella TA144, an Antarctic Bacterium. by Langin D, Laurell H, Holst LS, Belfrage P, Holm C.; 1993 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46620
•
Genetic and biochemical characterization of a new extracellular lipase from Streptomyces cinnamomeus. by Sommer P, Bormann C, Gotz F.; 1997 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168661
•
Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. by Baroni MG, Berni A, Romeo S, Arca M, Tesorio T, Sorropago G, Di Mario U, Galton DJ.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=201027
•
Heparin-binding defective lipoprotein lipase is unstable and causes abnormalities in lipid delivery to tissues. by Lutz EP, Merkel M, Kako Y, Melford K, Radner H, Breslow JL, Bensadoun A, Goldberg IJ.; 2001 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=209279
•
Hepatic lipase expression in macrophages contributes to atherosclerosis in apoEdeficient and LCAT-transgenic mice. by Nong Z, Gonzalez-Navarro H, Amar M, Freeman L, Knapper C, Neufeld EB, Paigen BJ, Hoyt RF, Fruchart-Najib J, SantamarinaFojo S.; 2003 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=166288
•
Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency. by Gotoda T, Yamada N, Kawamura M, Kozaki K, Mori N, Ishibashi S, Shimano H, Takaku F, Yazaki Y, Furuichi Y, et al.; 1991 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=295753
•
High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. by Patsch JR, Prasad S, Gotto AM Jr, Patsch W.; 1987 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=442243
•
High-affinity salicylic acid-binding protein 2 is required for plant innate immunity and has salicylic acid-stimulated lipase activity. by Kumar D, Klessig DF.; 2003 Dec 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=307699
68
Lipase
•
High-Level Formation of Active Pseudomonas cepacia Lipase after Heterologous Expression of the Encoding Gene and Its Modified Chaperone in Escherichia coli and Rapid In Vitro Refolding. by Quyen DT, Schmidt-Dannert C, Schmid RD.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91096
•
Homologous Expression of the Lipase and ABC Transporter Gene Cluster, tliDEFA, Enhances Lipase Secretion in Pseudomonas spp. by Ahn JH, Pan JG, Rhee JS.; 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93336
•
Homology of lipoprotein lipase to pancreatic lipase. by Ben-Avram CM, Ben-Zeev O, Lee TD, Haaga K, Shively JE, Goers J, Pedersen ME, Reeve JR Jr, Schotz MC.; 1986 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=323696
•
Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin. by Stralfors P, Bjorgell P, Belfrage P.; 1984 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=345498
•
Hormone-sensitive lipase in differentiated 3T3-L1 cells and its activation by cyclic AMP-dependent protein kinase. by Kawamura M, Jensen DF, Wancewicz EV, Joy LL, Khoo JC, Steinberg D.; 1981 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=319876
•
Identification of the tliDEF ABC Transporter Specific for Lipase in Pseudomonas fluorescens SIK W1. by Ahn JH, Pan JG, Rhee JS.; 1999 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93584
•
Identification, Purification, and Characterization of a Thermally Stable Lipase from Rice Bran. A New Member of the (Phospho) Lipase Family. by Bhardwaj K, Raju A, Rajasekharan R.; 2001 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=133576
•
Increase of adipose tissue lipoprotein lipase activity with weight loss. by Schwartz RS, Brunzell JD.; 1981 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370709
•
Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal plasma triglyceride and highdensity lipoprotein-cholesterol levels. by Levak-Frank S, Hofmann W, Weinstock PH, Radner H, Sattler W, Breslow JL, Zechner R.; 1999 Mar 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15913
•
Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. by Jin W, Millar JS, Broedl U, Glick JM, Rader DJ.; 2003 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151853
•
Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. by Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB.; 1999 May 11; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21893
Studies
69
•
Intercellular transport of lysosomal acid lipase mediates lipoprotein cholesteryl ester metabolism in a human vascular endothelial cell-fibroblast coculture system. by Sando GN, Ma GP, Lindsley KA, Wei YP.; 1990 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=361630
•
Involvement of cell surface heparin sulfate in the binding of lipoprotein lipase to cultured bovine endothelial cells. by Shimada K, Gill PJ, Silbert JE, Douglas WH, Fanburg BL.; 1981 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370886
•
Lingual Lipase and Its Role in the Digestion of Dietary Lipid. by Hamosh M, Scow RO.; 1973 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302230
•
Lingual lipase in cystic fibrosis. Quantitation of enzyme activity in the upper small intestine of patients with exocrine pancreatic insufficiency. by Abrams CK, Hamosh M, Hubbard VS, Dutta SK, Hamosh P.; 1984 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=425027
•
Lipase and Its Modulator from Pseudomonas sp. Strain KFCC 10818: Proline-toGlutamine Substitution at Position 112 Induces Formation of Enzymatically Active Lipase in the Absence of the Modulator. by Kim EK, Jang WH, Ko JH, Kang JS, Noh MJ, Yoo OJ.; 2001 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99672
•
Lipases of the euphorbiaceae family: purification of a lipase from Euphorbia characias latex and structure-function relationships with the B chain of ricin. by Moulin A, Teissere M, Bernard C, Pieroni G.; 1994 Nov 22; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=45224
•
Lipopolysaccharide regulation of lipoprotein lipase expression in murine macrophages. by Hill MR, Kelly K, Wu X, Wanker F, Bass H, Morgan C, Wang C, Gimble JM.; 1995 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=173082
•
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. by Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ.; 2003 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151861
•
Lipoprotein lipase cofactor activity of a carboxyl-terminal peptide of apolipoprotein C-II. by Musliner TA, Church EC, Herbert PN, Kingston MJ, Shulman RS.; 1977 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=431719
•
Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase. by Weinstock PH, Levak-Frank S, Hudgins LC, Radner H, Friedman JM, Zechner R, Breslow JL.; 1997 Sep 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23350
70
Lipase
•
Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. by Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I.; 1992 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=443265
•
Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. by Beisiegel U, Weber W, Bengtsson-Olivecrona G.; 1991 Oct 1; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=52504
•
Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. by Saxena U, Klein MG, Vanni TM, Goldberg IJ.; 1992 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=442862
•
Lipoprotein lipase is produced, regulated, and functional in rat brain. by Eckel RH, Robbins RJ.; 1984 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=392196
•
Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. by O'Brien KD, Gordon D, Deeb S, Ferguson M, Chait A.; 1992 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=443027
•
Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia. by Williams KJ, Petrie KA, Brocia RW, Swenson TL.; 1991 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=295599
•
Lipoprotein lipase secretion by human monocyte-derived macrophages. by Chait A, Iverius PH, Brunzell JD.; 1982 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370999
•
Lipoprotein lipase secretion by human monocytes and rabbit alveolar macrophages in culture. by Mahoney EM, Khoo JC, Steinberg D.; 1982 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=346031
•
Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. by Kawakami M, Pekala PH, Lane MD, Cerami A.; 1982 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=345863
•
Lipoprotein Metabolism during Acute Inhibition of Hepatic Triglyceride Lipase in the Cynomolgus Monkey. by Goldberg IJ, Le NA, Paterniti JR Jr, Ginsberg HN, Lindgren FT, Brown WV.; 1982 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=370335
Studies
71
•
Localization of a chromosomal mutation affecting expression of extracellular lipase in Staphylococcus aureus. by Smeltzer MS, Gill SR, Iandolo JJ.; 1992 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=206109
•
Low-Temperature Lipase from Psychrotrophic Pseudomonas sp. Strain KB700A. by Rashid N, Shimada Y, Ezaki S, Atomi H, Imanaka T.; 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93130
•
Lysogenic conversion of staphylococcal lipase is caused by insertion of the bacteriophage L54a genome into the lipase structural gene. by Lee CY, Iandolo JJ.; 1986 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=214616
•
Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. by Yla-Herttuala S, Lipton BA, Rosenfeld ME, Goldberg IJ, Steinberg D, Witztum JL.; 1991 Nov 15; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=52884
•
Mechanism of bacteriophage conversion of lipase activity in Staphylococcus aureus. by Lee CY, Iandolo JJ.; 1985 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=214242
•
Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of hormonesensitive lipase to the lipid storage droplet. by Egan JJ, Greenberg AS, Chang MK, Wek SA, Moos MC Jr, Londos C.; 1992 Sep 15; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=49955
•
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. by Wang CS, McConathy WJ, Kloer HU, Alaupovic P.; 1985 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423500
•
Molecular cloning and nucleotide sequence of rat lingual lipase cDNA. by Docherty AJ, Bodmer MW, Angal S, Verger R, Riviere C, Lowe PA, Lyons A, Emtage JS, Harris TJ.; 1985 Mar 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=341123
•
Molecular studies on primary lipoprotein lipase (LPL) deficiency. One base deletion (G916) in exon 5 of LPL gene causes no detectable LPL protein due to the absence of LPL mRNA transcript. by Takagi A, Ikeda Y, Tsutsumi Z, Shoji T, Yamamoto A.; 1992 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=442891
•
Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. by Levak-Frank S, Radner H, Walsh A, Stollberger R, Knipping G, Hoefler G, Sattler W, Weinstock PH, Breslow JL, Zechner R.; 1995 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=185285
72
Lipase
•
Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition. by Lee WL, Shalita AR, Suntharalingam K, Fikrig SM.; 1982 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=350997
•
Nucleotide sequence of human cDNA coding for a lipoprotein lipase (LPL) cloned from placental cDNA library. by Gotoda T, Senda M, Gamou T, Furuichi Y, Oka K.; 1989 Mar 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=317600
•
Nucleotide sequence of PvuII polymorphic site at the human lipoprotein lipase gene locus. by Oka K, Tkalcevic GT, Stocks J, Galton DJ, Brown WV.; 1989 Aug 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=318390
•
Nucleotide sequence of rat adipose hormone sensitive lipase cDNA. by Holm C, Kirchgessner TG, Svenson KL, Lusis AJ, Belfrage P, Schotz MC.; 1988 Oct 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=338807
•
Optimal Step Length EM Algorithm (OSLEM) for the estimation of haplotype frequency and its application in lipoprotein lipase genotyping. by Zhang P, Sheng H, Morabia A, Gilliam TC.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=149347
•
Oral Treatment with Lactococcus lactis Expressing Staphylococcus hyicus Lipase Enhances Lipid Digestion in Pigs with Induced Pancreatic Insufficiency. by Drouault S, Juste C, Marteau P, Renault P, Corthier G.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=123933
•
Organization of the human lipoprotein lipase gene and evolution of the lipase gene family. by Kirchgessner TG, Chuat JC, Heinzmann C, Etienne J, Guilhot S, Svenson K, Ameis D, Pilon C, d'Auriol L, Andalibi A, et al.; 1989 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=298558
•
Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. by Fan J, Wang J, Bensadoun A, Lauer SJ, Dang Q, Mahley RW, Taylor JM.; 1994 Aug 30; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=44679
•
Pharyngeal lipase and digestion of dietary triglyceride in man. by Hamosh M, Klaeveman HL, Wolf RO, Scow RO.; 1975 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=301833
•
Phase variation in Xenorhabdus luminescens: cloning and sequencing of the lipase gene and analysis of its expression in primary and secondary phases of the bacterium. by Wang H, Dowds BC.; 1993 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203960
Studies
73
•
Phase-Variable Expression of an Operon Encoding Extracellular Alkaline Protease, a Serine Protease Homolog, and Lipase in Pseudomonas brassicacearum. by Chabeaud P, de Groot A, Bitter W, Tommassen J, Heulin T, Achouak W.; 2001 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=95110
•
Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. by Wilson DE, Emi M, Iverius PH, Hata A, Wu LL, Hillas E, Williams RR, Lalouel JM.; 1990 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296788
•
Phospholipase C-gamma 1 can induce DNA synthesis by a mechanism independent of its lipase activity. by Smith MR, Liu YL, Matthews NT, Rhee SG, Sung WK, Kung HF.; 1994 Jul 5; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=44241
•
Physiological factors affecting production of extracellular lipase (LipA) in Acinetobacter calcoaceticus BD413: fatty acid repression of lipA expression and degradation of LipA. by Kok RG, Nudel CB, Gonzalez RH, Nugteren-Roodzant IM, Hellingwerf KJ.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=178462
•
Production of lipase by clinical isolates of Pseudomonas cepacia. by Lonon MK, Woods DE, Straus DC.; 1988 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266500
•
Production, purification, and properties of a lipase from a bacterium (Pseudomonas aeruginosa YS-7) capable of growing in water-restricted environments. by Shabtai Y, Daya-Mishne N.; 1992 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=195188
•
Purification and partial characterization of an alkaline lipase from Pseudomonas pseudoalcaligenes F-111. by Lin SF, Chiou CM, Yeh CM, Tsai YC.; 1996 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=167873
•
Purification of extracellular lipase from Pseudomonas aeruginosa. by Stuer W, Jaeger KE, Winkler UK.; 1986 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213604
•
Purification, gene cloning, amino acid sequence analysis, and expression of an extracellular lipase from an Aeromonas hydrophila human isolate. by Anguita J, Rodriguez Aparicio LB, Naharro G.; 1993 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=182299
•
Pvu-II RFLP at the human lipoprotein lipase (LPL) gene locus. by Li SR, Oka K, Galton D, Stocks J.; 1988 Mar 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=338244
74
Lipase
•
Recombinant human cachectin/tumor necrosis factor but not interleukin-1 alpha downregulates lipoprotein lipase gene expression at the transcriptional level in mouse 3T3-L1 adipocytes. by Zechner R, Newman TC, Sherry B, Cerami A, Breslow JL.; 1988 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=363437
•
Regulation of lipoprotein lipase in primary cultures of isolated human adipocytes. by Kern PA, Marshall S, Eckel RH.; 1985 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=423427
•
Regulation of lipoprotein lipase in the diabetic rat. by Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoffman AR, Kraemer FB.; 1992 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=443223
•
Regulation of lipoprotein lipase translation by epinephrine in 3T3-L1 cells. Importance of the 3' untranslated region. by Yukht A, Davis RC, Ong JM, Ranganathan G, Kern PA.; 1995 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=185896
•
Regulation of Mammary and Adipose Tissue Lipoprotein Lipase and Blood Triacylglycerol in Rats during Late Pregnancy EFFECT OF PROSTAGLANDINS. by Spooner PM, Garrison MM, Scow RO.; 1977 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=372415
•
Responses of Adipose and Muscle Lipoprotein Lipase to Chronic Infection and Subsequent Acute Lipopolysaccharide Challenge. by Picard F, Arsenijevic D, Richard D, Deshaies Y.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120025
•
RFLP for the human lipoprotein lipase (LPL) gene: HindIII. by Heinzmann C, Ladias J, Antonarakis S, Kirchgessner T, Schotz M, Lusis AJ.; 1987 Aug 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=306163
•
Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys. by Goldberg IJ, Blaner WS, Vanni TM, Moukides M, Ramakrishnan R.; 1990 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296748
•
Role of Phospholipase C-L2, a Novel Phospholipase C-Like Protein That Lacks Lipase Activity, in B-Cell Receptor Signaling. by Takenaka K, Fukami K, Otsuki M, Nakamura Y, Kataoka Y, Wada M, Tsuji K, Nishikawa SI, Yoshida N, Takenawa T.; 2003 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=230318
•
Role of Pseudomonas aeruginosa lipase in inflammatory mediator release from human inflammatory effector cells (platelets, granulocytes, and monocytes. by Konig B, Jaeger KE, Sage AE, Vasil ML, Konig W.; 1996 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=174215
Studies
75
•
Selective Measurement of Two Lipase Activities in Postheparin Plasma from Normal Subjects and Patients with Hyperlipoproteinemia. by Krauss RM, Levy RI, Fredrickson DS.; 1974 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=301659
•
Sequence Analysis of Amplified DNA Fragments Containing the Region Encoding the Putative Lipase Substrate-Binding Domain and Genotyping of Aeromonas hydrophila. by Watanabe N, Morita K, Furukawa T, Manzoku T, Endo E, Kanamori M.; 2004 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=321285
•
Sequence of a lipase gene from the antarctic psychrotroph Moraxella TA144. by Feller G, Thiry M, Gerday C.; 1990 Nov 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=332543
•
Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. by Weinstock PH, Bisgaier CL, AaltoSetala K, Radner H, Ramakrishnan R, Levak-Frank S, Essenburg AD, Zechner R, Breslow JL.; 1995 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=185959
•
Stimulation of Lipase Production During Bacterial Growth on Alkanes. by Breuil C, Shindler DB, Sijher JS, Kushner DJ.; 1978 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=222064
•
Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. by Osuga JI, Ishibashi S, Oka T, Yagyu H, Tozawa R, Fujimoto A, Shionoiri F, Yahagi N, Kraemer FB, Tsutsumi O, Yamada N.; 2000 Jan 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15409
•
Tetracycline Inhibition of a Lipase from Corynebacterium acnes. by Weaber K, Freedman R, Eudy WW.; 1971 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=377246
•
The effect of estrogen on the lipoprotein lipase activity of rat adipose tissue. by Hamosh M, Hamosh P.; 1975 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=301861
•
The lipA gene of Serratia marcescens which encodes an extracellular lipase having no N-terminal signal peptide. by Akatsuka H, Kawai E, Omori K, Komatsubara S, Shibatani T, Tosa T.; 1994 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205299
•
The Lipase Engineering Database: a navigation and analysis tool for protein families. by Fischer M, Pleiss J.; 2003 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=165462
76
Lipase
•
The Mechanism of Activation of Hormone-Sensitive Lipase in Human Adipose Tissue. by Khoo JC, Aquino AA, Steinberg D.; 1974 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=333098
•
THE REMOVAL OF LIPOPROTEIN LIPASE FROM THE BLOOD BY THE NORMAL AND DISEASED LIVER. by Connor WE, Eckstein JW.; 1959 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=444142
•
The three genes lipB, lipC, and lipD involved in the extracellular secretion of the Serratia marcescens lipase which lacks an N-terminal signal peptide. by Akatsuka H, Kawai E, Omori K, Shibatani T.; 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=177487
•
Tissue Lipoprotein Lipase in Normal Individuals and in Individuals with Exogenous Hypertriglyceridemia and the Relationship of This Enzyme to Assimilation of Fat. by Harlan WR Jr, Winesett PS, Wasserman AJ.; 1967 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=297042
•
Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. by Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI.; 2001 Jun 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=34701
•
Transport of lipoprotein lipase across endothelial cells. by Saxena U, Klein MG, Goldberg IJ.; 1991 Mar 15; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=51209
•
Two polymorphisms for the human hepatic lipase (HL) gene. by Heinzmann C, Ladias J, Antonarakis S, Diep A, Schotz M, Lusis AJ.; 1988 May 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=336678
•
Two polymorphisms in the human lipoprotein lipase (LPL) gene. by Fisher KL, FitzGerald GA, Lawn RM.; 1987 Sep 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=306290
•
Two RFLPs at the lipoprotein lipase (LPL) gene. by Hegele RA, Nakamura Y, Emi M, Lalouel JM, White R.; 1989 Dec 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=335281
•
Use of monoclonal antibodies to demonstrate different sites with different functional characteristics in a bacterial lipase from Pseudomonas aeruginosa YS-7. by DayaMishne N, Shabtai Y.; 1992 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=195301
Studies
77
•
Use of the pre-pro part of Staphylococcus hyicus lipase as a carrier for secretion of Escherichia coli outer membrane protein A (OmpA) prevents proteolytic degradation of OmpA by cell-associated protease(s) in two different gram-positive bacteria. by Meens J, Herbort M, Klein M, Freudl R.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168578
•
Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. by Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R.; 1994 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=330067
•
VNTR polymorphism in the hepatic lipase gene (LIPC). by Bhattacharya S, Ameis D, Cullen P, Narcisi TM, Bayliss J, Greten H, Schotz MC, Scott J.; 1991 Sep 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=328828
•
Weight reduction increases adipose tissue lipoprotein lipase responsiveness in obese women. by Eckel RH, Yost TJ.; 1987 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=442337
•
Xmn-1 and Bg1-II RFLPs at the human hepatic lipase (HL) gene locus. by Li SR, Chan L, Thorn J, Galton DJ, Stocks J.; 1989 Aug 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=318400
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with lipase, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “lipase” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for lipase (hyperlinks lead to article summaries):
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
78
Lipase
•
A case of subcutaneous nodular fat necrosis with lipase-secreting acinar cell carcinoma. Author(s): Ohno Y, Le Pavoux A, Saeki H, Asahina A, Tamaki K. Source: International Journal of Dermatology. 2003 May; 42(5): 384-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12755979
•
A common truncated variant of lipoprotein lipase in the Japanese population is characterized by pattern B phenotype. Author(s): Li J, Kondo A, Kanno T, Maekawa M. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 October; 41(10): 1304-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14580156
•
A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Author(s): Reymer PW, Groenemeyer BE, Gagne E, Miao L, Appelman EE, Seidel JC, Kromhout D, Bijvoet SM, van de Oever K, Bruin T, et al. Source: Human Molecular Genetics. 1995 September; 4(9): 1543-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8541837
•
A G----C change at the donor splice site of intron 1 causes lipoprotein lipase deficiency in a southern-Italian family. Author(s): Chimienti G, Capurso A, Resta F, Pepe G. Source: Biochemical and Biophysical Research Communications. 1992 September 16; 187(2): 620-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1530621
•
A missense mutation Pro157 Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity. Author(s): Bruin T, Kastelein JJ, Van Diermen DE, Ma Y, Henderson HE, Stuyt PM, Stalenhoef AF, Sturk A, Brunzell JD, Hayden MR. Source: European Journal of Biochemistry / Febs. 1992 September 1; 208(2): 267-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1521525
•
A novel hormone-sensitive lipase isoform expressed in pancreatic beta-cells. Author(s): Lindvall H, Nevsten P, Strom K, Wallenberg R, Sundler F, Langin D, Winzell MS, Holm C. Source: The Journal of Biological Chemistry. 2004 January 30; 279(5): 3828-36. Epub 2003 October 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14576146
Studies
79
•
A novel polymorphism A(+884)-->G in the hepatic lipase gene and its association with coronary artery disease. Author(s): Su ZG, Zhang SZ, Zhang L, Tong Y, Xiao CY, Hou YP, Liao LC. Source: Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao Acta Biochimica Et Biophysica Sinica. 2003 July; 35(7): 606-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12883629
•
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Author(s): Dinh TP, Freund TF, Piomelli D. Source: Chemistry and Physics of Lipids. 2002 December 31; 121(1-2): 149-58. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12505697
•
Adipose cell size and distribution in familial lipoprotein lipase deficiency. Author(s): Peeva E, Brun LD, Ven Murthy MR, Despres JP, Normand T, Gagne C, Lupien PJ, Julien P. Source: International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity. 1992 October; 16(10): 737-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1330953
•
Amylase, lipase, pancreatic isoamylase, and phospholipase A in diagnosis of acute pancreatitis. Author(s): Clave P, Guillaumes S, Blanco I, Nabau N, Merce J, Farre A, Marruecos L, Lluis F. Source: Clinical Chemistry. 1995 August; 41(8 Pt 1): 1129-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7543034
•
Analysis of ligand binding to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that lipoprotein lipase and the carboxyl-terminal domain of the receptor-associated protein bind to the same site. Author(s): Nielsen MS, Nykjaer A, Warshawsky I, Schwartz AL, Gliemann J. Source: The Journal of Biological Chemistry. 1995 October 6; 270(40): 23713-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7559542
•
Apolipoprotein B and E basic amino acid clusters influence low-density lipoprotein association with lipoprotein lipase anchored to the subendothelial matrix. Author(s): Saxena U, Auerbach BJ, Ferguson E, Wolle J, Marcel YL, Weisgraber KH, Hegele RA, Bisgaier CL. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 1995 August; 15(8): 1240-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7627718
80
Lipase
•
Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heartspecific lipoprotein lipase transgenic mouse. Author(s): Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, Goldberg IJ. Source: The Journal of Biological Chemistry. 2004 February 6; 279(6): 4204-11. Epub 2003 November 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14634011
•
Association between lipoprotein lipase (LPL) gene and blood lipids: a common variant for a common trait? Author(s): Morabia A, Cayanis E, Costanza MC, Ross BM, Bernstein MS, Flaherty MS, Alvin GB, Das K, Morris MA, Penchaszadeh GK, Zhang P, Gilliam TC. Source: Genetic Epidemiology. 2003 May; 24(4): 309-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12687649
•
Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels. Author(s): Mank-Seymour AR, Durham KL, Thompson JF, Seymour AB, Milos PM. Source: Biochimica Et Biophysica Acta. 2004 February 27; 1636(1): 40-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14984737
•
Association of bile-salt-dependent lipase with membranes of human pancreatic microsomes. Author(s): Bruneau N, de la Porte PL, Sbarra V, Lombardo D. Source: European Journal of Biochemistry / Febs. 1995 October 1; 233(1): 209-18. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7588748
•
Association of lipoprotein lipase Ser447Ter polymorphism with brain infarction: a population-based neuropathological study. Author(s): Myllykangas L, Polvikoski T, Sulkava R, Notkola IL, Rastas S, Verkkoniemi A, Tienari PJ, Niinisto L, Hardy J, Perez-Tur J, Kontula K, Haltia M. Source: Annals of Medicine. 2001 October; 33(7): 486-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11680797
•
Association of the hormone sensitive lipase -60C > G variant with fasting insulin levels in healthy young men. Author(s): Talmud PJ, Palmen J, Nicaud V, Tiret L; European Atherosclerosis Research II Study. Source: Nutr Metab Cardiovasc Dis. 2002 August; 12(4): 173-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12514936
Studies
81
•
Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Author(s): Berk-Planken II, Hoogerbrugge N, Stolk RP, Bootsma AH, Jansen H; DALI Study Group. Source: Diabetes Care. 2003 February; 26(2): 427-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12547874
•
Baboon lipoprotein lipase: cDNA sequence and variable tissue-specific expression of two transcripts. Author(s): Cole SA, Hixson JE. Source: Gene. 1995 August 19; 161(2): 265-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7665091
•
Bile salt-activated lipase. Author(s): Wang CS, Dashti A, Downs D. Source: Methods in Molecular Biology (Clifton, N.J.). 1999; 109: 71-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9918013
•
Bile salt-dependent lipase transcripts in human fetal tissues. Author(s): Roudani S, Miralles F, Margotat A, Escribano MJ, Lombardo D. Source: Biochimica Et Biophysica Acta. 1995 October 17; 1264(1): 141-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7578248
•
Bile salt-dependent lipase: its pathophysiological implications. Author(s): Lombardo D. Source: Biochimica Et Biophysica Acta. 2001 August 29; 1533(1): 1-28. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11514232
•
Bile salt-stimulated carboxyl ester lipase influences lipoprotein assembly and secretion in intestine: a process mediated via ceramide hydrolysis. Author(s): Kirby RJ, Zheng S, Tso P, Howles PN, Hui DY. Source: The Journal of Biological Chemistry. 2002 February 8; 277(6): 4104-9. Epub 2001 December 03. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11733511
•
Bile salt-stimulated lipase (BSSL) distribution in rat, mouse and transgenic mouse expressing human BSSL. Author(s): Poorkhalkali N, Lidmer AS, Lundberg LG, Dalrymple MA, Gibson Y, Taylor L, Temperley S, Stromqvist M, Helander HF. Source: Histochemistry and Cell Biology. 1998 October; 110(4): 367-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9792415
82
Lipase
•
Bile salt-stimulated lipase and digestion of non-breast milk fat. Author(s): McClean P, Harding M, Coward WA, Prentice A, Austin S, Weaver LT. Source: Journal of Pediatric Gastroenterology and Nutrition. 1998 January; 26(1): 39-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9443118
•
Bile salt-stimulated lipase in the milk of Fulani and Kanuri women in Nigeria and native Nepalese women. Author(s): Torres JE, VanderJagt D, Okolo SN, Magnussen M, Bhatta SK, Glew RH. Source: Journal of the National Medical Association. 2001 June; 93(6): 201-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11446391
•
Binding and intracellular trafficking of lipoprotein lipase and triacylglycerol-rich lipoproteins by liver cells. Author(s): Casaroli-Marano RP, Garcia R, Vilella E, Olivecrona G, Reina M, Vilaro S. Source: Journal of Lipid Research. 1998 April; 39(4): 789-806. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9555944
•
Binding of low density lipoproteins to lipoprotein lipase is dependent on lipids but not on apolipoprotein B. Author(s): Boren J, Lookene A, Makoveichuk E, Xiang S, Gustafsson M, Liu H, Talmud P, Olivecrona G. Source: The Journal of Biological Chemistry. 2001 July 20; 276(29): 26916-22. Epub 2001 April 30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11331277
•
Binding to heparan sulfate is a major event during catabolism of lipoprotein lipase by HepG2 and other cell cultures. Author(s): Sehayek E, Olivecrona T, Bengtsson-Olivecrona G, Vlodavsky I, Levkovitz H, Avner R, Eisenberg S. Source: Atherosclerosis. 1995 April 7; 114(1): 1-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7605368
•
Biochemical and physical properties of remnant-HDL2 and of pre beta 1-HDL produced by hepatic lipase. Author(s): Guendouzi K, Jaspard B, Barbaras R, Motta C, Vieu C, Marcel Y, Chap H, Perret B, Collet X. Source: Biochemistry. 1999 March 2; 38(9): 2762-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10052947
Studies
83
•
Bis-2-oxo amide triacylglycerol analogues: a novel class of potent human gastric lipase inhibitors. Author(s): Kotsovolou S, Chiou A, Verger R, Kokotos G. Source: The Journal of Organic Chemistry. 2001 February 9; 66(3): 962-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11430119
•
Black-white differences in postprandial triglyceride response and postheparin lipoprotein lipase and hepatic triglyceride lipase among young men. Author(s): Friday KE, Srinivasan SR, Elkasabany A, Dong C, Wattigney WA, Dalferes E Jr, Berenson GS. Source: Metabolism: Clinical and Experimental. 1999 June; 48(6): 749-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10381150
•
Blockade of pancreatic lipase. Author(s): Blackburn GL. Source: The American Journal of Clinical Nutrition. 2000 March; 71(3): 845-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10702184
•
Blockade of the glucocorticoid receptor with RU 486: effects in vitro and in vivo on human adipose tissue lipoprotein lipase activity. Author(s): Ottosson M, Marin P, Karason K, Elander A, Bjorntorp P. Source: Obesity Research. 1995 May; 3(3): 233-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7627771
•
Blood extracellular superoxide dismutase levels in hemodialysis patients pre- and post-hemodialysis and its association with lipoprotein lipase mass and free fatty acid. Author(s): Shimomura H, Maehata E, Takamiya T, Adachi T, Komoda T. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2003 February; 328(1-2): 113-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12559606
•
Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. Author(s): Nie L, Wang J, Clark LT, Tang A, Vega GL, Grundy SM, Cohen JC. Source: Journal of Lipid Research. 1998 May; 39(5): 1127-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9610782
84
Lipase
•
Brain monoglyceride lipase participating in endocannabinoid inactivation. Author(s): Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Source: Proceedings of the National Academy of Sciences of the United States of America. 2002 August 6; 99(16): 10819-24. Epub 2002 July 22. Erratum In: Proc Natl Acad Sci U S a 2002 October 15; 99(21): 13961. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12136125
•
Calreticulin promotes folding/dimerization of human lipoprotein lipase expressed in insect cells (sf21). Author(s): Zhang L, Wu G, Tate CG, Lookene A, Olivecrona G. Source: The Journal of Biological Chemistry. 2003 August 1; 278(31): 29344-51. Epub 2003 May 09. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12740382
•
Carboxyl ester lipase cofractionates with scavenger receptor BI in hepatocyte lipid rafts and enhances selective uptake and hydrolysis of cholesteryl esters from HDL3. Author(s): Camarota LM, Chapman JM, Hui DY, Howles PN. Source: The Journal of Biological Chemistry. 2004 June 25; 279(26): 27599-606. Epub 2004 April 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15105424
•
Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Author(s): Rundek T, Elkind MS, Pittman J, Boden-Albala B, Martin S, Humphries SE, Juo SH, Sacco RL. Source: Stroke; a Journal of Cerebral Circulation. 2002 May; 33(5): 1420-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11988625
•
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2002. A 69-year-old man with painful cutaneous nodules, elevated lipase levels, and abnormal results on abdominal scanning. Author(s): Ashley SW, Lauwers GY. Source: The New England Journal of Medicine. 2002 November 28; 347(22): 1783-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12456855
•
Characterization of the C-terminal region of molecular forms of human milk bile saltstimulated lipase. Author(s): McKillop AM, O'Hare MM, Craig JS, Halliday HL. Source: Acta Paediatrica (Oslo, Norway : 1992). 2004 January; 93(1): 10-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14989432
Studies
85
•
Characterization of the human lipoprotein lipase (LPL) promoter: evidence of two cisregulatory regions, LP-alpha and LP-beta, of importance for the differentiation-linked induction of the LPL gene during adipogenesis. Author(s): Enerback S, Ohlsson BG, Samuelsson L, Bjursell G. Source: Molecular and Cellular Biology. 1992 October; 12(10): 4622-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1406652
•
Characterization of the lipolytic activity of endothelial lipase. Author(s): McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Source: Journal of Lipid Research. 2002 June; 43(6): 921-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12032167
•
Cholecystokinin-stimulated peak lipase concentration in duodenal drainage fluid: a new pancreatic function test. Author(s): Conwell DL, Zuccaro G, Morrow JB, Van Lente F, Obuchowski N, Vargo JJ, Dumot JA, Trolli P, Shay SS. Source: The American Journal of Gastroenterology. 2002 June; 97(6): 1392-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12094856
•
Cholesterol ester transfer protein, apolipoprotein E and lipoprotein lipase genotypes in patients with coronary artery disease in the Turkish population. Author(s): Isbir T, Yilmaz H, Agachan B, Karaali ZE. Source: Clinical Genetics. 2003 September; 64(3): 228-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12919138
•
Chylomicronemia caused by lipoprotein lipase gene mutation related to a hyperresponse of insulin secretion to glucose. Author(s): Tanaka S, Tanabe Y, Tamura H, Ishii S, Shuto Y, Kamegai J, Sugihara H, Kobayashi M, Wakabayashi I, Murano T, Shirai K, Oikawa S. Source: Intern Med. 2002 April; 41(4): 300-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11993791
•
Circulating bile salt-dependent lipase originates from the pancreas via intestinal transcytosis. Author(s): Bruneau N, Bendayan M, Gingras D, Ghitescu L, Levy E, Lombardo D. Source: Gastroenterology. 2003 February; 124(2): 470-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12557152
86
Lipase
•
Cloning of rat lysosomal acid lipase cDNA and identification of the mutation in the rat model of Wolman's disease. Author(s): Nakagawa H, Matsubara S, Kuriyama M, Yoshidome H, Fujiyama J, Yoshida H, Osame M. Source: Journal of Lipid Research. 1995 October; 36(10): 2212-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8576647
•
Common variants in the lipoprotein lipase gene in Brazil: association with lipids and angiographically assessed coronary atherosclerosis. Author(s): Rios DL, Vargas AF, Ewald GM, Torres MR, Zago AJ, Callegari-Jacques SM, Hutz MH. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 October; 41(10): 1351-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14580165
•
Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the beta3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. Author(s): Campagna F, Montali A, Baroni MG, Maria AT, Ricci G, Antonini R, Verna R, Arca M. Source: Metabolism: Clinical and Experimental. 2002 October; 51(10): 1298-305. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12370850
•
Commutability of calibration and control materials for serum lipase. Author(s): Cattozzo G, Franzini C, Melzi d'Eril GM. Source: Clinical Chemistry. 2001 December; 47(12): 2108-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11719474
•
Comparison of the cDNA and amino acid sequences of lipoprotein lipase in eight species. Author(s): Raisonnier A, Etienne J, Arnault F, Brault D, Noe L, Chuat JC, Galibert F. Source: Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology. 1995 July; 111(3): 385-98. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7613763
•
Comparison of urine trypsinogen-2 test strip with serum lipase in the diagnosis of acute pancreatitis. Author(s): Kylanpaa-Back ML, Kemppainen E, Puolakkainen P, Hedstrom J, Haapiainen R, Korvuo A, Stenman UH. Source: Hepatogastroenterology. 2002 July-August; 49(46): 1130-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12143219
Studies
87
•
Crystal structure of human gastric lipase and model of lysosomal acid lipase, two lipolytic enzymes of medical interest. Author(s): Roussel A, Canaan S, Egloff MP, Riviere M, Dupuis L, Verger R, Cambillau C. Source: The Journal of Biological Chemistry. 1999 June 11; 274(24): 16995-7002. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10358049
•
Deceptive hyperbilirubinaemia in a newborn with familial lipoprotein lipase deficiency. Author(s): Ng PC, Lam CW, Fok TF, Lee CH, Lo DY, Chan LY, Sin NC, Packard CJ. Source: Journal of Paediatrics and Child Health. 2001 June; 37(3): 314-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11468054
•
Decreased activities of lipoprotein lipase and hepatic triglyceride lipase in patients with gout. Author(s): Tsutsumi Z, Yamamoto T, Moriwaki Y, Takahashi S, Hada T. Source: Metabolism: Clinical and Experimental. 2001 August; 50(8): 952-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11474484
•
Deficiency of choresteryl ester transfer protein and gene polymorphisms of lipoprotein lipase and hepatic lipase are not associated with longevity. Author(s): Arai Y, Hirose N, Yamamura K, Nakazawa S, Shimizu K, Takayama M, Ebihara Y, Homma S, Gondo Y, Masui Y, Inagaki H. Source: Journal of Molecular Medicine (Berlin, Germany). 2003 February; 81(2): 102-9. Epub 2003 February 11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12601526
•
Detection of missense mutations in the genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dyslipidemia undergoing coronary angiography. Author(s): Moennig G, Wiebusch H, Enbergs A, Dorszewski A, Kerber S, Schulte H, Vielhauer C, Haverkamp W, Assmann G, Breithardt G, Funke H. Source: Atherosclerosis. 2000 April; 149(2): 395-401. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10729390
•
Determinants of HDL particle size in patients with the null (P207L) or defective (D9N) mutation in the lipoprotein lipase gene: the Quebec LipD Study. Author(s): Ruel IL, Gaudet D, Perron P, Pascot A, Despres JP, Bergeron J, Julien P, Lamarche B. Source: Atherosclerosis. 2002 June; 162(2): 269-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11996946
88
Lipase
•
Determination and use of haplotypes: ethnic comparison and association of the lipoprotein lipase gene and coronary artery disease in Mexican-Americans. Author(s): Goodarzi MO, Guo X, Taylor KD, Quinones MJ, Samayoa C, Yang H, Saad MF, Palotie A, Krauss RM, Hsueh WA, Rotter JI. Source: Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2003 July-August; 5(4): 322-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12865761
•
Development and evaluation of a direct sandwich-enzyme-linked immunosorbent assay for the quantification of human hepatic triglyceride lipase mass in human plasma. Author(s): Nishimura M, Ohkaru Y, Ishii H, Sunahara N, Takagi A, Ikeda Y. Source: Journal of Immunological Methods. 2000 February 21; 235(1-2): 41-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10675756
•
Diabetic state induces lipid loading and altered expression and secretion of lipoprotein lipase in human monocyte-derived macrophages. Author(s): Dobrian AD, Lazar V, Sinescu C, Mincu D, Simionescu M. Source: Atherosclerosis. 2000 November; 153(1): 191-201. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11058715
•
Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. Author(s): Ordovas JM, Corella D, Demissie S, Cupples LA, Couture P, Coltell O, Wilson PW, Schaefer EJ, Tucker KL. Source: Circulation. 2002 October 29; 106(18): 2315-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12403660
•
Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: the 1998 Singapore National Health Survey. Author(s): Tai ES, Corella D, Deurenberg-Yap M, Cutter J, Chew SK, Tan CE, Ordovas JM; Singapore National Health Survey. Source: The Journal of Nutrition. 2003 November; 133(11): 3399-408. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14608050
•
Dietary fat modulates gastric lipase activity in healthy humans. Author(s): Armand M, Hamosh M, DiPalma JS, Gallagher J, Benjamin SB, Philpott JR, Lairon D, Hamosh P. Source: The American Journal of Clinical Nutrition. 1995 July; 62(1): 74-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7598069
Studies
89
•
Difference in substrate specificity between human and mouse lysosomal acid lipase: low affinity for cholesteryl ester in mouse lysosomal acid lipase. Author(s): Groener JE, Bax W, Stuani C, Pagani F. Source: Biochimica Et Biophysica Acta. 2000 September 27; 1487(2-3): 155-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11018468
•
Different reactivities of high density lipoprotein2 subfractions with hepatic lipase. Author(s): Mowri HO, Patsch W, Smith LC, Gotto AM Jr, Patsch JR. Source: Journal of Lipid Research. 1992 September; 33(9): 1269-79. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1402396
•
Differential effect of combined lipase deficiency (cld/cld) on human hepatic lipase and lipoprotein lipase secretion. Author(s): Boedeker JC, Doolittle MH, White AL. Source: Journal of Lipid Research. 2001 November; 42(11): 1858-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11714855
•
Differential expression of lipoprotein lipase gene in tissues of the rat model with visceral obesity and postprandial hyperlipidemia. Author(s): Hikita M, Bujo H, Yamazaki K, Taira K, Takahashi K, Kobayashi J, Saito Y. Source: Biochemical and Biophysical Research Communications. 2000 October 22; 277(2): 423-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11032739
•
Differentiation of human monocytes to monocyte-derived macrophages is associated with increased lipoprotein lipase-induced tumor necrosis factor-alpha expression and production: a process involving cell surface proteoglycans and protein kinase C. Author(s): Mamputu JC, Renier G. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 1999 June; 19(6): 1405-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10364070
•
Direct determination by high-performance liquid chromatography of sn-2 monopalmitin after enzymatic lipase hydrolysis. Author(s): Lopez-Lopez A, Castellote-Bargallo AI, Lopez-Sabater MC. Source: J Chromatogr B Biomed Sci Appl. 2001 August 25; 760(1): 97-105. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11522071
•
Diurnal variation in lipoprotein lipase activity. Author(s): Arasaradnam MP, Morgan L, Wright J, Gama R. Source: Annals of Clinical Biochemistry. 2002 March; 39(Pt 2): 136-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11928761
90
Lipase
•
DNA polymorphisms of lipase related genes. Author(s): Cao H, Hegele RA. Source: Journal of Human Genetics. 2003; 48(8): 443-6. Epub 2003 August 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12898288
•
Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Author(s): Maugeais C, Tietge UJ, Broedl UC, Marchadier D, Cain W, McCoy MG, Lund-Katz S, Glick JM, Rader DJ. Source: Circulation. 2003 October 28; 108(17): 2121-6. Epub 2003 September 29. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14517167
•
Early prediction of aetiology and severity of acute pancreatitis by serum amylase and lipase assays. Author(s): Manes G, Rabitti PG, Laccetti M, Pacelli L, Carraturo I, Uomo G. Source: Minerva Gastroenterol Dietol. 1995 September; 41(3): 211-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8519858
•
Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Author(s): Kobayashi J, Maruyama T, Masuda M, Shinomiya M. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2001 December; 314(1-2): 261-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11718706
•
Effects of a brisk walk on lipoprotein lipase activity and plasma triglyceride concentrations in the fasted and postprandial states. Author(s): Gill JM, Herd SL, Vora V, Hardman AE. Source: European Journal of Applied Physiology. 2003 April; 89(2): 184-90. Epub 2003 February 07. Erratum In: Eur J Appl Physiol. 2003 May; 89(3-4): 408. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12665983
•
Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal. Author(s): Goedecke JH, Barsdorf M, Beglinger C, Levitt NS, Lambert EV. Source: International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity. 2003 December; 27(12): 1479-85. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14634678
Studies
91
•
Effects of low and moderate exercise intensity on postprandial lipemia and postheparin plasma lipoprotein lipase activity in physically active men. Author(s): Katsanos CS, Grandjean PW, Moffatt RJ. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2004 January; 96(1): 181-8. Epub 2003 August 29. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12949025
•
Effects of nonlipolytic ligand function of endothelial lipase on high density lipoprotein metabolism in vivo. Author(s): Broedl UC, Maugeais C, Marchadier D, Glick JM, Rader DJ. Source: The Journal of Biological Chemistry. 2003 October 17; 278(42): 40688-93. Epub 2003 August 08. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12909635
•
Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. Author(s): Zhi J, Moore R, Kanitra L, Mulligan TE. Source: Journal of Clinical Pharmacology. 2003 April; 43(4): 428-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12723464
•
Effects of plasma adrenaline on hormone-sensitive lipase at rest and during moderate exercise in human skeletal muscle. Author(s): Watt MJ, Stellingwerff T, Heigenhauser GJ, Spriet LL. Source: The Journal of Physiology. 2003 July 1; 550(Pt 1): 325-32. Epub 2003 May 02. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12730334
•
Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions. Author(s): Yamamoto M, Morita SY, Kumon M, Kawabe M, Nishitsuji K, Saito H, Vertut-Doi A, Nakano M, Handa T. Source: Biochimica Et Biophysica Acta. 2003 June 10; 1632(1-3): 31-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12782148
•
Effects of sphingomyelin on apolipoprotein E- and lipoprotein lipase-mediated cell uptake of lipid particles. Author(s): Morita SY, Okuhira K, Tsuchimoto N, Vertut-Doi A, Saito H, Nakano M, Handa T. Source: Biochimica Et Biophysica Acta. 2003 March 17; 1631(2): 169-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12633683
92
Lipase
•
Effects of the hepatic lipase gene and physical activity on coronary heart disease risk. Author(s): Hokanson JE, Kamboh MI, Scarboro S, Eckel RH, Hamman RF. Source: American Journal of Epidemiology. 2003 November 1; 158(9): 836-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14585761
•
Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. Author(s): Rizzo M, Taylor JM, Barbagallo CM, Berneis K, Blanche PJ, Krauss RM. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 2004 January; 24(1): 141-6. Epub 2003 November 13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14615390
•
Enhanced lipoprotein lipase secretion and foam cell formation by macrophages of patients with growth hormone deficiency: possible contribution to increased risk of atherogenesis? Author(s): Serri O, Li L, Maingrette F, Jaffry N, Renier G. Source: The Journal of Clinical Endocrinology and Metabolism. 2004 February; 89(2): 979-85. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14764824
•
Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. Author(s): Duong M, Psaltis M, Rader DJ, Marchadier D, Barter PJ, Rye KA. Source: Biochemistry. 2003 November 25; 42(46): 13778-85. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14622025
•
Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Author(s): Arnadottir M, Thysell H, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Source: Kidney International. 1995 September; 48(3): 779-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7474664
•
Exaggerated postprandial lipaemia and lower post-heparin lipoprotein lipase activity in middle-aged men. Author(s): Jackson KG, Knapper-Francis JM, Morgan LM, Webb DH, Zampelas A, Williams CM. Source: Clinical Science (London, England : 1979). 2003 October; 105(4): 457-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12812518
Studies
93
•
Expression analysis of the Candida albicans lipase gene family during experimental infections and in patient samples. Author(s): Stehr F, Felk A, Gacser A, Kretschmar M, Mahnss B, Neuber K, Hube B, Schafer W. Source: Fems Yeast Research. 2004 January; 4(4-5): 401-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14734020
•
Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native high-density lipoprotein apolipoprotein A-I. Author(s): Rashid S, Trinh DK, Uffelman KD, Cohn JS, Rader DJ, Lewis GF. Source: Circulation. 2003 June 24; 107(24): 3066-72. Epub 2003 Jun 09. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12796142
•
Factors affecting lipoprotein lipase in hypertensive patients. Author(s): Marotta T, Ferrara LA, Di Marino L, Mancini M, Annuzzi G, Russo O, D'Orta G, Lucarelli C, Rossi F. Source: Metabolism: Clinical and Experimental. 1995 June; 44(6): 712-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7783654
•
Faecal immunoreactive lipase: a simple diagnostic test for cystic fibrosis. Author(s): Munch R, Bragger CP, Altorfer J, Hoppe B, Shmerling DH, Ammann R. Source: European Journal of Pediatrics. 1998 April; 157(4): 282-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9578961
•
Familial combined hyperlipidemia and abnormal lipoprotein lipase. Author(s): Babirak SP, Brown BG, Brunzell JD. Source: Arterioscler Thromb. 1992 October; 12(10): 1176-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1390589
•
Familial lipoprotein lipase (LPL) deficiency: a catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. Author(s): Mailly F, Palmen J, Muller DP, Gibbs T, Lloyd J, Brunzell J, Durrington P, Mitropoulos K, Betteridge J, Watts G, Lithell H, Angelico F, Humphries SE, Talmud PJ. Source: Human Mutation. 1997; 10(6): 465-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9401010
•
Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study. Author(s): Feoli-Fonseca JC, Levy E, Godard M, Lambert M. Source: The Journal of Pediatrics. 1998 September; 133(3): 417-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9738727
94
Lipase
•
Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. Author(s): Georges JL, Regis-Bailly A, Salah D, Rakotovao R, Siest G, Visvikis S, Tiret L. Source: Genetic Epidemiology. 1996; 13(2): 179-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8722745
•
Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor. Author(s): Franson K, Rossner S. Source: Journal of Internal Medicine. 2000 May; 247(5): 607-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10810001
•
Fatty acid and positional selectivities of gastric lipase from premature human infants: in vitro studies. Author(s): Jensen RG, deJong FA, Lambert-Davis LG, Hamosh M. Source: Lipids. 1994 June; 29(6): 433-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8090065
•
Fatty acid specificity of hormone-sensitive lipase. Implication in the selective hydrolysis of triacylglycerols. Author(s): Raclot T, Holm C, Langin D. Source: Journal of Lipid Research. 2001 December; 42(12): 2049-57. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11734578
•
Fatty acids liberated from high-density lipoprotein phospholipids by endothelialderived lipase are incorporated into lipids in HepG2 cells. Author(s): Strauss JG, Hayn M, Zechner R, Levak-Frank S, Frank S. Source: The Biochemical Journal. 2003 May 1; 371(Pt 3): 981-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12553881
•
Fecal immunoreactive lipase, a simple diagnostic test for cystic fibrosis. Author(s): Shmerling DH. Source: European Journal of Pediatrics. 1999 April; 158(4): 339. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10206136
•
Ferrocenylnaphthalene diimide-based electrochemical hybridization assay for a heterozygous deficiency of the lipoprotein lipase gene. Author(s): Yamashita K, Takagi A, Takagi M, Kondo H, Ikeda Y, Takenaka S. Source: Bioconjugate Chemistry. 2002 November-December; 13(6): 1193-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12440853
Studies
95
•
Food deprivation increases post-heparin lipoprotein lipase activity in humans. Author(s): Ruge T, Svensson A, Eriksson JW, Olivecrona T, Olivecrona G. Source: European Journal of Clinical Investigation. 2001 December; 31(12): 1040-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11903489
•
Fourier-transform infrared assay of bile salt-stimulated lipase activity in reversed micelles. Author(s): O'Connor CJ, Cleverly DR. Source: Journal of Chemical Technology and Biotechnology (Oxford, Oxfordshire : 1986). 1994 November; 61(3): 209-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7527225
•
Frequency and allelic association of common variants in the lipoprotein lipase gene in different ethnic groups: the Wandsworth Heart and Stroke Study. Author(s): Hall S, Talmud PJ, Cook DG, Wicks PD, Rothwell MJ, Strazzullo P, Sagnella GA, Cappuccio FP. Source: Genetic Epidemiology. 2000 March; 18(3): 203-16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10723106
•
Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase. Author(s): Shen Y, Lookene A, Nilsson S, Olivecrona G. Source: The Journal of Biological Chemistry. 2002 February 8; 277(6): 4334-42. Epub 2001 November 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11719505
•
Functional characterization of 4 polymorphisms in promoter region of hepatic lipase gene. Author(s): van't Hooft FM, Lundahl B, Ragogna F, Karpe F, Olivecrona G, Hamsten A. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 2000 May; 20(5): 1335-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10807751
•
Functional characterization of a chimeric lipase genetically engineered from human lipoprotein lipase and human hepatic lipase. Author(s): Dichek HL, Parrott C, Ronan R, Brunzell JD, Brewer HB Jr, Santamarina-Fojo S. Source: Journal of Lipid Research. 1993 August; 34(8): 1393-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8409770
96
Lipase
•
Functional role of N-linked glycosylation in human hepatic lipase: asparagine-56 is important for both enzyme activity and secretion. Author(s): Wolle J, Jansen H, Smith LC, Chan L. Source: Journal of Lipid Research. 1993 December; 34(12): 2169-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8301235
•
Functional variants in the lipoprotein lipase gene and risk cardiovascular disease. Author(s): Hokanson JE. Source: Current Opinion in Lipidology. 1999 October; 10(5): 393-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10554701
•
G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Author(s): Pihlajamaki J, Karjalainen L, Karhapaa P, Vauhkonen I, Taskinen MR, Deeb SS, Laakso M. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 2000 July; 20(7): 1789-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10894818
•
Gastric lipase secretion after sham feeding and cholinergic blockade. Author(s): Wojdemann M, Olsen O, Norregaard P, Sternby B, Rehfeld JF. Source: Digestive Diseases and Sciences. 1997 May; 42(5): 1070-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9149064
•
Gastric lipase: crystal structure and activity. Author(s): Canaan S, Roussel A, Verger R, Cambillau C. Source: Biochimica Et Biophysica Acta. 1999 November 23; 1441(2-3): 197-204. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10570247
•
Gender differences in the effect of type 2 diabetes on serum lipids, pre-heparin plasma lipoprotein lipase mass and other metabolic parameters in Japanese population. Author(s): Kobayashi J, Maruyama T, Watanabe H, Kudoh A, Tateishi S, Sasaki T, Murano S, Watanabe M. Source: Diabetes Research and Clinical Practice. 2003 October; 62(1): 39-45. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14581156
•
Gender specific associations of the Trp64Arg mutation in the beta3-adrenergic receptor gene with obesity-related phenotypes in a Mediterranean population: interaction with a common lipoprotein lipase gene variation. Author(s): Corella D, Guillen M, Portoles O, Sorli JV, Alonso V, Folch J, Saiz C. Source: Journal of Internal Medicine. 2001 October; 250(4): 348-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11576322
Studies
97
•
Gender-related association between the -93T-->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. Author(s): Hoffer MJ, Bredie SJ, Snieder H, Reymer PW, Demacker PN, Havekes LM, Boomsma DI, Stalenhoef AF, Frants RR, Kastelein JJ. Source: Atherosclerosis. 1998 May; 138(1): 91-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9678774
•
Genetic polymorphisms and mutations of the lipoprotein lipase gene in Japanese schoolchildren with hypoalphalipoproteinemia. Author(s): Yamana K, Yanagi H, Hirano C, Kobayashi K, Tanaka M, Tomura S, Tsuchiya S, Hamaguchi H. Source: J Atheroscler Thromb. 1998; 4(3): 97-101. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9730139
•
Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: do they add up yet? Author(s): Anderson JL, Carlquist JF. Source: Journal of the American College of Cardiology. 2003 June 4; 41(11): 1990-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12798570
•
Genetic screening of the lipoprotein lipase gene for mutations associated with high triglyceride/low HDL-cholesterol levels. Author(s): Razzaghi H, Aston CE, Hamman RF, Kamboh MI. Source: Human Genetics. 2000 September; 107(3): 257-67. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11071388
•
Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation in LIPC gene associates with clinical outcomes in patients with established CAD. Author(s): Baroni MG, Berni A, Romeo S, Arca M, Tesorio T, Sorropago G, Di Mario U, Galton DJ. Source: Bmc Medical Genetics [electronic Resource]. 2003 September 10; 4(1): 8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12964943
•
Genetic underpinnings of LDL size and density: a role for hepatic lipase? Author(s): Havel RJ. Source: The American Journal of Clinical Nutrition. 2000 June; 71(6): 1390-1. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10837276
98
Lipase
•
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Author(s): Groenemeijer BE, Hallman MD, Reymer PW, Gagne E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ. Source: Circulation. 1997 June 17; 95(12): 2628-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9193431
•
Genetic variation at the lipoprotein lipase locus and plasma lipoprotein and insulin levels in the Quebec Family Study. Author(s): Ukkola O, Garenc C, Perusse L, Bergeron J, Despres JP, Rao DC, Bouchard C. Source: Atherosclerosis. 2001 September; 158(1): 199-206. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11500192
•
Genetic variations of the hepatic lipase gene in Korean patients with coronary artery disease. Author(s): Hong SH, Song J, Kim JQ. Source: Clinical Biochemistry. 2000 June; 33(4): 291-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10936588
•
Genetics of the lipoprotein lipase gene and hypertriglyceridaemia. Author(s): McDonnell MG, Young IS, Nicholls DP, Archbold GP, Graham CA. Source: British Journal of Biomedical Science. 2003; 60(2): 84-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12866915
•
GH but not IGF-I or insulin increases lipoprotein lipase activity in muscle tissues of hypophysectomised rats. Author(s): Oscarsson J, Ottosson M, Vikman-Adolfsson K, Frick F, Enerback S, Lithell H, Eden S. Source: The Journal of Endocrinology. 1999 February; 160(2): 247-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9924194
•
Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase. Author(s): Zdunek J, Martinez GV, Schleucher J, Lycksell PO, Yin Y, Nilsson S, Shen Y, Olivecrona G, Wijmenga S. Source: Biochemistry. 2003 February 25; 42(7): 1872-89. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12590574
Studies
99
•
Glucose ingestion blunts hormone-sensitive lipase activity in contracting human skeletal muscle. Author(s): Watt MJ, Krustrup P, Secher NH, Saltin B, Pedersen BK, Febbraio MA. Source: American Journal of Physiology. Endocrinology and Metabolism. 2004 January; 286(1): E144-50. Epub 2003 September 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14506077
•
Glycerol interference in serum lipase assay falsely indicates pancreas injury. Author(s): Bilodeau L, Grotte DA, Preese LM, Apple FS. Source: Gastroenterology. 1992 September; 103(3): 1066-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1499907
•
Glycosylation of bile salt-dependent lipase (cholesterol esterase). Author(s): Mas E, Sadoulet MO, el Battari A, Lombardo D. Source: Methods Enzymol. 1997; 284: 340-53. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9379944
•
HDL regulates the displacement of hepatic lipase from cell surface proteoglycans and the hydrolysis of VLDL triacylglycerol. Author(s): Ramsamy TA, Boucher J, Brown RJ, Yao Z, Sparks DL. Source: Journal of Lipid Research. 2003 April; 44(4): 733-41. Epub 2003 January 16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12562872
•
Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. Author(s): Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD. Source: Journal of Lipid Research. 2003 July; 44(7): 1279-86. Epub 2003 March 16. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12639974
•
Hepatic lipase C-480T polymorphism modifies the effect of HDL cholesterol on the risk of acute myocardial infarction in men: a prospective population based study. Author(s): Fan YM, Salonen JT, Koivu TA, Tuomainen TP, Nyyssonen K, Lakka TA, Salonen R, Seppanen K, Nikkari ST, Tahvanainen E, Lehtimaki T. Source: Journal of Medical Genetics. 2004 March; 41(3): E28. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14985399
•
Hepatic lipase C514T polymorphism and its relationship with plasma HDL-C levels and coronary artery disease in Koreans. Author(s): Park KW, Choi JH, Chae IH, Cho HJ, Oh S, Kim HS, Lee MM, Park YB, Choi YS. Source: J Biochem Mol Biol. 2003 March 31; 36(2): 237-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12689525
100
Lipase
•
Hepatic lipase genotype, diabetes risk, and implications for preventative medicine. Author(s): Shuldiner AR, Hoppman N, Pollin TI. Source: The Journal of Clinical Endocrinology and Metabolism. 2004 May; 89(5): 2015-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15126513
•
Hepatic lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent from SR-BI. Author(s): Brundert M, Heeren J, Greten H, Rinninger F. Source: Journal of Lipid Research. 2003 May; 44(5): 1020-32. Epub 2003 March 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12611911
•
Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Author(s): Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, Yoshida H. Source: Kidney International. 2003 November; 64(5): 1829-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14531818
•
Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. Author(s): Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG. Source: Journal of the American College of Cardiology. 2003 June 4; 41(11): 1972-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12798568
•
Hepatic lipase promoter C-514T polymorphism influences serial changes in HDL cholesterol levels since childhood: the Bogalusa Heart Study. Author(s): Chen W, Srinivasan SR, Boerwinkle E, Berenson GS; Bogalusa Heart Study. Source: Atherosclerosis. 2003 July; 169(1): 175-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12860265
•
Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. Author(s): Lambert G, Chase MB, Dugi K, Bensadoun A, Brewer HB Jr, SantamarinaFojo S. Source: Journal of Lipid Research. 1999 July; 40(7): 1294-303. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10393214
•
Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Author(s): Zambon A, Deeb SS, Pauletto P, Crepaldi G, Brunzell JD. Source: Current Opinion in Lipidology. 2003 April; 14(2): 179-89. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12642787
Studies
101
•
Hepatic lipase: a pro- or anti-atherogenic protein? Author(s): Jansen H, Verhoeven AJ, Sijbrands EJ. Source: Journal of Lipid Research. 2002 September; 43(9): 1352-62. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12235167
•
Hepatic lipase: structure/function relationship, synthesis, and regulation. Author(s): Perret B, Mabile L, Martinez L, Terce F, Barbaras R, Collet X. Source: Journal of Lipid Research. 2002 August; 43(8): 1163-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12177160
•
Hepatic triglyceride lipase promotes low density lipoprotein receptor-mediated catabolism of very low density lipoproteins in vitro. Author(s): Medh JD, Bowen SL, Fry GL, Ruben S, Hill J, Wong H, Chappell DA. Source: Journal of Lipid Research. 1999 July; 40(7): 1263-75. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10393211
•
High-density lipoprotein-cholesterol, its subfractions, and responses to exercise training are dependent on endothelial lipase genotype. Author(s): Halverstadt A, Phares DA, Ferrell RE, Wilund KR, Goldberg AP, Hagberg JM. Source: Metabolism: Clinical and Experimental. 2003 November; 52(11): 1505-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14624415
•
Hormone-sensitive lipase activity and fatty acyl-CoA content in human skeletal muscle during prolonged exercise. Author(s): Watt MJ, Heigenhauser GJ, O'Neill M, Spriet LL. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2003 July; 95(1): 314-21. Epub 2003 February 28. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12611761
•
Hormone-sensitive lipase in skeletal muscle: regulatory mechanisms. Author(s): Langfort J, Donsmark M, Ploug T, Holm C, Galbo H. Source: Acta Physiologica Scandinavica. 2003 August; 178(4): 397-403. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12864745
•
Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydrolysis. Author(s): Kraemer FB, Shen WJ. Source: Journal of Lipid Research. 2002 October; 43(10): 1585-94. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12364542
102
Lipase
•
Hormone-sensitive lipase--new roles for an old enzyme. Author(s): Yeaman SJ. Source: The Biochemical Journal. 2004 April 1; 379(Pt 1): 11-22. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14725507
•
Human hepatic and lipoprotein lipase: the loop covering the catalytic site mediates lipase substrate specificity. Author(s): Dugi KA, Dichek HL, Santamarina-Fojo S. Source: The Journal of Biological Chemistry. 1995 October 27; 270(43): 25396-401. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7592706
•
Identification of a lipoprotein lipase cofactor-binding site by chemical cross-linking and transfer of apolipoprotein C-II-responsive lipolysis from lipoprotein lipase to hepatic lipase. Author(s): McIlhargey TL, Yang Y, Wong H, Hill JS. Source: The Journal of Biological Chemistry. 2003 June 20; 278(25): 23027-35. Epub 2003 April 07. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12682050
•
Identification of a novel lipase gene mutated in lpd mice with hypertriglyceridemia and associated with dyslipidemia in humans. Author(s): Wen XY, Hegele RA, Wang J, Wang DY, Cheung J, Wilson M, Yahyapour M, Bai Y, Zhuang L, Skaug J, Young TK, Connelly PW, Koop BF, Tsui LC, Stewart AK. Source: Human Molecular Genetics. 2003 May 15; 12(10): 1131-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12719377
•
Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. Author(s): Ling C, Svensson L, Oden B, Weijdegard B, Eden B, Eden S, Billig H. Source: The Journal of Clinical Endocrinology and Metabolism. 2003 April; 88(4): 1804-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12679477
•
Identification of genetic variants in endothelial lipase in persons with elevated highdensity lipoprotein cholesterol. Author(s): deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ. Source: Circulation. 2002 September 10; 106(11): 1321-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12221047
Studies
103
•
Immunohistochemical localization of endothelial cell-derived lipase in atherosclerotic human coronary arteries. Author(s): Azumi H, Hirata K, Ishida T, Kojima Y, Rikitake Y, Takeuchi S, Inoue N, Kawashima S, Hayashi Y, Itoh H, Quertermous T, Yokoyama M. Source: Cardiovascular Research. 2003 June 1; 58(3): 647-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12798438
•
In vitro lipolysis by human pancreatic lipase is specifically abolished by its inactive forms. Author(s): Miled N, Berti-Dupuis L, Riviere M, Carriere F, Verger R. Source: Biochimica Et Biophysica Acta. 2003 February 21; 1645(2): 241-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12573254
•
Increased circulating malondialdehyde-modified LDL in the patients with familial combined hyperlipidemia and its relation with the hepatic lipase activity. Author(s): Yamazaki K, Bujo H, Taira K, Itou N, Shibasaki M, Takahashi K, Saito Y. Source: Atherosclerosis. 2004 January; 172(1): 181-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14709374
•
Increased expression of lipoprotein lipase in transgenic rabbits does not lead to abnormalities in skeletal and heart muscles. Author(s): Koike T, Wang X, Unoki H, Liang J, Ichikawa T, Kitajima S, Watanabe T, Fan J. Source: Muscle & Nerve. 2002 December; 26(6): 823-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12451608
•
Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. Author(s): Miserez AR, Muller PY, Spaniol V. Source: Aids (London, England). 2002 August 16; 16(12): 1587-94. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12172079
•
Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Author(s): Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Source: Atherosclerosis. 2001 December; 159(2): 367-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11730816
104
Lipase
•
Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. Author(s): Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Source: The Journal of Clinical Investigation. 2003 February; 111(3): 357-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12569161
•
Inhibition of lipase activity in antibiotic-resistant propionibacterium acnes strains. Author(s): Gloor M, Wasik B, Becker A, Hoffler U. Source: Dermatology (Basel, Switzerland). 2002; 205(3): 260-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12399674
•
Inhibitory effect of the pancreatic lipase C-terminal domain on intestinal lipolysis in rats fed a high-fat diet: chronic study. Author(s): Sebban-Kreuzer C, Ayvazian L, Juhel C, Salles JP, Chapus C, Kerfelec B. Source: International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity. 2003 March; 27(3): 319-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12629558
•
Inhibitory effects of human and porcine alpha-amylase on CCK-8-stimulated lipase secretion of isolated rat pancreatic acini. Author(s): Jonas L, Mikkat U, Lehmann R, Schareck W, Walzel H, Schroder W, Lopp H, Pussa T, Toomik P. Source: Pancreatology : Official Journal of the International Association of Pancreatology (Iap). [et Al.]. 2003; 3(4): 342-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12890998
•
Interaction effect of Serine447Stop variant of the lipoprotein lipase gene and C-514T variant of the hepatic lipase gene on serum triglyceride levels in young adults: the Bogalusa Heart Study. Author(s): Xin X, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS. Source: Metabolism: Clinical and Experimental. 2003 October; 52(10): 1337-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14564687
•
Interaction of the lipoprotein lipase asparagine 291-->serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors, and healthy adults. Author(s): Fisher RM, Mailly F, Peacock RE, Hamsten A, Seed M, Yudkin JS, Beisiegel U, Feussner G, Miller G, Humphries SE, et al. Source: Journal of Lipid Research. 1995 October; 36(10): 2104-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8576637
Studies
105
•
Interfacial binding of human gastric lipase to lipid monolayers, measured with an ELISA. Author(s): Aoubala M, Ivanova M, Douchet I, De Caro A, Verger R. Source: Biochemistry. 1995 August 29; 34(34): 10786-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7545008
•
Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. Author(s): Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, Galitzky J. Source: The Journal of Biological Chemistry. 2003 December 5; 278(49): 48617-26. Epub 2003 September 10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12970365
•
Is blockade of pancreatic lipase the answer? Author(s): Halsted CH. Source: The American Journal of Clinical Nutrition. 1999 June; 69(6): 1059-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10357720
•
Isolation and characterization of human milk bile salt-activated lipase C-tail fragment. Author(s): Wang CS, Dashti A, Jackson KW, Yeh JC, Cummings RD, Tang J. Source: Biochemistry. 1995 August 22; 34(33): 10639-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7654718
•
Kinetic behavior of the pancreatic lipase-colipase-lipid system. Author(s): Brockman HL. Source: Biochimie. 2000 November; 82(11): 987-95. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11099795
•
Kinetic behaviour of pancreatic lipase in five species using emulsions and monomolecular films of synthetic glycerides. Author(s): Gargouri Y, Bensalah A, Douchet I, Verger R. Source: Biochimica Et Biophysica Acta. 1995 August 3; 1257(3): 223-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7647098
•
Kinetics of in vitro lipolysis of human very low-density lipoprotein by lipoprotein lipase. Author(s): Schreier L, Berg G, Zago V, Gonzalez AI, Wikinski R. Source: Nutr Metab Cardiovasc Dis. 2002 February; 12(1): 13-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12125224
106
Lipase
•
Kinetics of lipolysis of very low density lipoproteins by lipoprotein lipase. Importance of particle number and noncompetitive inhibition by particles with low triglyceride content. Author(s): Connelly PW, Maguire GF, Vezina C, Hegele RA, Kuksis A. Source: The Journal of Biological Chemistry. 1994 August 12; 269(32): 20554-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8051155
•
Lack of association of lipoprotein lipase gene polymorphisms with coronary artery disease in the Saudi Arab population. Author(s): Abu-Amero KK, Wyngaard CA, Al-Boudari OM, Kambouris M, Dzimiri N. Source: Archives of Pathology & Laboratory Medicine. 2003 May; 127(5): 597-600. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12708905
•
Lectin-like Ox-LDL receptor is expressed in human INT-407 intestinal cells: involvement in the transcytosis of pancreatic bile salt-dependent lipase. Author(s): Bruneau N, Richard S, Silvy F, Verine A, Lombardo D. Source: Molecular Biology of the Cell. 2003 July; 14(7): 2861-75. Epub 2003 April 04. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12857870
•
Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. Author(s): Maingrette F, Renier G. Source: Diabetes. 2003 August; 52(8): 2121-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12882931
•
Letting lipids go: hormone-sensitive lipase. Author(s): Haemmerle G, Zimmermann R, Zechner R. Source: Current Opinion in Lipidology. 2003 June; 14(3): 289-97. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12840660
•
Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. Author(s): O'Donovan D, Feinle-Bisset C, Wishart J, Horowitz M. Source: The British Journal of Nutrition. 2003 November; 90(5): 849-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14667178
•
Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity. Author(s): Mathus-Vliegen EM, Van Ierland-Van Leeuwen ML, Terpstra A. Source: Alimentary Pharmacology & Therapeutics. 2004 March 1; 19(5): 601-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14987329
Studies
107
•
Lipolysis: more than just a lipase. Author(s): Birnbaum MJ. Source: The Journal of Cell Biology. 2003 June 23; 161(6): 1011-2. Epub 2003 Jun 16. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12810703
•
Lipoprotein lipase (LPL) gene variation and progression of carotid artery plaque. Author(s): Spence JD, Ban MR, Hegele RA. Source: Stroke; a Journal of Cerebral Circulation. 2003 May; 34(5): 1176-80. Epub 2003 April 10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12690214
•
Lipoprotein lipase activity and common gene variants in severely hypertriglyceridemic patients with and without diabetes. Author(s): Chadarevian R, Foubert L, Beucler I, Kottler ML, Raisonnier A, Ajlouni A, Giral P, Turpin G, Bruckert E. Source: Hormone Research. 2003; 60(2): 61-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12876415
•
Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II). Author(s): Cheung MC, Sibley SD, Palmer JP, Oram JF, Brunzell JD. Source: Journal of Lipid Research. 2003 August; 44(8): 1552-8. Epub 2003 June 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12777470
•
Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Author(s): Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Source: Scandinavian Journal of Clinical and Laboratory Investigation. 2003; 63(1): 45-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12729069
•
Lipoprotein lipase gene is in linkage with blood pressure phenotypes in Chinese pedigrees. Author(s): Yang W, Huang J, Ge D, Yao C, Duan X, Shen Y, Qiang B, Gu D. Source: Human Genetics. 2004 June; 115(1): 8-12. Epub 2004 May 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15127290
•
Lipoprotein lipase gene polymorphisms in Croatian patients with coronary artery disease. Author(s): Ferencak G, Pasalic D, Grskovic B, Cheng S, Fijal B, Sesto M, Skodlar J, Rukavina AS. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 April; 41(4): 541-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12747600
108
Lipase
•
Lipoprotein lipase gene variants and progression of nephropathy in hypercholesterolaemic patients with type 2 diabetes. Author(s): Solini A, Passaro A, Fioretto P, Nannipieri M, Ferrannini E. Source: Journal of Internal Medicine. 2004 July; 256(1): 30-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15189363
•
Lipoprotein lipase gene variants and the effect of environmental factors on cardiovascular disease risk. Author(s): Talmud PJ, Stephens JW. Source: Diabetes, Obesity & Metabolism. 2004 January; 6(1): 1-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14686956
•
Lipoprotein lipase is a gene for insulin resistance in Mexican Americans. Author(s): Goodarzi MO, Guo X, Taylor KD, Quinones MJ, Saad MF, Yang H, Hsueh WA, Rotter JI. Source: Diabetes. 2004 January; 53(1): 214-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14693718
•
Lipoprotein lipase protects bovine endothelial cells from human NK cytotoxic activity. Author(s): De Sanctis JB, Arciniegas E, Bianco NE. Source: Cellular Immunology. 2004 January; 227(1): 59-69. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15051515
•
Lipoprotein metabolism in subjects with hepatic lipase deficiency. Author(s): Tilly-Kiesi M, Schaefer EJ, Knudsen P, Welty FK, Dolnikowski GG, Taskinen MR, Lichtenstein AH. Source: Metabolism: Clinical and Experimental. 2004 April; 53(4): 520-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15045702
•
Liver receptor homolog 1 controls the expression of carboxyl ester lipase. Author(s): Fayard E, Schoonjans K, Annicotte JS, Auwerx J. Source: The Journal of Biological Chemistry. 2003 September 12; 278(37): 35725-31. Epub 2003 July 09. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12853459
Studies
109
•
Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein e knockout mice but not in C57BL/6 mice. Author(s): Wilson K, Fry GL, Chappell DA, Sigmund CD, Medh JD. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 2001 November; 21(11): 1809-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11701470
•
Mapping of the epitope on lipoprotein lipase recognized by a monoclonal antibody (5D2) which inhibits lipase activity. Author(s): Liu MS, Ma Y, Hayden MR, Brunzell JD. Source: Biochimica Et Biophysica Acta. 1992 September 22; 1128(1): 113-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1382603
•
Maturation of hepatic lipase. Formation of functional enzyme in the endoplasmic reticulum is the rate-limiting step in its secretion. Author(s): Ben-Zeev O, Doolittle MH. Source: The Journal of Biological Chemistry. 2004 February 13; 279(7): 6171-81. Epub 2003 November 20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14630921
•
Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: Comparison with postheparin plasma. Author(s): Hirano T, Nishioka F, Murakami T. Source: Metabolism: Clinical and Experimental. 2004 April; 53(4): 526-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15045703
•
Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Author(s): Rashid S, Watanabe T, Sakaue T, Lewis GF. Source: Clinical Biochemistry. 2003 September; 36(6): 421-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12951168
•
Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females. Author(s): De Oliveira e Silva ER, Kong M, Han Z, Starr C, Kass EM, Juo SH, Foster D, Dansky HM, Merkel M, Cundey K, Brinton EA, Breslow JL, Smith JD. Source: Journal of Lipid Research. 1999 July; 40(7): 1211-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10393206
110
Lipase
•
Metabolic characteristics of a human hepatoma cell line stably transfected with hormone-sensitive lipase. Author(s): Pease RJ, Wiggins D, Saggerson ED, Tree J, Gibbons GF. Source: The Biochemical Journal. 1999 July 15; 341 ( Pt 2): 453-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10393105
•
Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits. Author(s): Kee P, Rye KA, Taylor JL, Barrett PH, Barter PJ. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 2002 November 1; 22(11): 1912-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12426224
•
Metabolism of chylomicron-like emulsions in carriers of the S447X lipoprotein lipase polymorphism. Author(s): Almeida KA, Schreiber R, Amancio RF, Bydlowski SP, Debes-Bravo A, Issa JS, Strunz CM, Maranhao RC. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2003 September; 335(1-2): 157-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12927697
•
Mice expressing only covalent dimeric heparin binding-deficient lipoprotein lipase: muscles inefficiently secrete dimeric enzyme. Author(s): Lutz EP, Kako Y, Yagyu H, Heeren J, Marks S, Wright T, Melford K, BenZeev O, Radner H, Merkel M, Bensadoun A, Wong H, Goldberg IJ. Source: The Journal of Biological Chemistry. 2004 January 2; 279(1): 238-44. Epub 2003 October 21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14570890
•
Mismatch PCR: a rapid method to screen for the Pro207-->Leu mutation in the lipoprotein lipase (LPL) gene. Author(s): Bijvoet SM, Hayden MR. Source: Human Molecular Genetics. 1992 October; 1(7): 541. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1307255
•
Missense mutations in exon 5 of the human lipoprotein lipase gene. Inactivation correlates with loss of dimerization. Author(s): Hata A, Ridinger DN, Sutherland SD, Emi M, Kwong LK, Shuhua J, Lubbers A, Guy-Grand B, Basdevant A, Iverius PH, et al. Source: The Journal of Biological Chemistry. 1992 October 5; 267(28): 20132-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1400331
Studies
111
•
Moderate hyperalphalipoproteinaemia in a Brazilian population is related to lipoprotein lipase activity, apolipoprotein A-I concentration, age and body mass index. Author(s): Alarcon SB, Oliveira HC, Harada LM, Nunes VS, Kaplan D, Quintao EC, de Faria EC. Source: Clinical Science (London, England : 1979). 2004 January; 106(1): 11-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12889988
•
Molecular cloning and characterization of the mouse carboxyl ester lipase gene and evidence for expression in the lactating mammary gland. Author(s): Lidmer AS, Kannius M, Lundberg L, Bjursell G, Nilsson J. Source: Genomics. 1995 September 1; 29(1): 115-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8530060
•
Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. Author(s): Levak-Frank S, Radner H, Walsh A, Stollberger R, Knipping G, Hoefler G, Sattler W, Weinstock PH, Breslow JL, Zechner R. Source: The Journal of Clinical Investigation. 1995 August; 96(2): 976-86. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7635990
•
Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. Author(s): Pimstone SN, Gagne SE, Gagne C, Lupien PJ, Gaudet D, Williams RR, Kotze M, Reymer PW, Defesche JC, Kastelein JJ, et al. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 1995 October; 15(10): 170412. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7583547
•
Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen city heart study. Author(s): Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Deeb SS, Brunzell JD, Jensen G, Nordestgaard BG. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 1999 June; 19(6): 1535-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10364086
•
Myocardial dysfunction and male mortality in peroxisome proliferator-activated receptor alpha knockout mice overexpressing lipoprotein lipase in muscle. Author(s): Nohammer C, Brunner F, Wolkart G, Staber PB, Steyrer E, Gonzalez FJ, Zechner R, Hoefler G. Source: Laboratory Investigation; a Journal of Technical Methods and Pathology. 2003 February; 83(2): 259-69. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12594240
112
Lipase
•
Neonatal pancreatitis associated with familial lipoprotein lipase deficiency. Author(s): Siafakas CG, Brown MR, Miller TL. Source: Journal of Pediatric Gastroenterology and Nutrition. 1999 July; 29(1): 95-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10400113
•
New mutations in the lipoprotein lipase gene in a young boy with chylomicronaemia syndrome and in his family. Author(s): Brites F, Henriksen F, Fernandez K, Brusgaard K, Castro G, Wikinski R. Source: Acta Paediatrica (Oslo, Norway : 1992). 2003 May; 92(5): 621-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12839295
•
No association between the lipoprotein lipase S447X polymorphism and Alzheimer's disease. Author(s): Fidani L, Compton D, Hardy J, Petersen RC, Tangalos E, Mirtsou V, Goulas A, De Vrieze FW. Source: Neuroscience Letters. 2002 April 12; 322(3): 192-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11897170
•
No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61-->stop) in the lipoprotein lipase gene. Author(s): Ebara T, Okubo M, Horinishi A, Adachi M, Murase T, Hirano T. Source: Atherosclerosis. 2001 December; 159(2): 375-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11730817
•
No linkage of the lipoprotein lipase locus to hypertension in Caucasians. Author(s): Hunt SC, Province MA, Atwood LD, Sholinsky P, Lalouel JM, Rao DC, Williams RR, Leppert MF. Source: Journal of Hypertension. 1999 January; 17(1): 39-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10100092
•
Normal and pathological human testes express hormone-sensitive lipase and the lipid receptors CLA-1/SR-BI and CD36. Author(s): Arenas MI, Lobo MV, Caso E, Huerta L, Paniagua R, Martin-Hidalgo MA. Source: Human Pathology. 2004 January; 35(1): 34-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14745722
•
Novel compound heterozygous mutations for lipoprotein lipase deficiency. A G-to-T transversion at the first position of exon 5 causing G154V missense mutation and a 5' splice site mutation of intron 8. Author(s): Ikeda Y, Takagi A, Nakata Y, Sera Y, Hyoudou S, Hamamoto K, Nishi Y, Yamamoto A. Source: Journal of Lipid Research. 2001 July; 42(7): 1072-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11441134
Studies
113
•
Novel site in lipoprotein lipase (LPL415;-438) essential for substrate interaction and dimer stability. Author(s): Keiper T, Schneider JG, Dugi KA. Source: Journal of Lipid Research. 2001 August; 42(8): 1180-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11483618
•
Nutrient regulation of post-heparin lipoprotein lipase activity in obese subjects. Author(s): Ranganath LR, Beety JM, Wright J, Morgan LM. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 2001 January; 33(1): 57-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11280717
•
Nutritional regulation of lipoprotein lipase. Author(s): Olivecrona T, Bergo M, Hultin M, Olivecrona G. Source: The Canadian Journal of Cardiology. 1995 October; 11 Suppl G: 73G-78G. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7585297
•
One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Author(s): Finer N, James WP, Kopelman PG, Lean ME, Williams G. Source: International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity. 2000 March; 24(3): 306-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10757623
•
Optimal step length EM algorithm (OSLEM) for the estimation of haplotype frequency and its application in lipoprotein lipase genotyping. Author(s): Zhang P, Sheng H, Morabia A, Gilliam TC. Source: Bmc Bioinformatics [electronic Resource]. 2003 January 15; 4(1): 3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12529185
•
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Author(s): Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ. Source: The American Journal of Clinical Nutrition. 1999 June; 69(6): 1108-16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10357727
114
Lipase
•
Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Author(s): Ferreira LD, Pulawa LK, Jensen DR, Eckel RH. Source: Diabetes. 2001 May; 50(5): 1064-8. Erratum In: Diabetes 2001 June; 50(6): 1512. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11334409
•
Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. Author(s): Conde-Knape K, Bensadoun A, Sobel JH, Cohn JS, Shachter NS. Source: Journal of Lipid Research. 2002 December; 43(12): 2136-45. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12454276
•
Overexpression of human lipoprotein lipase protects diabetic transgenic mice from diabetic hypertriglyceridemia and hypercholesterolemia. Author(s): Shimada M, Ishibashi S, Gotoda T, Kawamura M, Yamamoto K, Inaba T, Harada K, Ohsuga J, Perrey S, Yazaki Y, et al. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 1995 October; 15(10): 168894. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7583545
•
Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholesterolemia and atherosclerosis. Author(s): Fan J, Unoki H, Kojima N, Sun H, Shimoyamada H, Deng H, Okazaki M, Shikama H, Yamada N, Watanabe T. Source: The Journal of Biological Chemistry. 2001 October 26; 276(43): 40071-9. Epub 2001 July 26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11477088
•
Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis. Author(s): Ichikawa T, Kitajima S, Liang J, Koike T, Wang X, Sun H, Okazaki M, Morimoto M, Shikama H, Watanabe T, Yamada N, Fan J. Source: Laboratory Investigation; a Journal of Technical Methods and Pathology. 2004 June; 84(6): 715-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15122303
•
Overexpression of lipoprotein lipase in transgenic Watanabe heritable hyperlipidemic rabbits improves hyperlipidemia and obesity. Author(s): Koike T, Liang J, Wang X, Ichikawa T, Shiomi M, Liu G, Sun H, Kitajima S, Morimoto M, Watanabe T, Yamada N, Fan J. Source: The Journal of Biological Chemistry. 2004 February 27; 279(9): 7521-9. Epub 2003 December 03. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14660566
Studies
115
•
Oxidative modifications of LDL increase its binding to extracellular matrix from human aortic intima: influence of lesion development, lipoprotein lipase and calcium. Author(s): Wang X, Greilberger J, Ratschek M, Jurgens G. Source: The Journal of Pathology. 2001 September; 195(2): 244-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11592105
•
Pancreatic bile salt-dependent lipase induces smooth muscle cells proliferation. Author(s): Auge N, Rebai O, Lepetit-Thevenin J, Bruneau N, Thiers JC, Mas E, Lombardo D, Negre-Salvayre A, Verine A. Source: Circulation. 2003 July 8; 108(1): 86-91. Epub 2003 June 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12821548
•
Pancreatic lipase-related protein 2 is the major colipase-dependent pancreatic lipase in suckling mice. Author(s): D'Agostino D, Lowe ME. Source: The Journal of Nutrition. 2004 January; 134(1): 132-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14704305
•
Pancreatic triacylglycerol lipase in a hibernating mammal. I. Novel genomic organization. Author(s): Squire TL, Andrews MT. Source: Physiological Genomics. 2003 December 16; 16(1): 119-30. Epub 2003 October 28. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14583598
•
Pancreatic triacylglycerol lipase in a hibernating mammal. II. Cold-adapted function and differential expression. Author(s): Squire TL, Lowe ME, Bauer VW, Andrews MT. Source: Physiological Genomics. 2003 December 16; 16(1): 131-40. Epub 2003 October 28. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14583599
•
Pathogenic mutations of the lipoprotein lipase gene in Chinese patients with hypertriglyceridemic type 2 diabetes. Author(s): Yang T, Pang CP, Tsang MW, Lam CW, Poon PM, Chan LY, Wu XQ, Tomlinson B, Baum L. Source: Human Mutation. 2003 April; 21(4): 453. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12655575
•
Plasma lipoprotein lipase, hepatic lipase activities, VLDL, LDL compositions at different times of hemodialysis. Author(s): Mekki K, Prost J, Bouchenak M, Remaoun M, Belleville J. Source: Atherosclerosis. 2003 August; 169(2): 269-77. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12921978
116
Lipase
•
Postprandial triglyceride levels in familial combined hyperlipidemia. The role of apolipoprotein E and lipoprotein lipase polymorphisms. Author(s): Reiber I, Mezo I, Kalina A, Palos G, Romics L, Csaszar A. Source: The Journal of Nutritional Biochemistry. 2003 July; 14(7): 394-400. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12915220
•
Pre-heparin lipoprotein lipase mass. Author(s): Kobayashi J. Source: J Atheroscler Thromb. 2004; 11(1): 1-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15067192
•
Preparation and characterization of reference materials for human pancreatic lipase: BCR 693 (from human pancreatic juice) and BCR 694 (recombinant). Author(s): Lessinger JM, Arzoglou P, Ramos P, Visvikis A, Parashou S, Calam D, Profilis C, Ferard G. Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 2003 February; 41(2): 169-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12667003
•
Pyrrolopyrazinedione-based inhibitors of human hormone-sensitive lipase. Author(s): Slee DH, Bhat AS, Nguyen TN, Kish M, Lundeen K, Newman MJ, McConnell SJ. Source: Journal of Medicinal Chemistry. 2003 March 27; 46(7): 1120-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12646020
•
Quantification of lipoprotein lipase (LPL) by dissociation-enhanced lanthanide fluorescence immunoassay. Comparison of immunoreactivity of LPL mass and enzyme activity of LPL. Author(s): Wicher I, Sattler W, Ibovnik A, Kostner GM, Zechner R, Malle E. Source: Journal of Immunological Methods. 1996 June 10; 192(1-2): 1-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8699004
•
Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22. Author(s): Wu DA, Bu X, Warden CH, Shen DD, Jeng CY, Sheu WH, Fuh MM, Katsuya T, Dzau VJ, Reaven GM, Lusis AJ, Rotter JI, Chen YD. Source: The Journal of Clinical Investigation. 1996 May 1; 97(9): 2111-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8621801
Studies
117
•
Race differences in the response of postheparin plasma lipoprotein lipase and hepatic lipase activities to endurance exercise training in men: results from the HERITAGE Family Study. Author(s): Bergeron J, Couillard C, Despres JP, Gagnon J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Source: Atherosclerosis. 2001 December; 159(2): 399-406. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11730820
•
Rapid exchange of pancreatic lipase between triacylglycerol droplets. Author(s): Haiker H, Lengsfeld H, Hadvary P, Carriere F. Source: Biochimica Et Biophysica Acta. 2004 June 1; 1682(1-3): 72-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15158758
•
Redesigning the active site of Geotrichum candidum lipase. Author(s): Schrag JD, Vernet T, Laramee L, Thomas DY, Recktenwald A, Okoniewska M, Ziomek E, Cygler M. Source: Protein Engineering. 1995 August; 8(8): 835-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8637854
•
Regulation of lipolysis and lipoprotein lipase after weight loss in obese, postmenopausal women. Author(s): Berman DM, Nicklas BJ, Ryan AS, Rogus EM, Dennis KE, Goldberg AP. Source: Obesity Research. 2004 January; 12(1): 32-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14742840
•
Relation between pancreatic lipase activity and gastric emptying rate in children with cystic fibrosis. Author(s): Symonds EL, Omari TI, Webster JM, Davidson GP, Butler RN. Source: The Journal of Pediatrics. 2003 December; 143(6): 772-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14657826
•
Relationship between serum HDL-C levels and common genetic variants of the endothelial lipase gene in Japanese school-aged children. Author(s): Yamakawa-Kobayashi K, Yanagi H, Endo K, Arinami T, Hamaguchi H. Source: Human Genetics. 2003 September; 113(4): 311-5. Epub 2003 July 12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12884003
•
Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins. Author(s): Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G. Source: Biochemical Society Transactions. 2003 October; 31(Pt 5): 1070-4. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14505482
118
Lipase
•
Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. Author(s): Collet X, Tall AR, Serajuddin H, Guendouzi K, Royer L, Oliveira H, Barbaras R, Jiang XC, Francone OL. Source: Journal of Lipid Research. 1999 July; 40(7): 1185-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10393203
•
Requirement for enzymatically active lipoprotein lipase in neuronal differentiation: a site-directed mutagenesis study. Author(s): Paradis E, Julien P, Ven Murthy MR. Source: Brain Research. Developmental Brain Research. 2004 March 22; 149(1): 29-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15013626
•
Retroviral-mediated gene transfer and expression of human lipoprotein lipase in somatic cells. Author(s): Lewis ME, Forsythe IJ, Marth JD, Brunzell JD, Hayden MR, Humphries RK. Source: Human Gene Therapy. 1995 July; 6(7): 853-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7578404
•
Sequence analysis of amplified DNA fragments containing the region encoding the putative lipase substrate-binding domain and genotyping of Aeromonas hydrophila. Author(s): Watanabe N, Morita K, Furukawa T, Manzoku T, Endo E, Kanamori M. Source: Applied and Environmental Microbiology. 2004 January; 70(1): 145-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14711636
•
Serum amylase and lipase alone are not cost-effective screening methods for pediatric pancreatic trauma. Author(s): Adamson WT, Hebra A, Thomas PB, Wagstaff P, Tagge EP, Othersen HB. Source: Journal of Pediatric Surgery. 2003 March; 38(3): 354-7; Discussion 354-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12632348
•
Serum amylase and lipase in diabetic ketoacidosis. Author(s): Rizvi AA. Source: Diabetes Care. 2003 November; 26(11): 3193-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14578269
•
Serum levels of bile salt-stimulated lipase and breast feeding. Author(s): Shamir R, Nganga A, Berkowitz D, Diamond E, Lischinsky S, Lombardo D, Shehadeh N. Source: J Pediatr Endocrinol Metab. 2003 December; 16(9): 1289-94. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14714753
Studies
119
•
Severe acute necrotizing pancreatitis associated with lipoprotein lipase deficiency in childhood. Author(s): van Walraven LA, de Klerk JB, Postema RR. Source: Journal of Pediatric Surgery. 2003 September; 38(9): 1407-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14523833
•
Spontaneous rupture of mediastinal cystic teratoma with high levels of amylase, lipase, CA 19-9, CA 125 and CEA in cystic fluid: a case report. Author(s): Ege G, Akman H, Cakiroglu G, Kalayci G. Source: Acta Radiologica (Stockholm, Sweden : 1987). 2004 February; 45(1): 111-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15164790
•
Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. Author(s): O'Hare MM, McMaster C, Dodge JA. Source: Journal of Pediatric Gastroenterology and Nutrition. 1995 July; 21(1): 59-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8576816
•
Structure of the pancreatic lipase-procolipase complex. Author(s): van Tilbeurgh H, Sarda L, Verger R, Cambillau C. Source: Nature. 1992 September 10; 359(6391): 159-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1522902
•
Synthesis of monocaprin catalyzed by lipase. Author(s): Da Silva MA, Medeiros VC, Langone MA, Freire DM. Source: Applied Biochemistry and Biotechnology. 2003 Spring; 105 -108: 757-67. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12721413
•
Systemic and forearm triglyceride metabolism: fate of lipoprotein lipase-generated glycerol and free fatty acids. Author(s): Miles JM, Park YS, Walewicz D, Russell-Lopez C, Windsor S, Isley WL, Coppack SW, Harris WS. Source: Diabetes. 2004 March; 53(3): 521-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14988233
•
Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Author(s): Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Source: American Journal of Physiology. Endocrinology and Metabolism. 2003 June; 284(6): E1112-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12736156
120
Lipase
•
The amino acid sequences of the carboxyl termini of human and mouse hepatic lipase influence cell surface association. Author(s): Brown RJ, Schultz JR, Ko KW, Hill JS, Ramsamy TA, White AL, Sparks DL, Yao Z. Source: Journal of Lipid Research. 2003 July; 44(7): 1306-14. Epub 2003 April 16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12700335
•
The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. Author(s): Todorova B, Kubaszek A, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study. Source: The Journal of Clinical Endocrinology and Metabolism. 2004 May; 89(5): 2019-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15126514
•
The interactive effects of hepatic lipase gene promoter polymorphisms with sex and obesity on high-density-lipoprotein cholesterol levels in Taiwanese-Chinese. Author(s): Ko YL, Hsu LA, Hsu KH, Ko YH, Lee YS. Source: Atherosclerosis. 2004 January; 172(1): 135-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14709367
•
The lipoprotein lipase gene HindIII polymorphism is associated with lipid levels in early-onset type 2 diabetic patients. Author(s): Ma YQ, Thomas GN, Ng MC, Critchley JA, Chan JC, Tomlinson B. Source: Metabolism: Clinical and Experimental. 2003 March; 52(3): 338-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12647273
•
The lipoprotein lipase Ser447Ter mutation and risk of stroke in the Chinese. Author(s): Zhao SP, Tong QG, Xiao ZJ, Cheng YC, Zhou HN, Nie S. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2003 April; 330(1-2): 161-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12636935
•
The presence of a catalytically inactive form of hormone-sensitive lipase is associated with decreased lipolysis in abdominal subcutaneous adipose tissue of obese subjects. Author(s): Ray H, Beylot M, Arner P, Larrouy D, Langin D, Holm C, Large V. Source: Diabetes. 2003 June; 52(6): 1417-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12765952
Studies
121
•
Triacylglycerols based on 2-(N-tert-butoxycarbonylamino)oleic acid are potent inhibitors of pancreatic lipase. Author(s): Magrioti V, Verger R, Constantinou-Kokotou V. Source: Journal of Medicinal Chemistry. 2004 January 15; 47(2): 288-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14711301
•
Two cases with transient lipoprotein lipase (LPL) activity impairment: evidence for the possible involvement of an LPL inhibitor. Author(s): Nagasaka H, Kikuta H, Chiba H, Murano T, Harashima H, Ohtake A, Senzaki H, Sasaki N, Inoue I, Katayama S, Shirai K, Kobayashi K. Source: European Journal of Pediatrics. 2003 March; 162(3): 132-8. Epub 2003 January 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12655414
•
Underestimation of acute pancreatitis: patients with only a small increase in amylase/lipase levels can also have or develop severe acute pancreatitis. Author(s): Lankisch PG, Burchard-Reckert S, Lehnick D. Source: Gut. 1999 April; 44(4): 542-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10075962
•
Upregulation of macrophage lipoprotein lipase in patients with type 2 diabetes: role of peripheral factors. Author(s): Sartippour MR, Renier G. Source: Diabetes. 2000 April; 49(4): 597-602. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10871197
•
Uptake of hypertriglyceridemic very low density lipoproteins and their remnants by HepG2 cells: the role of lipoprotein lipase, hepatic triglyceride lipase, and cell surface proteoglycans. Author(s): Huff MW, Miller DB, Wolfe BM, Connelly PW, Sawyez CG. Source: Journal of Lipid Research. 1997 July; 38(7): 1318-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9254059
•
Use of naturally fluorescent triacylglycerols from Parinari glaberrimum to detect low lipase activities from Arabidopsis thaliana seedlings. Author(s): Beisson F, Ferte N, Nari J, Noat G, Arondel V, Verger R. Source: Journal of Lipid Research. 1999 December; 40(12): 2313-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10588957
•
Use of pyrenemethyl laurate for fluorescence-based determination of lipase activity in intact living lymphoblastoid cells and for the diagnosis of acid lipase deficiency. Author(s): Negre-Salvayre A, Dagan A, Gatt S, Salvayre R. Source: The Biochemical Journal. 1993 September 15; 294 ( Pt 3): 885-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8397511
122
Lipase
•
Variants in the cholesterol ester transfer protein and lipoprotein lipase genes are predictors of plasma cholesterol response to dietary change. Author(s): Wallace AJ, Mann JI, Sutherland WH, Williams S, Chisholm A, Skeaff CM, Gudnason V, Talmud PJ, Humphries SE. Source: Atherosclerosis. 2000 October; 152(2): 327-36. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10998460
•
Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status. Author(s): Peacock RE, Temple A, Gudnason V, Rosseneu M, Humphries SE. Source: Genetic Epidemiology. 1997; 14(3): 265-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9181356
•
Variation in the promoter of the human hormone sensitive lipase gene shows gender specific effects on insulin and lipid levels: results from the Ely study. Author(s): Talmud PJ, Palmen J, Luan J, Flavell D, Byrne CD, Waterworth DM, Wareham NJ. Source: Biochimica Et Biophysica Acta. 2001 November 29; 1537(3): 239-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11731226
•
Variation near the region of the lipoprotein lipase gene and hypertension or blood pressure levels in Chinese. Author(s): Yang W, Huang J, Ge D, Yao C, Duan X, Gan W, Huang G, Zhao J, Hui R, Shen Y, Qiang B, Gu D. Source: Hypertens Res. 2003 June; 26(6): 459-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12862202
•
Very-low-density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro. Author(s): Arnadottir M, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Source: Metabolism: Clinical and Experimental. 1996 June; 45(6): 686-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8637441
•
Virolytic action of lipoprotein lipase on hepatitis C virus in human sera. Author(s): Thomssen R, Bonk S. Source: Medical Microbiology and Immunology. 2002 May; 191(1): 17-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12137195
Studies
123
•
Visceral adiposity, C-peptide levels, and low lipase activities predict HIVdyslipidemia. Author(s): Yarasheski KE, Tebas P, Claxton S, Marin D, Coleman T, Powderly WG, Semenkovich CF. Source: American Journal of Physiology. Endocrinology and Metabolism. 2003 October; 285(4): E899-905. Epub 2003 July 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12837664
•
Visceral obesity attenuates the effect of the hepatic lipase -514C>T polymorphism on plasma HDL-cholesterol levels in French-Canadian men. Author(s): St-Pierre J, Miller-Felix I, Paradis ME, Bergeron J, Lamarche B, Despres JP, Gaudet D, Vohl MC. Source: Molecular Genetics and Metabolism. 2003 January; 78(1): 31-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12559845
•
Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes. Author(s): Sibley SD, Palmer JP, Hirsch IB, Brunzell JD. Source: The Journal of Clinical Endocrinology and Metabolism. 2003 July; 88(7): 3379-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12843191
•
VLDL-bound lipoprotein lipase facilitates the cholesteryl ester transfer proteinmediated transfer of cholesteryl esters from HDL to VLDL. Author(s): Pruneta V, Pulcini T, Lalanne F, Marcais C, Berthezene F, Ponsin G, Moulin P. Source: Journal of Lipid Research. 1999 December; 40(12): 2333-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10588959
•
What is the long-term efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity in primary care? Author(s): Leiser JP, Gunning K. Source: The Journal of Family Practice. 2000 June; 49(6): 572-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10923560
125
CHAPTER 2. NUTRITION AND LIPASE Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and lipase.
Finding Nutrition Studies on Lipase The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “lipase” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
126
Lipase
The following is a typical result when searching for recently indexed consumer information on lipase: •
Characteristics and benefits of bile salt-stimulated lipase in human milk. Source: Nutrition-reviews (USA). (November 1984). volume 42(11) page 372-373.
Additional consumer oriented references include: •
Free fatty acids in plasma may exert feed-back control of lipoprotein lipase activity. Author(s): Department of Biochemistry, Vanderbilt University, Nashville, TN 37232. Source: Coniglio, J G Nutr-Revolume 1993 January; 51(1): 18-9 0029-6643
•
Gastric lipase and digestion of human milk fat. Source: Schoeller, D.A. Nutr-Rev. New York, N.Y. : Springer-Verlag New York Inc. October 1990. volume 48 (10) page 385-387. 0029-6643
•
Lipoprotein lipase genetic variation and gender-specific ischemic cerebrovascular disease risk. Author(s): Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA. Source: Ordovas, J M Nutr-Revolume 2000 October; 58(10): 315-8 0029-6643
•
Rapid movement of lipoprotein lipase among substrate globules. Source: Nutr-Rev. Washington, D.C. : Nutrition Foundation. January 1985. volume 43 (1) page 29-30. 0029-6643
The following information is typical of that found when using the “Full IBIDS Database” to search for “lipase” (or a synonym): •
The effects of the long-term feeding of dietary lipase on the performance of laying hens. Author(s): Mendelova Zemedelska a Lesnicka Univ., Brno (Czech Republic). Ustav Chovu Hospodarskych Zvirat Source: Lichovnikova, M. Zeman, L. Klecker, D. Fialova, M. Czech-Journal-of-AnimalScience-UZPI (Czech Republic). (April 2002). volume 47(4) page 141-145.
Additional physician-oriented references include: •
A novel missense mutation in the gene for lipoprotein lipase resulting in a highly conservative amino acid substitution (Asp180 replaced by Glu) causes familial chylomicronemia (Type 1 hyperlipoproteinemia). Source: Haubenwallner, S. Horl, G. Shachter, N.S. Presta, E. Fried, S.K. Hofler, G. Kostner, G.M. Breslow, J.L. Zechner, R. Genomics. Orlando, Fla. : Academic Press, Inc. November 1993. volume 18 (2) page 392-396. 0888-7543
•
Alternate conformations observed in catalytic serine of Bacillus subtilis lipase determined at 1.3 A resolution. Author(s): Structural Biology Group, Research Institute of Biological Resources, National Institute of Advanced Industrial Science and Technology (AIST), 2-17-2-1 Tsukisamu-Higashi, Toyohira, Sapporo 062-8517, Japan. Source: Kawasaki, K Kondo, H Suzuki, M Ohgiya, S Tsuda, S Acta-Crystallogr-D-BiolCrystallogr. 2002 July; 58(Pt 7): 1168-74 0907-4449
Nutrition
127
•
Blocking the tunnel: engineering of Candida rugosa lipase mutants with short chain length specificity. Author(s): Institute of Technical Biology, University of Stuttgart, Allmandring 31, D70569 Stuttgart, Germany. Source: Schmitt, J Brocca, S Schmid, R D Pleiss, J Protein-Eng. 2002 July; 15(7): 595-601 0269-2139
•
Changes in lipid content and lipase activity in the hen liver before and after the onset of laying. Source: Fujii, M. Fukunaga, T. Koga, K. New strategies for improving animal production for human welfare : proceedings / the Fifth World Conference on Animal Production, August 14-19, 1983. Tokyo, Japan : Japanese Society of Zootechnical Science, 1983. volume 2 page 285-286.
•
Changes of gastric lipase activity after ethanol and indomethacin administration: influence of pretreatment with allopurinol, pentoxifylline and L-DOPA. Author(s): Department of Pharmacology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovak Republic. Source: Sedlakova, A Kohut, A Sarissky, M Physiol-Res. 2001; 50(3): 299-307 0862-8408
•
Combined effect of a lecithin and a bile salt on pancreatic lipase activity. Source: Lykidis, A. Avranas, A. Arzoglou, P. Comp-biochem-physiol-Part-B,-Biochemmol-biol. Tarrytown, NY : Elsevier Science Inc. January 1997. volume 116B (1) page 5155.
•
Conversion of Bacillus thermocatenulatus lipase into an efficient phospholipase with increased activity towards long-chain fatty acyl substrates by directed evolution and rational design. Author(s): Institute for Technical Biochemistry, University of Stuttgart, Allmandring 31, D-70569 Stuttgart, Germany. Source: Kauffmann, I Schmidt Dannert, C Protein-Eng. 2001 November; 14(11): 919-28 0269-2139
•
Effect of dichlorvos on the activity of lipoprotein lipase from adipose tissue, on plasma lipids and postheparin lipolytic plasma activity in rats. Source: Kozlowska, A. Sadurska, B. Szymczyk, T. Arch-Toxicol. Berlin, W. Ger. : Springer. 1988. volume 62 (2/3) page 227-229. 0340-5761
•
Effect of dietary fatty acids on lipoprotein lipase gene expression in the liver and visceral adipose tissue of fed and starved red sea bream Pagrus major. Author(s): National Research Institute of Aquaculture, Nansei, Mie 516-0193, Japan. Source: Liang, X F Ogata, H Y Oku, H Comp-Biochem-Physiol-A-Mol-Integr-Physiol. 2002 August; 132(4): 913-9 1095-6433
•
Effect of lipase activities of Propionibacterium granulosum and Propionibacterium acnes. Author(s): Department of Dermatology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan. Source: Higaki, S Nakamura, M Kitagawa, T Morohashi, M Yamagishi, T Drugs-ExpClin-Res. 2001; 27(5-6): 161-4 0378-6501
•
Effects of hepatic lipase gene promoter nucleotide variations on serum HDL cholesterol concentration in the general Japanese population. Author(s): The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.
[email protected]
128
Lipase
Source: Inazu, A Nishimura, Y Terada, Y Mabuchi, H J-Hum-Genet. 2001; 46(4): 172-7 1434-5161 •
Effects of hormones, fasting and diabetes on triglyceride lipase activities in rat heart and liver. Source: Stam, H. Schoonderwoerd, K. Breeman, W. Hulsmann, W.C. Horm-Metab-Res. Stuttgart, W. Ger. : Georg Thieme. June 1984. volume 16 (6) page 293-297. ill. 0018-5043
•
Familial lipoprotein lipase deficiency and related disorders of chylomicron metabolism. Source: Nikkila, E.A. The Metabolic basis of inherited disease / [edited by] John B. Stanbury. [et al.]. 5th ed. New York : McGraw-Hill, 1983. page 622-642. ill. ISBN: 0070607265
•
Hydrolysis of plant oils by means of lipase from Rhizopus nigricans. Source: Rucka, M. Turkiewicz, B. Zuk, J.S. Krystynowicz, A. Galas, E. Bioprocess-Eng. Berlin, W. Ger. : Springer-Verlag. November 1991. volume 7 (3) page 133-135. 0178-515X
•
Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. Author(s): Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, B.C, Canada. Source: Ramaswamy, Manisha Yau, Edwin Wasan, Kishor M Boulanger, Kathy D Li, Ming Pritchard, P Haydn J-Pharm-Pharm-Sci. 2002 April; 5(1): 29-38 1482-1826
•
Influence of processing temperature and seasonal change in diet on lipase activity and lipolysis during the mechanical separation of bovine milk. Source: Needs, E.C. Anderson, M. Payne, S.J. Ridout, E.A. J-Dairy-Res. Cambridge : Cambridge University Press. May 1985. volume 52 (2) page 255-266. ill. 0022-0299
•
Interaction of the common apolipoprotein C-III (APOC3 -482C > T) and hepatic lipase (LIPC -514C > T) promoter variants affects glucose tolerance in young adults. European Atherosclerosis Research Study II (EARS-II). Author(s): Department of Internal Medicien, Erasmus University, Rotterdam, The Netherlands.
[email protected] Source: Jansen, H Waterworth, D M Nicaud, V Ehnholm, C Talmud, P J Ann-HumGenet. 2001 May; 65(Pt 3): 237-43 0003-4800
•
Lipoprotein lipase and lysosomal acid lipase: two key enzymes of lipid metabolism. Source: Ameris, D. Greten, H. NATO-ASI-ser,-Ser-A,-Life-sci. New York : Plenum, 1984-. 1994. volume 266 page 121-128. 0258-1213
•
Microwave-assisted rapid characterization of lipase selectivities. Author(s): Biotechnology Department, Center for Chemistry and Chemical Engineering, Lund University, Box 124, SE-22100, Lund, Sweden. Source: Bradoo, Sapna Rathi, Pooja Saxena, R K Gupta, Rani J-Biochem-BiophysMethods. 2002 April 18; 51(2): 115-20 0165-022X
•
Modifying the chain-length selectivity of the lipase from Burkholderia cepacia KWI56 through in vitro combinatorial mutagenesis in the substrate-binding site. Author(s): Laboratory of Molecular Biotechnology, Graduate School of Biological and Agricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan. Source: Yang, J Koga, Y Nakano, H Yamane, T Protein-Eng. 2002 February; 15(2): 147-52 0269-2139
Nutrition
129
•
Modulation of adipocyte lipoprotein lipase expression as a strategy for preventing or treating visceral obesity. Author(s): Pantox Laboratories, 4622 Santa Fe St, San Diego, CA 92109, USA. Source: McCarty, M F Med-Hypotheses. 2001 August; 57(2): 192-200 0306-9877
•
Retinal pigment epithelial acid lipase activity and lipoprotein receptors: effects of dietary omega-3 fatty acids. Author(s): Department of Ophthalmology, University of Michigan, Ann Arbor, USA. Source: Elner, V M Trans-Am-Ophthalmol-Soc. 2002; 100: 301-38 0065-9533
•
Site differences in lipoprotein lipase activity. Source: Lithell, H. Recent-Adv-Obesity-Res. London : John Libbey & Company. 1987. page 77-81. 0306-7548
•
Structural characterization of the N-linked oligosaccharides in bile salt-stimulated lipase originated from human breast milk. Source: Mechref, Y. Chen, P. Novotny, M.V. Glycobiology. Oxford : Oxford University Press. March 1999. volume 9 (3) page 227-234. 0959-6658
•
Studies on the production of lipase from recombinant Staphylococcus carnosus. Source: Falk, M.P.F. Sanders, E.A. Deckwer, W.D. Appl-Microbiol-Biotech. Berlin, W. Ger. : Springer International. April 1991. volume 35 (1) page 10-13. 0175-7598
•
Synthesis of extracellular lipase by a strain of Pseudomonas fluorescens isolated from raw camel milk. Source: Al Saleh, A.A. Zahran, A.S. Food-microbiol. London; Orlando : Academic Press, c1984-. April 1999. volume 16 (2) page 149-156. 0740-0020
•
The crystal and molecular structure of the Rhizomucor miehei triacylglyceride lipase at 1.9 angstrom resolution. Source: Derewenda, Z.S. Derewenda, U. Dodson, G.G. J-Mol-Biol. London : Academic Press. October 5, 1992. volume 227 (3) page 818-839. 0022-2836
•
The Drosophila melanogaster lipase homologs: a gene family with tissue and developmental specific expression. Source: Pistillo, D. Manzi, A. Tino, A. Boyl, P.P. Graziani, F. Malva, C. J-mol-biol. London; New York : Academic Press, 1959-. March 13, 1998. volume 276 (5) page 877885. 0022-2836
•
The effects of feeding condition and dietary lipid level on lipoprotein lipase gene expression in liver and visceral adipose tissue of red sea bream Pagrus major. Author(s): Fish Nutrition Division, National Research Institute of Aquaculture, Nansei, Mie 516-0193, Japan. Source: Liang, Xu Fang Oku, Hiromi Ogata, Hiroshi Y Comp-Biochem-Physiol-A-MolIntegr-Physiol. 2002 February; 131(2): 335-42 1095-6433
•
The role of nitrogen sources, vitamines and growth factors in lipase production by Penicillium lanosum westling. Source: Elwan, S.H. El Naggar, M.R. El Sheikh, H.H. J-Coll-Sci-King-Saud-Univ. Riyadh, Saudi Arabia : University Libraries, King Saud University. 1982. volume 13 (2) page 215226. 0735-9799
•
The structure of truncated recombinant human bile salt-stimulated lipase reveals bile salt-independent conformational flexibility at the active-site loop and provides insights into heparin binding. Author(s): Institute of Molecular Biosciences, Massey University, Palmerston North, New Zealand.
130
Lipase
Source: Moore, S A Kingston, R L Loomes, K M Hernell, O Blackberg, L Baker, H M Baker, E N J-Mol-Biol. 2001 September 21; 312(3): 511-23 0022-2836 •
Yeast whole-cell biocatalyst constructed by intracellular overproduction of Rhizopus oryzae lipase is applicable to biodiesel fuel production. Author(s): Division of Molecular Science, Graduate School of Science and Technology, Kobe University, Japan. Source: Matsumoto, T Takahashi, S Kaieda, M Ueda, M Tanaka, A Fukuda, H Kondo, A Appl-Microbiol-Biotechnol. 2001 November; 57(4): 515-20 0175-7598
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
Nutrition
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
131
133
CHAPTER 3. ALTERNATIVE MEDICINE AND LIPASE Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to lipase. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to lipase and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “lipase” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to lipase: •
2,3,7,8-Tetrachlorodibenzo-p-dioxin mechanism of action to reduce lipoprotein lipase activity in the 3T3-L1 preadipocyte cell line. Author(s): Olsen H, Enan E, Matsumura F. Source: Journal of Biochemical and Molecular Toxicology. 1998; 12(1): 29-39. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9414485
•
3-Methylethergalangin isolated from Alpinia officinarum inhibits pancreatic lipase. Author(s): Shin JE, Joo Han M, Kim DH. Source: Biological & Pharmaceutical Bulletin. 2003 June; 26(6): 854-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12808299
•
A novel spectrophotometric assay for lipase activity utilizing cis-parinaric acid. Author(s): Rogel AM, Stone WL, Adebonojo FO.
134
Lipase
Source: Lipids. 1989 June; 24(6): 518-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2770430 •
A rapid colorimetric assay for the extracellular lipase of Pseudomonas fluorescens B52 using beta-naphthyl caprylate. Author(s): McKellar RC. Source: The Journal of Dairy Research. 1986 February; 53(1): 117-27. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3082952
•
A vanadyl sulfate-bovine serum albumin complex stimulates the release of lipoprotein lipase activity from isolated rat fat pads through an increase in the cellular content of cAMP and myo-inositol 1,4,5-trisphosphate. Author(s): Motoyashiki T, Miyake M, Yoshida A, Morita T, Ueki H. Source: Biological & Pharmaceutical Bulletin. 1999 August; 22(8): 780-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10480313
•
Acid lipase in rat intestinal mucosa: physiological parameters. Author(s): Rao RH, Mansbach CM 2nd. Source: Biochimica Et Biophysica Acta. 1990 April 17; 1043(3): 273-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2322572
•
Adaptation of pancreatic lipase to the amount and nature of dietary lipids in the growing pig. Author(s): Simoes Nunes C. Source: Reproduction, Nutrition, Development. 1986; 26(6): 1273-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3823602
•
Adipose hormone-sensitive lipase preferentially releases polyunsaturated fatty acids from triglycerides. Author(s): Gavino VC, Gavino GR. Source: Lipids. 1992 December; 27(12): 950-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1362594
•
Ajoene prevents fat digestion by human gastric lipase in vitro. Author(s): Gargouri Y, Moreau H, Jain MK, de Haas GH, Verger R. Source: Biochimica Et Biophysica Acta. 1989 November 6; 1006(1): 137-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2804064
•
Alkaline lipase in rat intestinal mucosa: physiological parameters. Author(s): Rao RH, Mansbach CM 2nd.
Alternative Medicine 135
Source: Archives of Biochemistry and Biophysics. 1993 August 1; 304(2): 483-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8346923 •
An accessory gene, lipB, required for the production of active Pseudomonas glumae lipase. Author(s): Frenken LG, Bos JW, Visser C, Muller W, Tommassen J, Verrips CT. Source: Molecular Microbiology. 1993 August; 9(3): 579-89. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8412704
•
Anti-lipase activity of Kampo formulations, coptidis rhizoma and its alkaloids against Propionibacterium acnes. Author(s): Higaki S, Nakamura M, Morohashi M, Hasegawa Y, Yamagishi T. Source: The Journal of Dermatology. 1996 May; 23(5): 310-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8675819
•
Anti-lipase activity of Unsei-in against Propionibacterium avidum in the human axilla. Author(s): Higaki S, Morohashi M, Yamagishi T. Source: International Journal of Antimicrobial Agents. 2003 June; 21(6): 597-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12791480
•
Anti-obesity effect of Dioscorea nipponica Makino with lipase-inhibitory activity in rodents. Author(s): Kwon CS, Sohn HY, Kim SH, Kim JH, Son KH, Lee JS, Lim JK, Kim JS. Source: Bioscience, Biotechnology, and Biochemistry. 2003 July; 67(7): 1451-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12913286
•
Anti-obesity effects of lipase inhibitor CT-II, an extract from edible herbs, Nomame Herba, on rats fed a high-fat diet. Author(s): Yamamoto M, Shimura S, Itoh Y, Ohsaka T, Egawa M, Inoue S. Source: International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity. 2000 June; 24(6): 758-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10878683
•
ATP-induced potentiation of G-protein-dependent phospholipase D activity in a cellfree system from U937 promonocytic leukocytes. Author(s): Kusner DJ, Schomisch SJ, Dubyak GR. Source: The Journal of Biological Chemistry. 1993 September 25; 268(27): 19973-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8376359
•
Basic fibroblast growth factor-stimulated arachidonic acid release in rat pancreatic acini: sequential action of tyrosine kinase, phospholipase C, protein kinase C and
136
Lipase
diacylglycerol lipase. Author(s): Hou W, Arita Y, Morisset J. Source: Cellular Signalling. 1996 November; 8(7): 487-96. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9023013 •
Beneficial effects of fish-oil supplements on lipids, lipoproteins, and lipoprotein lipase in patients with glycogen storage disease type I. Author(s): Levy E, Thibault L, Turgeon J, Roy CC, Gurbindo C, Lepage G, Godard M, Rivard GE, Seidman E. Source: The American Journal of Clinical Nutrition. 1993 June; 57(6): 922-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8503363
•
Bile salt-dependent lipase biosynthesis in rat pancreatic AR 4-2 J cells. Essential requirement of N-linked oligosaccharide for secretion and expression of a fully active enzyme. Author(s): Abouakil N, Mas E, Bruneau N, Benajiba A, Lombardo D. Source: The Journal of Biological Chemistry. 1993 December 5; 268(34): 25755-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8245011
•
Biocatalytic potential of Fusarium globulosum lipase in selective acetylation/deacetylation reactions and in ester synthesis. Author(s): Gulati R, Bhattacharya A, Prasad AK, Gupta R, Parmar VS, Saxena RK. Source: Journal of Applied Microbiology. 2001 April; 90(4): 609-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11309073
•
Biochemical analysis of a native and proteolytic fragment of a high-molecular-weight thermostable lipase from a mesophilic Bacillus sp. Author(s): Dosanjh NS, Kaur J. Source: Protein Expression and Purification. 2002 February; 24(1): 71-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11812225
•
Biotechnology for the production of nutraceuticals enriched in conjugated linoleic acid: I. Uniresponse kinetics of the hydrolysis of corn oil by a pseudomonas sp. lipase immobilized in a hollow fiber reactor Author(s): Sehanputri PS, Hill CG Jr. Source: Biotechnology and Bioengineering. 1999 September 5; 64(5): 568-79. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10404237
•
Biotechnology for the production of nutraceuticals enriched in conjugated linoleic acid: II. Multiresponse kinetics of the hydrolysis of corn oil by a Pseudomonas sp. lipase immobilized in a hollow-fiber reactor. Author(s): Sehanputri PS, Hill CG Jr.
Alternative Medicine 137
Source: Biotechnology and Bioengineering. 2000 August 20; 69(4): 450-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10862683 •
Calcium ion-dependent reactivation of a Pseudomonas lipase by its specific modulating protein, LipB. Author(s): Shibata H, Kato H, Oda J. Source: Journal of Biochemistry. 1998 January; 123(1): 136-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9504420
•
Changes in lipolysis and hormone-sensitive lipase expression caused by procyanidins in 3T3-L1 adipocytes. Author(s): Ardevol A, Blade C, Salvado MJ, Arola L. Source: International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity. 2000 March; 24(3): 319-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10757625
•
Characterisation of a phospholipase C produced by Pseudomonas fluorescens. Author(s): Ivanov A, Titball RW, Kostadinova S. Source: New Microbiol. 1996 April; 19(2): 113-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8722307
•
Characterization and physicochemical properties of a lipase from Pseudomonas mendocina 3121-1. Author(s): Surinenaite B, Bendikiene V, Juodka B, Bachmatova I, Marcinkevichiene L. Source: Biotechnology and Applied Biochemistry. 2002 August; 36(Pt 1): 47-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12149122
•
Characterization of a highly thermostable extracellular lipase from Lactobacillus plantarum. Author(s): Lopes Mde F, Leitao AL, Regalla M, Marques JJ, Carrondo MJ, Crespo MT. Source: International Journal of Food Microbiology. 2002 June 5; 76(1-2): 107-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12038566
•
Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. Author(s): Ruel IL, Couture P, Gagne C, Deshaies Y, Simard J, Hegele RA, Lamarche B. Source: Journal of Lipid Research. 2003 August; 44(8): 1508-14. Epub 2003 June 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12777476
•
Characterization of a pyoverdine-deficient mutant of Pseudomonas fluorescens impaired in the secretion of extracellular lipase. Author(s): Fernandez L, San Jose C, Cholette H, McKellar RC.
138
Lipase
Source: Archives of Microbiology. 1988; 150(6): 523-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3144957 •
Characterization of LDL particle size among carriers of a defective or a null mutation in the lipoprotein lipase gene: the Quebec LIPD Study. Author(s): Ruel IL, Gaudet D, Perron P, Bergeron J, Julien P, Lamarche B. Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 2002 July 1; 22(7): 1181-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12117735
•
Characterization of lipoprotein lipase activity, secretion, and degradation at different sites of post-translational processing in primary cultures of rat adipocytes. Author(s): Simsolo RB, Ong JM, Kern PA. Source: Journal of Lipid Research. 1992 December; 33(12): 1777-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1479287
•
Comparative effects of dietary fish oil and carbohydrate on plasma lipids and hepatic activities of phosphatidate phosphohydrolase, diacylglycerol acyltransferase and neutral lipase activities in the rat. Author(s): Marsh JB, Topping DL, Nestel PJ. Source: Biochimica Et Biophysica Acta. 1987 November 21; 922(2): 239-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2823908
•
Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients. Author(s): Gan KH, Heijerman HG, Geus WP, Bakker W, Lamers CB. Source: Alimentary Pharmacology & Therapeutics. 1994 December; 8(6): 603-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7696449
•
Comparison of the lipolysis of chylomicron remnants derived from corn oil or olive oil by hepatic lipase in vitro. Author(s): Botham KM, Mayes PA, Avella M, Cantafora A, Bravo E. Source: Biochemical Society Transactions. 1995 May; 23(2): 284S. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7672310
•
Corn oil, palm oil and butterfat fractions affect postprandial lipemia and lipoprotein lipase in meal-fed rats. Author(s): Lai HC, Ney DM. Source: The Journal of Nutrition. 1995 June; 125(6): 1536-45. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7782908
•
Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Author(s): Kim YS, Jung EA, Shin JE, Chang JC, Yang HK, Kim NJ, Cho KH, Bae HS, Moon SK, Kim DH.
Alternative Medicine 139
Source: Biological & Pharmaceutical Bulletin. 2002 November; 25(11): 1442-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12419956 •
Degradation of arachidonyl phospholipids catalyzed by two phospholipases A2 and phospholipase C in a lipopolysaccharide-treated macrophage cell line RAW264.7. Author(s): Tanaka Y, Amano F, Kishi H, Nishijima M, Akamatsu Y. Source: Archives of Biochemistry and Biophysics. 1989 July; 272(1): 210-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2500062
•
Differences in glucose-dependent insulinotrophic polypeptide hormone and hepatic lipase in subjects of southern and northern Europe: implications for postprandial lipemia. Author(s): Jackson KG, Zampelas A, Knapper JM, Roche HM, Gibney MJ, Kafatos A, Gould BJ, Wright JW, Williams CM. Source: The American Journal of Clinical Nutrition. 2000 January; 71(1): 13-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10617941
•
Digestion of triacylglycerols containing long-chain polyenoic fatty acids in vitro by colipase-dependent pancreatic lipase and human milk bile salt-stimulated lipase. Author(s): Chen Q, Blackberg L, Nilsson A, Sternby B, Hernell O. Source: Biochimica Et Biophysica Acta. 1994 January 3; 1210(2): 239-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8280776
•
Does the bile salt-stimulated lipase of human milk have a role in the use of the milk long-chain polyunsaturated fatty acids? Author(s): Hernell O, Blackberg L, Chen Q, Sternby B, Nilsson A. Source: Journal of Pediatric Gastroenterology and Nutrition. 1993 May; 16(4): 426-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8315552
•
Does vitellogenin inhibit lipoprotein lipase in the laying hen? Author(s): Griffin H. Source: Comparative Biochemistry and Physiology. B, Comparative Biochemistry. 1986; 85(2): 469-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3096631
•
Dyslipidaemia in a boy with recurrent abdominal pain, hypersalivation and decreased lipoprotein lipase activity. Author(s): Matern D, Seydewitz H, Niederhoff H, Wiebusch H, Brandis M. Source: European Journal of Pediatrics. 1996 August; 155(8): 660-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8839720
140
Lipase
•
Effect of 6 dietary fatty acids on the postprandial lipid profile, plasma fatty acids, lipoprotein lipase, and cholesterol ester transfer activities in healthy young men. Author(s): Tholstrup T, Sandstrom B, Bysted A, Holmer G. Source: The American Journal of Clinical Nutrition. 2001 February; 73(2): 198-208. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11157314
•
Effect of Acanthopanax senticosus on lipoprotein lipase in 3T3-L1 adipocytes. Author(s): Yang JY, Lee KS, Kim MK, Moon SK, Kang MK, Park BH, Kim JS, Park JW. Source: Phytotherapy Research : Ptr. 2004 February; 18(2): 160-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15022170
•
Effect of bacterial or porcine lipase with low- or high-fat diets on nutrient absorption in pancreatic-insufficient dogs. Author(s): Suzuki A, Mizumoto A, Rerknimitr R, Sarr MG, DiMango EP. Source: Gastroenterology. 1999 February; 116(2): 431-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9922325
•
Effect of capsaicin on skeletal muscle lipoprotein lipase in rats fed high fat diet. Author(s): Srinivasan MR, Satyanarayana MN. Source: Indian J Exp Biol. 1989 October; 27(10): 910-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2635151
•
Effect of cod liver oil supplementation on plasma lipids, lipoproteins, lipase activity and platelet aggregation in normotensive and hypertensive volunteers. Author(s): Jethmalani SM, Viswanathan G, Noronha JM. Source: Indian J Exp Biol. 1989 December; 27(12): 1103-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2633973
•
Effect of dietary fatty acids on lipoprotein lipase gene expression in the liver and visceral adipose tissue of fed and starved red sea bream Pagrus major. Author(s): Liang XF, Ogata HY, Oku H. Source: Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology. 2002 August; 132(4): 913-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12095871
•
Effect of dietary fiber on pancreatic lipase activity in vitro. Author(s): Hansen WE. Source: Pancreas. 1987; 2(2): 195-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2819858
•
Effect of dietary saturated fatty acids on intracellular free fatty acids and kinetic properties of hormone-sensitive lipase of rat adipocytes. Author(s): Awad AB, Chattopadhyay JP.
Alternative Medicine 141
Source: The Journal of Nutrition. 1986 June; 116(6): 1095-100. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3723204 •
Effect of hepatoprotective ayurvedic drugs on lipases following CCl4 induced hepatic injury in rats. Author(s): Patil S, Kanase A, Varute AT. Source: Indian J Exp Biol. 1989 November; 27(11): 955-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2620934
•
Effect of lipase activities of Propionibacterium granulosum and Propionibacterium acnes. Author(s): Higaki S, Nakamura M, Kitagawa T, Morohashi M, Yamagishi T. Source: Drugs Exp Clin Res. 2001; 27(5-6): 161-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11951573
•
Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. Author(s): Pilichiewicz A, O'Donovan D, Feinle C, Lei Y, Wishart JM, Bryant L, Meyer JH, Horowitz M, Jones KL. Source: The Journal of Clinical Endocrinology and Metabolism. 2003 August; 88(8): 3829-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12915676
•
Effect of obesity on HDL and LDL particle sizes in carriers of the null P207L or defective D9N mutation in the lipoprotein lipase gene: the Quebec LipD Study. Author(s): Ruel IL, Gaudet D, Perron P, Bergeron J, Julien P, Lamarche B; Quebec LipD Study. Source: International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity. 2003 May; 27(5): 631-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12704407
•
Effect of phosphatidylcholine and free fatty acids on the activity of pancreatic lipasecolipase. Author(s): Larsson A, Erlanson-Albertsson C. Source: Biochimica Et Biophysica Acta. 1986 May 21; 876(3): 543-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3707983
•
Effect of taxol on the heparin-induced secretion of lipoprotein lipase from cardiac myocytes. Author(s): Severson DL, Carroll R. Source: Molecular and Cellular Biochemistry. 1989 June 27-July 24; 88(1-2): 17-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2571074
142
Lipase
•
Effect of temperature, moisture, and carbon supplementation on lipase production by solid-state fermentation of soy cake by Penicillium simplicissimum. Author(s): Di Luccio M, Capra F, Ribeiro NP, Vargas GD, Freire DM, de Oliveira D. Source: Applied Biochemistry and Biotechnology. 2004 Spring; 113-116: 173-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15054204
•
Effects of arachidonic and docosahexaenoic acids on secretion and degradation of bile salt-dependent lipase in AR4-2J cells. Author(s): Le Petit-Thevenin J, Bruneau N, Nganga A, Lombardo D, Verine A. Source: Journal of Lipid Research. 2001 August; 42(8): 1220-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11483623
•
Effects of cholestyramine feeding on tissue lipase activities and plasma fatty acids in the pregnant rat. Author(s): Haave NC, Innis SM. Source: J Dev Physiol. 1989 July; 12(1): 11-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2614036
•
Effects of dietary saturated and polyunsaturated fat on lipoprotein lipase and hepatic triglyceride lipase activity. Author(s): Coiffier E, Paris R, Lecerf J. Source: Comparative Biochemistry and Physiology. B, Comparative Biochemistry. 1987; 88(1): 187-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3677597
•
Effects of diets supplemented with lard fat or mackerel oil on plasma lipoprotein lipid concentrations and lipoprotein lipase activities in domestic swine. Author(s): Groot PH, Scheek LM, Dubelaar ML, Verdouw PD, Hartog JM, Lamers JM. Source: Atherosclerosis. 1989 May; 77(1): 1-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2719757
•
Effects of human pancreatic lipase-colipase and carboxyl ester lipase on eicosapentaenoic and arachidonic acid ester bonds of triacylglycerols rich in fish oil fatty acids. Author(s): Chen Q, Sternby B, Akesson B, Nilsson A. Source: Biochimica Et Biophysica Acta. 1990 May 1; 1044(1): 111-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2340300
•
Effects of manufactured soluble dietary fiber from Quercus mongolica on hepatic HMG-CoA reductase and lipoprotein lipase activities in epididymal adipose tissue of rats fed high cholesterol diets. Author(s): Chai YM, Lim BK, Lee JY, Kim MN, Park MR, Rhee SJ.
Alternative Medicine 143
Source: Journal of Medicinal Food. 2003 Winter; 6(4): 329-36. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14977441 •
Effects of omega-3 fish oils on plasma lipids, lipoprotein composition, and postheparin lipoprotein lipase in women with IDDM. Author(s): Bagdade JD, Buchanan WE, Levy RA, Subbaiah PV, Ritter MC. Source: Diabetes. 1990 April; 39(4): 426-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2318345
•
Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat. Author(s): Fernandez E, Borgstrom B. Source: Biochimica Et Biophysica Acta. 1989 February 20; 1001(3): 249-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2917150
•
Enhancement of the vanadate-stimulated release of lipoprotein lipase activity by astilbin from the leaves of Engelhardtia chrysolepis. Author(s): Motoyashiki T, Miyake M, Morita T, Mizutani K, Masuda H, Ueki H. Source: Biological & Pharmaceutical Bulletin. 1998 May; 21(5): 517-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9635510
•
Enzymatic hydrolysis of carotenoid fatty acid esters of red pepper (Capsicum annuum L.) by a lipase from Candida rugosa. Author(s): Breithaupt DE. Source: Z Naturforsch [c]. 2000 November-December; 55(11-12): 971-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11204204
•
Enzymatic synthesis of a capsinoid by the acylation of vanillyl alcohol with fatty acid derivatives catalyzed by lipases. Author(s): Kobata K, Kawaguchi M, Watanabe T. Source: Bioscience, Biotechnology, and Biochemistry. 2002 February; 66(2): 319-27. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11999404
•
Esterification of polyunsaturated fatty acids by various forms of immobilized lipase from Rhizomucor miehei. Author(s): Kosugi Y, Roy PK, Chang Q, Shu-Gui C, Fukatsu M, Kanazawa K, Nakanishi H. Source: Lipids. 2000 April; 35(4): 461-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10858032
•
Evidence of GTP-binding protein regulation of phospholipase A2 activity in isolated human platelet membranes. Author(s): Silk ST, Clejan S, Witkom K.
144
Lipase
Source: The Journal of Biological Chemistry. 1989 December 25; 264(36): 21466-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2513318 •
Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism. Author(s): Ruel IL, Couture P, Cohn JS, Bensadoun A, Marcil M, Lamarche B. Source: Journal of Lipid Research. 2004 August; 45(8): 1528-37. Epub 2004 June 01. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15175359
•
Extracellular protease and phospholipase C are controlled by the global regulatory gene gacA in the biocontrol strain Pseudomonas fluorescens CHA0. Author(s): Sacherer P, Defago G, Haas D. Source: Fems Microbiology Letters. 1994 February 15; 116(2): 155-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8150259
•
Fatty acid steryl, stanyl, and steroid esters by esterification and transesterification in vacuo using Candida rugosa lipase as catalyst. Author(s): Weber N, Weitkamp P, Mukherjee KD. Source: Journal of Agricultural and Food Chemistry. 2001 January; 49(1): 67-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11170561
•
Further characterization of the acidic GPI-hydrolyzing phospholipase present in human sera. Author(s): Stambuk BU, Cardoso-de-Almeida ML. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 1994 February; 27(2): 383-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8081253
•
Glycosylation, activity and secretion of lipoprotein lipase in cultured brown adipocytes of newborn mice. Effect of tunicamycin, monensin, 1deoxymannojirimycin and swainsonine. Author(s): Masuno H, Schultz CJ, Park JW, Blanchette-Mackie EJ, Mateo C, Scow RO. Source: The Biochemical Journal. 1991 August 1; 277 ( Pt 3): 801-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1831351
•
Hydrolysis of long-chain, n-3 fatty acid enriched chylomicrons by cardiac lipoprotein lipase. Author(s): Levy R, Herzberg GR. Source: Canadian Journal of Physiology and Pharmacology. 1999 October; 77(10): 813-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10588486
Alternative Medicine 145
•
Hydrolysis of menhaden oil by a Candida cylindracea lipase immobilized in a hollow-fiber reactor. Author(s): Rice KE, Watkins J, Hill CG Jr. Source: Biotechnology and Bioengineering. 1999 April 5; 63(1): 33-45. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10099579
•
Hydrolysis of steryl esters by a lipase (Lip 3) from Candida rugosa. Author(s): Tenkanen M, Kontkanen H, Isoniemi R, Spetz P, Holmbom B. Source: Applied Microbiology and Biotechnology. 2002 October; 60(1-2): 120-7. Epub 2002 August 10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12382052
•
Hypotriglyceridemic action of omega-3 fatty acids in healthy subjects does not occur by enhanced lipoprotein lipase and hepatic lipase activities. Author(s): Desager JP, Dricot J, Harvengt C. Source: Res Commun Chem Pathol Pharmacol. 1989 August; 65(2): 269-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2587847
•
Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans. Author(s): Chen SC, Wright LC, Santangelo RT, Muller M, Moran VR, Kuchel PW, Sorrell TC. Source: Infection and Immunity. 1997 February; 65(2): 405-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9009289
•
Identification of the ricin lipase site and implication in cytotoxicity. Author(s): Morlon-Guyot J, Helmy M, Lombard-Frasca S, Pignol D, Pieroni G, Beaumelle B. Source: The Journal of Biological Chemistry. 2003 May 9; 278(19): 17006-11. Epub 2003 February 28. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12611897
•
Immobilization of lipases on polyethylene and application to perilla oil hydrolysis for production of alpha-linolenic acid. Author(s): Watanabe T, Suzuki Y, Sagesaka Y, Kohashi M. Source: J Nutr Sci Vitaminol (Tokyo). 1995 June; 41(3): 307-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7472675
•
Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Author(s): Harris WS, Lu G, Rambjor GS, Walen AI, Ontko JA, Cheng Q, Windsor SL.
146
Lipase
Source: The American Journal of Clinical Nutrition. 1997 August; 66(2): 254-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9250102 •
Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. Author(s): Ramaswamy M, Yau E, Wasan KM, Boulanger KD, Li M, Pritchard PH. Source: Journal of Pharmacy & Pharmaceutical Sciences [electronic Resource] : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques. 2002 January-April; 5(1): 29-38. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12042117
•
Inhibition of Candida rugosa lipase by berberine and structurally related alkaloids, evaluated by high-performance liquid chromatography. Author(s): Grippa E, Valla R, Battinelli L, Mazzanti G, Saso L, Silvestrini B. Source: Bioscience, Biotechnology, and Biochemistry. 1999 September; 63(9): 1557-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10540743
•
Inhibition of human gastric lipase by intraduodenal fat involves glucagon-like peptide-1 and cholecystokinin. Author(s): Wojdemann M, Riber C, Bisgaard T, Sternby B, Larsen S, Rehfeld JF, Holst JJ, Olsen O. Source: Regulatory Peptides. 1999 April 30; 80(3): 101-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10425652
•
Inhibition of lipase activities by citrus pectin. Author(s): Tsujita T, Sumiyosh M, Han LK, Fujiwara T, Tsujita J, Okuda H. Source: J Nutr Sci Vitaminol (Tokyo). 2003 October; 49(5): 340-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14703309
•
Inhibitory effect of spice oils on lipase and mycotoxin production. Author(s): Hasan HA, Mahmoud AL. Source: Zentralbl Mikrobiol. 1993 December; 148(8): 543-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8303954
•
Inhibitory effects of grape seed extract on lipases. Author(s): Moreno DA, Ilic N, Poulev A, Brasaemle DL, Fried SK, Raskin I. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2003 October; 19(10): 876-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14559324
•
Involvement of phospholipase A2 and arachidonic acid in the depolarization-evoked accumulation of Ca2+ in hippocampal mossy fiber nerve endings. Author(s): Damron DS, Dorman RV.
Alternative Medicine 147
Source: Neurochemical Research. 1993 December; 18(12): 1231-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8272188 •
Kinetic assay of human gastric lipase on short- and long-chain triacylglycerol emulsions. Author(s): Gargouri Y, Pieroni G, Riviere C, Sauniere JF, Lowe PA, Sarda L, Verger R. Source: Gastroenterology. 1986 October; 91(4): 919-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3743968
•
Lipase activity and gene cloning of Acinetobacter calcoaceticus LP009. Author(s): Dharmsthiti S, Pratuangdejkul J, Theeragool GT, Luchai S. Source: J Gen Appl Microbiol. 1998 April; 44(2): 139-145. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12501281
•
Lipase and protease extraction from activated sludge. Author(s): Gessesse A, Dueholm T, Petersen SB, Nielsen PH. Source: Water Research. 2003 September; 37(15): 3652-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12867331
•
Lipase from Chromobacterium viscosum: biochemical characterization indicating homology to the lipase from Pseudomonas glumae. Author(s): Taipa MA, Liebeton K, Costa JV, Cabral JM, Jaeger KE. Source: Biochimica Et Biophysica Acta. 1995 June 6; 1256(3): 396-402. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7786905
•
Lipase mediated upgradation of dietary fats and oils. Author(s): Gupta R, Rathi P, Bradoo S. Source: Critical Reviews in Food Science and Nutrition. 2003; 43(6): 635-44. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14669881
•
Lipase production by Aspergillus niger under various growth conditions using solid state fermentation. Author(s): Olama ZA, el-Sabaeny AH. Source: Microbiologia. 1993 December; 9(2): 134-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8172691
•
Lipase-catalyzed chemo- and enantioselective acetylation of 2-alkyl/aryl-3hydroxypropiophenones. Author(s): Kumar R, Azim A, Kumar V, Sharma SK, Prasad AK, Howarth OW, Olsen CE, Jain SC, Parmar VS.
148
Lipase
Source: Bioorganic & Medicinal Chemistry. 2001 October; 9(10): 2643-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11557352 •
Lipase-catalyzed ethanolysis of fish oils: multi-response kinetics. Author(s): Torres CF, Moeljadi M, Hill CG Jr. Source: Biotechnology and Bioengineering. 2003 August 5; 83(3): 274-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12783483
•
Lipase-catalyzed interesterification of soybean oil with an omega-3 polyunsaturated fatty acid concentrate prepared from sardine oil. Author(s): Akimoto M, Izawa M, Hoshino K, Abe K, Takahashi H. Source: Applied Biochemistry and Biotechnology. 2003 February; 104(2): 105-18. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12603099
•
Lipase-mediated acidolysis of butteroil with free conjugated linoleic acid in a packed bed reactor. Author(s): Sehanputri PS, Hill CG Jr. Source: Biotechnology and Bioengineering. 2003 September 5; 83(5): 608-17. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12827703
•
Lipolysis of menhaden oil triacylglycerols and the corresponding fatty acid alkyl esters by pancreatic lipase in vitro: a reexamination. Author(s): Yang LY, Kuksis A, Myher JJ. Source: Journal of Lipid Research. 1990 January; 31(1): 137-47. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2313198
•
Lipolysis of polyenoic fatty acid esters of human chylomicrons by lipoprotein lipase. Author(s): Ekstrom B, Nilsson A, Akesson B. Source: European Journal of Clinical Investigation. 1989 June; 19(3): 259-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2553422
•
Lipophorin lipase from the yolk of Manduca sexta eggs: identification and partial characterization. Author(s): Van Antwerpen R, Law JH. Source: Archives of Insect Biochemistry and Physiology. 1992; 20(1): 1-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1623220
•
Lipoprotein lipase activation by red ginseng saponins in hyperlipidemia model animals. Author(s): Inoue M, Wu CZ, Dou DQ, Chen YJ, Ogihara Y.
Alternative Medicine 149
Source: Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 1999 October; 6(4): 257-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10589445 •
Lipoprotein lipase activity in skeletal muscles of the rat: effects of denervation and tenotomy. Author(s): Smol E, Zernicka E, Czarnowski D, Langfort J. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2001 March; 90(3): 954-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11181606
•
Lipoprotein lipase in rats fed fish oil: apparent relationship to plasma insulin levels. Author(s): Baltzell JK, Wooten JT, Otto DA. Source: Lipids. 1991 April; 26(4): 289-94. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1865765
•
Lipoprotein lipase synthesis and secretion: effects of concentration and type of fatty acids in adipocyte cell culture. Author(s): Montalto MB, Bensadoun A. Source: Journal of Lipid Research. 1993 March; 34(3): 397-407. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8468524
•
Lipoprotein lipases, lipoprotein density gradient profile and LDL receptor activity in miniature pigs fed fish oil and corn oil. Author(s): Huff MW, Telford DE, Edmonds BW, McDonald CG, Evans AJ. Source: Biochimica Et Biophysica Acta. 1993 December 2; 1210(1): 113-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8257713
•
Lipoprotein lipases, lipoproteins and tissue lipids in rats fed fish oil or coconut oil. Author(s): Haug A, Hostmark AT. Source: The Journal of Nutrition. 1987 June; 117(6): 1011-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3598712
•
Low-temperature lipase from psychrotrophic Pseudomonas sp. strain KB700A. Author(s): Rashid N, Shimada Y, Ezaki S, Atomi H, Imanaka T. Source: Applied and Environmental Microbiology. 2001 September; 67(9): 4064-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11526006
•
Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU. Author(s): Tamura M, Ajayi T, Allmond LR, Moriyama K, Wiener-Kronish JP, Sawa T.
150
Lipase
Source: Biochemical and Biophysical Research Communications. 2004 April 2; 316(2): 323-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15020221 •
Mechanism of angiotensin II-induced arachidonic acid metabolite release in aortic smooth muscle cells: involvement of phospholipase D. Author(s): Shinoda J, Kozawa O, Suzuki A, Watanabe-Tomita Y, Oiso Y, Uematsu T. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 1997 February; 136(2): 207-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9116917
•
Mechanism of cAMP-induced Ca2+ influx in Dictyostelium: role of phospholipase A2. Author(s): Schaloske R, Malchow D. Source: The Biochemical Journal. 1997 October 1; 327 ( Pt 1): 233-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9355757
•
Method for the measurement of lipase activity in milk. Author(s): Humbert G, Guingamp MF, Linden G. Source: The Journal of Dairy Research. 1997 August; 64(3): 465-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9275261
•
Milk lipid digestion in the neonatal dog: the combined actions of gastric and bile salt stimulated lipases. Author(s): Iverson SJ, Kirk CL, Hamosh M, Newsome J. Source: Biochimica Et Biophysica Acta. 1991 April 24; 1083(1): 109-19. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2031934
•
Modulation of adipocyte lipoprotein lipase expression as a strategy for preventing or treating visceral obesity. Author(s): McCarty MF. Source: Medical Hypotheses. 2001 August; 57(2): 192-200. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11461172
•
Monoclonal antibodies to avian lipoprotein lipase. Purification of the enzyme by immunoaffinity chromatography. Author(s): Gershenwald JE, Bensadoun A, Saluja A. Source: Biochimica Et Biophysica Acta. 1985 October 2; 836(3): 286-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=4041471
•
Monoglyceride and diglyceride lipases from human platelet microsomes. Author(s): Chau LY, Tai HH.
Alternative Medicine 151
Source: Biochimica Et Biophysica Acta. 1988 December 16; 963(3): 436-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3143416 •
Mutations in the lipoprotein lipase gene as a cause of hypertriglyceridemia and pancreatitis in Taiwan. Author(s): Jap TS, Jenq SF, Wu YC, Chiu CY, Cheng HM. Source: Pancreas. 2003 August; 27(2): 122-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12883259
•
New enteric-coated high-lipase pancreatic extract in the treatment of pancreatic steatorrhea. Author(s): Malesci A, Mariani A, Mezzi G, Bocchia P, Basilico M. Source: Journal of Clinical Gastroenterology. 1994 January; 18(1): 32-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8113582
•
Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Author(s): Drouault S, Juste C, Marteau P, Renault P, Corthier G. Source: Applied and Environmental Microbiology. 2002 June; 68(6): 3166-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12039786
•
Overproduction in Escherichia coli, purification and characterization of a family I.3 lipase from Pseudomonas sp. MIS38. Author(s): Amada K, Haruki M, Imanaka T, Morikawa M, Kanaya S. Source: Biochimica Et Biophysica Acta. 2000 May 23; 1478(2): 201-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10825531
•
Pancreatic adaptation to dietary lipids is mediated by changes in lipase mRNA. Author(s): Wicker C, Scheele GA, Puigserver A. Source: Biochimie. 1988 September; 70(9): 1277-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2465787
•
Paracellular leakage of lipoprotein lipase across the mammary epithelium of the goat. Author(s): Azzara CD, Dimick PS. Source: Journal of Dairy Science. 1989 May; 72(5): 1159-68. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2745824
•
Partial purification and characterization of phosphatidic acid-specific phospholipase A(1) in porcine platelet membranes. Author(s): Miyazawa D, Ikemoto A, Fujii Y, Okuyama H.
152
Lipase
Source: Biochimica Et Biophysica Acta. 2003 February 20; 1631(1): 17-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12573445 •
Phospholipase C, protein kinase C, Ca/calmodulin-dependent protein kinase II, and redox state are involved in epigallocatechin gallate-induced phospholipase D activation in human astroglioma cells. Author(s): Kim SY, Ahn BH, Kim J, Bae YS, Kwak JY, Min G, Kwon TK, Chang JS, Lee YH, Yoon SH, Min do S. Source: European Journal of Biochemistry / Febs. 2004 September; 271(17): 3470-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15317582
•
Phosphorylation of the rat pancreatic bile-salt-dependent lipase by casein kinase II is essential for secretion. Author(s): Pasqualini E, Caillol N, Valette A, Lloubes R, Verine A, Lombardo D. Source: The Biochemical Journal. 2000 January 1; 345 Pt 1: 121-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10600647
•
Plant sources of acid stable lipases: potential therapy for cystic fibrosis. Author(s): Tursi JM, Phair PG, Barnes GL. Source: Journal of Paediatrics and Child Health. 1994 December;